<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurochem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurochem</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1471-4159</journal-id>
<journal-id journal-id-type="publisher-id">JNC</journal-id>
<journal-title-group>
<journal-title>Journal of Neurochemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3042</issn>
<issn pub-type="epub">1471-4159</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27306859</article-id>
<article-id pub-id-type="pmc">5094566</article-id>
<article-id pub-id-type="doi">10.1111/jnc.13600</article-id>
<article-id pub-id-type="publisher-id">JNC13600</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Frontotemporal dementias: From molecular mechanisms to therapy</subject>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Tau physiology and pathomechanisms in frontotemporal lobar degeneration</article-title>
<alt-title alt-title-type="left-running-head">L.‐G. Bodea <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="jnc13600-cr-0001">
<name>
<surname>Bodea</surname>
<given-names>Liviu‐Gabriel</given-names>
</name>
<xref ref-type="aff" rid="jnc13600-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="jnc13600-cr-0002">
<name>
<surname>Eckert</surname>
<given-names>Anne</given-names>
</name>
<xref ref-type="aff" rid="jnc13600-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="jnc13600-cr-0003">
<name>
<surname>Ittner</surname>
<given-names>Lars Matthias</given-names>
</name>
<xref ref-type="aff" rid="jnc13600-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="jnc13600-cr-0004">
<name>
<surname>Piguet</surname>
<given-names>Olivier</given-names>
</name>
<xref ref-type="aff" rid="jnc13600-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="jnc13600-cr-0005">
<name>
<surname>Götz</surname>
<given-names>Jürgen</given-names>
</name>
<xref ref-type="aff" rid="jnc13600-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="jnc13600-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Clem Jones Centre for Ageing Dementia Research</institution>
<institution>Queensland Brain Institute</institution>
<institution>The University of Queensland</institution>
<named-content content-type="city">Brisbane</named-content>
<named-content content-type="country-part">QLD</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="jnc13600-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Neurobiology Laboratory</institution>
<institution>Psychiatric University Clinics Basel</institution>
<institution>University of Basel</institution>
<named-content content-type="city">Basel</named-content>
<country country="CH">Switzerland</country>
</aff>
<aff id="jnc13600-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Dementia Research Unit</institution>
<institution>School of Medical Sciences</institution>
<institution>Faculty of Medicine</institution>
<institution>University of New South Wales</institution>
<named-content content-type="city">Sydney</named-content>
<named-content content-type="country-part">NSW</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="jnc13600-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Neuroscience Research Australia</institution>
<named-content content-type="city">Sydney</named-content>
<named-content content-type="country-part">NSW</named-content>
<country country="AU">Australia</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>Address correspondence and reprint requests to Jürgen Götz, Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane 4072, Queensland, Australia. E‐mail: <email>j.goetz@uq.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2016</year>
</pub-date>
<volume>138</volume>
<issue>Suppl Suppl 1</issue>
<issue-id pub-id-type="doi">10.1111/jnc.2016.138.issue-S1</issue-id>
<issue-title content-type="special-issue-title">Frontotemporal dementias: From molecular mechanisms to therapy</issue-title>
<fpage>71</fpage>
<lpage>94</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>31</day>
<month>1</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 International Society for Neurochemistry <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The Authors. <italic>Journal of Neurochemistry</italic> published by John Wiley &amp; Sons Ltd on behalf of International Society for Neurochemistry</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:JNC-138-71.pdf" xlink:type="simple"></self-uri>
<abstract id="jnc13600-abs-0001">
<title>Abstract</title>
<sec id="jnc13600-sec-1502">
<p>Frontotemporal lobar degeneration (<styled-content style="fixed-case">FTLD</styled-content>) has been associated with toxic intracellular aggregates of hyperphosphorylated tau (<styled-content style="fixed-case">FTLD</styled-content>‐tau). Moreover, genetic studies identified mutations in the <italic><styled-content style="fixed-case">MAPT</styled-content></italic> gene encoding tau in familial cases of the disease. In this review, we cover a range of aspects of tau function, both in the healthy and diseased brain, discussing several <italic>in vitro</italic> and <italic>in vivo</italic> models. Tau structure and function in the healthy brain is presented, accentuating its distinct compartmentalization in neurons and its role in microtubule stabilization and axonal transport. Furthermore, tau‐driven pathology is discussed, introducing current concepts and the underlying experimental evidence. Different aspects of pathological tau phosphorylation, the protein's genomic and domain organization as well as its spreading in disease, together with <italic><styled-content style="fixed-case">MAPT</styled-content></italic>‐associated mutations and their respective models are presented. Dysfunction related to other post‐transcriptional modifications and their effect on normal neuronal functions such as cell cycle, epigenetics and synapse dynamics are also discussed, providing a mechanistic explanation for the observations made in <styled-content style="fixed-case">FTLD</styled-content>‐tau cases, with the possibility for therapeutic intervention.</p>
</sec>
<sec id="jnc13600-sec-1002">
<p>
<boxed-text content-type="graphic" id="jnc13600-blkfxd-0002" orientation="portrait" position="anchor"><graphic id="nlm-graphic-1" orientation="portrait" position="anchor" xlink:href="JNC-138-71-g004.jpg"></graphic></boxed-text>
In this review, we cover aspects of tau function, both in the healthy and diseased brain, referring to different <italic>in vitro</italic> and <italic>in vivo</italic> models. In healthy neurons, tau is compartmentalized, with higher concentrations found in the distal part of the axon. Cargo molecules are sensitive to this gradient. A disturbed tau distribution, as found in frontotemporal lobar degeneration (<styled-content style="fixed-case">FTLD</styled-content>‐tau), has severe consequences for cellular physiology: tau accumulates in the neuronal soma and dendrites, leading among others to microtubule depolymerization and impaired axonal transport. Tau forms insoluble aggregates that sequester additional molecules stalling cellular physiology. Neuronal communication is gradually lost as toxic tau accumulates in dendritic spines with subsequent degeneration of synapses and synaptic loss. Thus, by providing a mechanistic explanation for the observations made in <styled-content style="fixed-case">FTLD</styled-content>‐tau cases, arises a possibility for therapeutic interventions.</p>
<p>
<bold>This article is part of the</bold> <underline underline-style="single"><ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1471-4159/homepage/special_issues.htm">Frontotemporal Dementia special issue</ext-link>.</underline>
</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="jnc13600-kwd-0001">microtubule</kwd>
<kwd id="jnc13600-kwd-0002">phosphorylation</kwd>
<kwd id="jnc13600-kwd-0003">post‐translational</kwd>
<kwd id="jnc13600-kwd-0004">spreading</kwd>
<kwd id="jnc13600-kwd-0005">synapse</kwd>
<kwd id="jnc13600-kwd-0006">transgenic</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>State Government of Queensland</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>Federal Government of Australia</funding-source>
<award-id>ACT900116</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>Australian Research Council</funding-source>
<award-id>DP1330010193 2</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>National Health and Medical Research Council of Australia</funding-source>
<award-id>APP1037746</award-id>
<award-id>APP1003150</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="24"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>jnc13600</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>August 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.6 mode:remove_FC converted:03.11.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<def-list id="jnc13600-dl-0001" list-content="abbreviations">
<title>Abbreviations used</title>
<def-item>
<term>0N or 1N or 2N</term>
<def>
<p>no or 1 or 2 N‐terminal repeats domain</p>
</def>
</def-item>
<def-item>
<term>2R or 3R</term>
<def>
<p>2 or 3 C‐terminal repeats domain</p>
</def>
</def-item>
<def-item>
<term>AAV</term>
<def>
<p>adeno‐associated virus</p>
</def>
</def-item>
<def-item>
<term>AD</term>
<def>
<p>Alzheimer's disease</p>
</def>
</def-item>
<def-item>
<term>aFTLD‐U</term>
<def>
<p>atypical FTLD with ubiquitinated inclusion</p>
</def>
</def-item>
<def-item>
<term>AGD</term>
<def>
<p>argyrophilic grain disease</p>
</def>
</def-item>
<def-item>
<term>AGE products</term>
<def>
<p>advanced glycation end products</p>
</def>
</def-item>
<def-item>
<term>ALS</term>
<def>
<p>amyotropic lateral sclerosis</p>
</def>
</def-item>
<def-item>
<term>AMPA</term>
<def>
<p>α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid</p>
</def>
</def-item>
<def-item>
<term>APP</term>
<def>
<p>amyloid precursor protein</p>
</def>
</def-item>
<def-item>
<term>Aβ</term>
<def>
<p>amyloid‐β</p>
</def>
</def-item>
<def-item>
<term>BIBD</term>
<def>
<p>basophilic inclusions body disease</p>
</def>
</def-item>
<def-item>
<term>CamKII‐tTA promoter</term>
<def>
<p>CaMKll promoter regulating the tetracycline transactivator</p>
</def>
</def-item>
<def-item>
<term>CBD</term>
<def>
<p>cortical basal degeneration</p>
</def>
</def-item>
<def-item>
<term>CDK5</term>
<def>
<p>cyclin‐dependent kinase 5</p>
</def>
</def-item>
<def-item>
<term>C‐terminal</term>
<def>
<p>carboxy‐terminal</p>
</def>
</def-item>
<def-item>
<term>Cx3cr1</term>
<def>
<p>CX3C chemokine receptor 1</p>
</def>
</def-item>
<def-item>
<term>Drp1</term>
<def>
<p>dynamin‐related 1</p>
</def>
</def-item>
<def-item>
<term>dTau</term>
<def>
<p>
<italic>Drosphila</italic> tau</p>
</def>
</def-item>
<def-item>
<term>ERK</term>
<def>
<p>extracellular‐regulated kinase</p>
</def>
</def-item>
<def-item>
<term>ESCs</term>
<def>
<p>embryonic stem cells</p>
</def>
</def-item>
<def-item>
<term>FLIM/FRET</term>
<def>
<p>Fluorescence Lifetime Imaging Microscopy/Fluorescence Resonance Energy Transfer</p>
</def>
</def-item>
<def-item>
<term>FTD‐3</term>
<def>
<p>FTLD linked to chromosome 3</p>
</def>
</def-item>
<def-item>
<term>FTDP‐17</term>
<def>
<p>FTLD with parkinsonism linked to chromosome 17</p>
</def>
</def-item>
<def-item>
<term>FTDP‐17T</term>
<def>
<p>FTLD with parkinsonism linked to chromosome 17 with <italic>MAPT</italic> mutations</p>
</def>
</def-item>
<def-item>
<term>FTLD</term>
<def>
<p>Frontotemporal lobar degeneration</p>
</def>
</def-item>
<def-item>
<term>FUS</term>
<def>
<p>fused in sarcoma</p>
</def>
</def-item>
<def-item>
<term>GFP</term>
<def>
<p>green fluorescent protein</p>
</def>
</def-item>
<def-item>
<term>
<italic>GRN</italic>
</term>
<def>
<p>progranulin gene</p>
</def>
</def-item>
<def-item>
<term>GSK3</term>
<def>
<p>glycogen synthase‐3</p>
</def>
</def-item>
<def-item>
<term>iPSCs</term>
<def>
<p>induced pluripotent stem cells</p>
</def>
</def-item>
<def-item>
<term>JNK</term>
<def>
<p>c‐Jun N‐terminal kinase</p>
</def>
</def-item>
<def-item>
<term>ko</term>
<def>
<p>knock‐out</p>
</def>
</def-item>
<def-item>
<term>LTD</term>
<def>
<p>long‐term depression</p>
</def>
</def-item>
<def-item>
<term>LTP</term>
<def>
<p>long‐term potentiation</p>
</def>
</def-item>
<def-item>
<term>MAP2</term>
<def>
<p>microtubule‐associated protein 2</p>
</def>
</def-item>
<def-item>
<term>MAP4</term>
<def>
<p>microtubule‐associated protein 4</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>mitogen‐activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>MAP</term>
<def>
<p>microtubule‐associated protein</p>
</def>
</def-item>
<def-item>
<term>
<italic>MAPT</italic>
</term>
<def>
<p>microtubule‐associated protein tau gene</p>
</def>
</def-item>
<def-item>
<term>MARK</term>
<def>
<p>microtubule‐affinity regulating kinase</p>
</def>
</def-item>
<def-item>
<term>mRNA</term>
<def>
<p>messenger RNA</p>
</def>
</def-item>
<def-item>
<term>MSTD</term>
<def>
<p>multiple system tauopathy with dementia</p>
</def>
</def-item>
<def-item>
<term>mThy1.2 or hThy1.2 promoter</term>
<def>
<p>mouse or human Thy1.2 promoter</p>
</def>
</def-item>
<def-item>
<term>NDT‐dementia</term>
<def>
<p>neurofibrillary tangle predominant dementia</p>
</def>
</def-item>
<def-item>
<term>NFT</term>
<def>
<p>neurofibrillary tangle</p>
</def>
</def-item>
<def-item>
<term>NIFID</term>
<def>
<p>neuronal intermediate filament inclusion disease</p>
</def>
</def-item>
<def-item>
<term>NREM</term>
<def>
<p>non‐rapid eye movement</p>
</def>
</def-item>
<def-item>
<term>N‐terminal</term>
<def>
<p>amino‐terminal</p>
</def>
</def-item>
<def-item>
<term>O‐GlcNAc</term>
<def>
<p>O‐linked N‐acetylglucosamine</p>
</def>
</def-item>
<def-item>
<term>PAC</term>
<def>
<p>P1‐derived artificial chromosome</p>
</def>
</def-item>
<def-item>
<term>Par1</term>
<def>
<p>protease‐activated receptor 1</p>
</def>
</def-item>
<def-item>
<term>PDGFβ</term>
<def>
<p>platelet‐derived growth factor β‐chain</p>
</def>
</def-item>
<def-item>
<term>PD</term>
<def>
<p>Parkinson's disease</p>
</def>
</def-item>
<def-item>
<term>PHF</term>
<def>
<p>paired helical filaments</p>
</def>
</def-item>
<def-item>
<term>PiD</term>
<def>
<p>Pick's disease</p>
</def>
</def-item>
<def-item>
<term>PolyI:C</term>
<def>
<p>polyriboinosinic‐polyribocytidilic acid</p>
</def>
</def-item>
<def-item>
<term>PP1A or PP2A</term>
<def>
<p>protein phosphatase 2A or 2B</p>
</def>
</def-item>
<def-item>
<term>PrP</term>
<def>
<p>prion protein promotor</p>
</def>
</def-item>
<def-item>
<term>PSD‐95</term>
<def>
<p>post‐synaptic density protein 95</p>
</def>
</def-item>
<def-item>
<term>PSEN1</term>
<def>
<p>presenilin 1 gene</p>
</def>
</def-item>
<def-item>
<term>PSP</term>
<def>
<p>progressive supranuclear palsy</p>
</def>
</def-item>
<def-item>
<term>Ptl‐1</term>
<def>
<p>protein with tau‐like repeats‐1</p>
</def>
</def-item>
<def-item>
<term>PXXP</term>
<def>
<p>proline‐rich motif</p>
</def>
</def-item>
<def-item>
<term>RNAi</term>
<def>
<p>RNA interference</p>
</def>
</def-item>
<def-item>
<term>ROS</term>
<def>
<p>reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term>SAGE</term>
<def>
<p>serial analysis of gene expression</p>
</def>
</def-item>
<def-item>
<term>SFPQ</term>
<def>
<p>splicing factor proline/glutamine‐rich</p>
</def>
</def-item>
<def-item>
<term>Sgg</term>
<def>
<p>protein kinase shaggy</p>
</def>
</def-item>
<def-item>
<term>SH1/2/3</term>
<def>
<p>Src homology domain 1/2/3</p>
</def>
</def-item>
<def-item>
<term>SLM</term>
<def>
<p>stratum lacunosum moleculare</p>
</def>
</def-item>
<def-item>
<term>SPR</term>
<def>
<p>surface plasmon resonance</p>
</def>
</def-item>
<def-item>
<term>STEP</term>
<def>
<p>striatal‐enriched protein tyrosine phosphatase</p>
</def>
</def-item>
<def-item>
<term>SUMO</term>
<def>
<p>small ubiquitin‐related modifiers</p>
</def>
</def-item>
<def-item>
<term>
<italic>TARDP</italic>
</term>
<def>
<p>TAR DNA‐binding protein 43 gene</p>
</def>
</def-item>
<def-item>
<term>UPS</term>
<def>
<p>ubiquitin proteasome system</p>
</def>
</def-item>
<def-item>
<term>
<italic>VCP</italic>
</term>
<def>
<p>valosin containing protein gene</p>
</def>
</def-item>
<def-item>
<term>WMT‐GGI</term>
<def>
<p>white matter tauopathy with globular glial inclusions</p>
</def>
</def-item>
</def-list>
<p>Frontotemporal dementia or frontotemporal lobar degeneration (FTLD) is a debilitating disease that results from progressive neurodegeneration and eventually, atrophy of the frontal and temporal cortex as well as subcortical regions. The onset of FTLD is insidious, with heterogeneous progressive clinical features that exhibit at least two of the following three sets of symptoms: behavioural and personality changes, cognitive deficits and Parkinson‐like motor dysfunctions (Ghetti <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0075">2015</xref>).</p>
<p>The first paper describing temporal lobar cortical atrophy is attributed to Arnold Pick (Pick <xref ref-type="ref" rid="jnc13600-bib-0191">1892</xref>). Subsequently, other neuropathologists made similar observations on frontotemporal atrophy, which differs from the widespread atrophy that characterizes senile dementia. At the turn of the 19<sup>th</sup> century, an important contribution was made by Alois Alzheimer who described cases of lobar cortical atrophy with intracytoplasmic argyrophilic inclusions and ballooned neurons, without the plaques characteristic of the disease that now carries his name (Alzheimer <xref ref-type="ref" rid="jnc13600-bib-0005">1907</xref>, <xref ref-type="ref" rid="jnc13600-bib-0006">1911</xref>). In the 20th century, progress was made to better identify and characterize what would later be named FTLD. The 1950s saw the first comprehensive clinico‐pathological studies of FTLD (Delay <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0052">1957</xref>), and further characterization of FTLD led to a set of criteria to allow a more accurate neuropathologic diagnosis and classification (Cairns <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0031">2007</xref>). A current alternative classification of FTLD is based on the observed changes in behaviour, language, movement and/or cognition caused by atrophy of the frontal and temporal cortex. In this system of cognitive syndromes, FTLD cases with mainly behavioural changes are grouped under the umbrella term of ‘behavioural‐variant FTD’ (Rascovsky <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0197">2011</xref>), whereas those with language deficits are classified as primary progressive aphasias that are further subdivided into semantic dementia and progressive non‐fluent aphasia (Gorno‐Tempini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0087">2011</xref>). A genetic component of FTLD has also been identified, with approximately 40% of affected patients being reported to have some form of family history of FTLD or dementia, but only 10% of cases being dominantly inherited (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0082">2012</xref>). Recently, Mackenzie and colleagues up‐dated the previously established classification of FTLD based on the specific pattern of pathology (Mackenzie <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0169">2010</xref>). Accordingly, a first molecular group was defined as FTLD‐tau, characterized by tau deposits and encompassing Pick's disease (PiD), cortical basal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain disease (AGD), multiple system tauopathy with dementia, neurofibrillary tangle predominant dementia (NFT‐dementia) and white matter tauopathy with globular glial inclusions. Further categories are FTLD‐TDP (associated with deposits of TDP‐43), FTLD‐UPS (linked to chromosome 3), FTLD‐FUS and FTLD without overt inclusions. However, this classification is not absolute and has its limitations. For example frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP‐17) is not included since it is not characterized by a consistent pattern of pathology (Mackenzie <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0169">2010</xref>).</p>
<sec id="jnc13600-sec-0002">
<title>Tau and FTLD‐tau</title>
<p>Tau protein inclusions are the hallmark of neurodegenerative diseases collectively referred to as tauopathies (Lee <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0155">2001</xref>). Tau belongs to the family of microtubule‐associated proteins (MAPs), which are found throughout the entire animal kingdom, from <italic>Caenorhabditis elegans</italic> and <italic>Drosophila melanogaster</italic> to rodents, non‐human primates and humans (Buée <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0028">2000</xref>; Dehmelt and Halpain <xref ref-type="ref" rid="jnc13600-bib-0051">2005</xref>). The MAPs have evolved to fulfil various cellular functions: as microtubule motors, centrosome‐associated proteins, enzymatically active MAPs and structural MAPs with scaffolding function. In mammals, the latter category is represented by the neuronal proteins microtubule‐associated protein 2 (MAP2), tau and the non‐neuronal protein microtubule‐associated protein 4 (Dehmelt and Halpain <xref ref-type="ref" rid="jnc13600-bib-0051">2005</xref>).</p>
<p>The study of tau began in the 1970s, when Weingarten and colleagues described a protein that is essential for the assembly of microtubules, a cytoskeletal element composed of polymers of tubulin, and named it tau (tubulin‐associated unit) or τ (Weingarten <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0248">1975</xref>). The following decade saw the initial identification of the tau‐encoding microtubule‐associated protein tau gene (<italic>MAPT</italic>) gene (Drubin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0058">1984</xref>; Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0078">1988</xref>). The protein tau was found to bind to the carboxy‐terminal region of tubulin through a region known as the microtubule‐binding domain (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0079">1989</xref>), and it was reported to localize to axonal microtubules in the healthy brain, whereas under pathological conditions it is abnormally concentrated in a hyperphosphorylated form in the somato‐dendritic compartment of neurons (Kosik <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0141">1986</xref>; Wood <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0253">1986</xref>). Hyperphosphorylated forms of tau were also found to constitute the major proteinaceous component of the neurofibrillary tangles (NFTs) found in Alzheimer's disease (AD) brains, and of the Pick bodies found in PiD (Grundke‐Iqbal <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0094">1986</xref>). In the 1990s, familial forms of FTLD were linked to chromosome 17q21–22 (Wilhelmsen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0249">1994</xref>; Murrell <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0186">1997</xref>) and named FTDP‐17, culminating in the identification of pathogenic mutations in <italic>MAPT</italic> (Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Poorkaj <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0194">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0220">1998b</xref>). Today, it is accepted that FTLD associated with <italic>MAPT</italic> mutations is a highly heterogeneous disorder that affects behaviour, language, memory and motor functions. FTLD‐tau often begins with psychiatric symptoms and has similarities to other neurodegenerative diseases, such as AD (Spillantini and Goedert <xref ref-type="ref" rid="jnc13600-bib-0218">2013</xref>). The diagnosis of FTLD‐tau can be challenging when based solely on a clinical or histopathological assessment, as tau inclusions are present in all aforementioned neurodegenerative diseases (Cairns <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0031">2007</xref>; Goedert <xref ref-type="ref" rid="jnc13600-bib-0076">2015</xref>).</p>
</sec>
<sec id="jnc13600-sec-0003">
<title>Tau function in the healthy human brain</title>
<p>Tau is an intrinsically disordered protein, with a structure that can be subdivided into four domains: N‐terminal, proline‐rich, microtubule‐binding and C‐terminal (Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>). Tau is rich in polar charged amino acids, displaying a generally basic character, except for the first 120 amino acids that are acidic (Mandelkow and Mandelkow <xref ref-type="ref" rid="jnc13600-bib-0170">2012</xref>). Interestingly, about 50% of the sequence comprises only five amino acids: glycine, lysine, proline, serine and threonine. The single gene encoding tau, <italic>MAPT</italic>, is found on chromosome 17q21–22 and consists of 16 exons (Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>a). In Caucasians, there are two haplotypes of <italic>MAPT</italic> resulting from a 900 kb inversion (H1) or non‐inversion (H2) polymorphism (Baker <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0015">1999</xref>; Stefansson <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0221">2005</xref>), with the former increasing the risk of neurodegenerative diseases such as PSP (Baker <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0015">1999</xref>; Höglinger <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0106">2011</xref>), CBD (Cruchaga <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0047">2009</xref>), amyotrophic lateral sclerosis or Parkinson's disease (Sundar <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0224">2006</xref>).</p>
<fig fig-type="Figure" id="jnc13600-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Structure of human microtubule‐associated protein tau gene (<italic><styled-content style="fixed-case">MAPT</styled-content></italic>) and protein. (a) <italic><styled-content style="fixed-case">MAPT</styled-content></italic> contains 16 exons. In the brain, 11 of these exons are alternatively spliced, leading to the expression of different tau isoforms. Exons 4a, 6 and 8 are insufficiently studied. The exons are colour‐coded matching the corresponding tau protein domains; (b) The general structure of the longest human tau protein encompasses an N‐terminal projection domain, a proline‐rich region, a microtubule‐binding domain and a C‐terminal region. The N‐terminal region can contain acidic regions (N1, N2), followed by a proline‐rich region bearing up to seven <styled-content style="fixed-case">PXXP</styled-content> motifs that can interact with other proteins via Src‐homology 3 (<styled-content style="fixed-case">SH</styled-content>3) domains. Preceding the C‐terminal region, tau possess a microtubule‐binding domain composed of tubulin‐binding repetitions (R1, R2, R3, R4); (c) The principal 6 isoforms of human tau that are expressed in brain contain a common backbone represented by three tubulin‐binding repeats (R1, R3 and R4), to which either N1, N1 together with N2 or none of these acidic domains are added, resulting in the 2N3R, 1N3R or 0N3R isoforms. Inclusion of exon 10 of <italic><styled-content style="fixed-case">MAPT</styled-content></italic> leads to the presence of the R2 tubulin‐binding domain, resulting in the 2N4R, 1N4R or 0N4R tau isoforms.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="JNC-138-71-g001"></graphic>
</fig>
<p>The constitutively expressed exons of <italic>MAPT</italic> are 1, 4, 5, 7, 9, 11 and 12, whereas exons 2, 3 and 10 are alternatively spliced, giving rise to six major adult brain‐specific isoforms, ranging from 352 to 441 amino acids (Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>) (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0080">1992</xref>). Exons 4A, 6 and 8 have not been identified in any human brain mRNA at any developmental stage, even though exon 4A is expressed in peripheral nerves (Georgieff <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0074">1993</xref>). Exon 6‐containing transcripts have been insufficiently studied to date (Wei and Andreadis <xref ref-type="ref" rid="jnc13600-bib-0247">1998</xref>). The N‐terminus or so‐called projection domain is not instrumental in binding to microtubules (Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>b). It consists of highly acidic inserts represented by expression of either exon 2 alone (1N, 29 amino acids), exons 2 and 3 (2N, 58 amino acids in total) or neither of them (0N; Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>c). These inserts are followed by a basic, proline‐rich region. The C‐terminal half of tau is composed of tubulin‐binding motifs, represented by either three or four repeat‐domains (3R or 4R respectively; Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>c), and a C‐terminal tail. The presence of the repeat motifs correlates with the capacity of tau to bind, and thus stabilize, microtubules, with 4R increasing the interaction with microtubules (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0079">1989</xref>; Goedert and Jakes <xref ref-type="ref" rid="jnc13600-bib-0077">1990</xref>).</p>
<p>During human brain development, 3R tau predominates, whereas in the adult brain, 3R and 4R are found in an approximately equimolar ratio, both at the mRNA and protein level (Avila <xref ref-type="ref" rid="jnc13600-bib-0013">2009</xref>). Changes to this ratio can lead to neurodegeneration and dementia: in the case of PSP and CBD, the 4R isoform predominates, whereas in PiD, the 3R tau is majoritarly expressed (Buée <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0028">2000</xref>). Interestingly, neuronal subpopulations differ in their isoform expression, e.g. granular cells of the hippocampal dentate gyrus lack mRNAs containing exon 10, leading to the absence of 4R tau (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0079">1989</xref>). Moreover, in the retina and peripheral neurons with long axons, an additional high molecular weight tau isoform, called ‘big tau’ has been identified, characterized by the expression of exon 4A (Georgieff <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0074">1993</xref>). Together, these findings suggest a role for cell‐specific tau isoforms in assuming distinct physiological roles.</p>
<p>By binding to microtubules, which are formed by protofibrils of α‐ and β‐tubulin heterodimers, it has been postulated that tau confers structural stability to the microtubules (Weingarten <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0248">1975</xref>). In this model (Fig. <xref ref-type="fig" rid="jnc13600-fig-0002">2</xref>a), the tubulin‐binding repeats recognize specific sites on the protofilaments in either a cis‐ or trans‐configuration, thereby contributing to microtubule assembly, whereas the positively charged proline‐rich regions are tightly bound to the negatively charged surface of the protofibrils and the negatively charged N‐terminal domain projects further away from the microtubule surface, possibly because of electrostatic repulsion (Kar <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0131">2003</xref>; Santarella <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0208">2004</xref>). Because tau's projection domain determines the distance between axonal microtubules as observed in an insect cell model (Chen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0036">1992</xref>), it seems likely that the N‐terminal region of tau is crucial for the organization of axons (Buée <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0028">2000</xref>).</p>
<fig fig-type="Figure" id="jnc13600-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Tau‐microtubule dynamics under healthy and pathological conditions; (a) Heterodimers of α‐ and β‐tubulin assemble into protofibrils, which then form microtubules. Tau can interact with microtubules in a physiologically phosphorylated form. Increased phosphorylation of tau (e.g. as a consequence of glycogen synthase‐3, <styled-content style="fixed-case">GSK</styled-content>3, activity) results in detachment from microtubules. Tau is reintroduced in the cycle by the action of protein phosphatases (e.g. <styled-content style="fixed-case">PP</styled-content>2A); (b) Hyperphosphorylation of tau sequesters it from its physiological cycle (thicker arrow), resulting in the formation of intracellular tau deposits and eventually neurofibrillary tangles (<styled-content style="fixed-case">NFT</styled-content>s), and an increasing microtubule break‐down (thickest arrows).</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="JNC-138-71-g002"></graphic>
</fig>
<p>Notably, there is a different organization between axons and dendrites in regards to microtubules and the presence of MAP2/tau. Axonal microtubules have a uniform orientation, with the active polymerizing end positioned towards the distal extremity, contributing to axonal specification (Tanaka and Kirschner <xref ref-type="ref" rid="jnc13600-bib-0229">1991</xref>). The axon is also presenting the highest concentration of tau, with a gradient towards its distal part (Black <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0019">1996</xref>). In contrast, dendritic microtubules have a heterogeneous orientation and although tau is also found in dendrites, albeit at lower levels, MAP2 is fully confined to this compartment (Xia <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0254">2015</xref>). A biochemical study revealed the possibility of microtubule stabilization by an electrostatic zipper‐like dimerization of tau, with the highly negatively charged N‐terminal domain of one tau molecule interacting with the highly positively charged proline‐rich region of an adjacent tau molecule (Rosenberg <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0201">2008</xref>). This model may explain the tight arrangement of microtubules in axons.</p>
<p>A recent study in neuronal cells was able to visualize and characterize the dynamics of tau molecules, proposing a new fast‐paced ‘kiss‐and‐hop’ mechanism (Janning <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0126">2014</xref>). In this report, the interaction of tau with microtubules was shown to last for only ≈40 ms rather than ≈4s, as was previously thought (Konzack <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0139">2007</xref>). Furthermore, the seemingly undirected trajectory of tau movements did not interfere with the normal physiological polymerization of microtubules (Janning <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0126">2014</xref>). These findings seem to be in concordance with the <italic>in vitro</italic> and <italic>in vivo</italic> findings of another group, that observed that the population of tau‐bound microtubules has the highest turnover rate when compared with any other MAPs (Fanara <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0065">2010</xref>). Based on this, the initial postulate that tau confers stability to microtubules seems questionable or at least incomplete (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0182">2011</xref>). Besides microtubules, tau can also bind other molecules (for review see Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0182">2011</xref>; Mandelkow and Mandelkow <xref ref-type="ref" rid="jnc13600-bib-0170">2012</xref>). Interestingly, tau interacts with actin, as demonstrated both <italic>in vitro</italic> (Zmuda and Rivas <xref ref-type="ref" rid="jnc13600-bib-0265">2000</xref>; Sharma <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0215">2007</xref>) and <italic>in vivo</italic> (Fulga <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0070">2007</xref>). This interaction is also mediated <italic>in vivo</italic> by the microtubule‐binding domain, possibly contributing to a cytoskeleton‐associated function (He <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0101">2009</xref>).</p>
</sec>
<sec id="jnc13600-sec-0004">
<title>Tau in model organisms</title>
<p>Historically, tauopathy‐related mechanisms were derived from <italic>in vitro</italic> biochemical studies or observations on animal models. For example whereas the initial studies observed the role of tau in microtubule assembly <italic>in vitro</italic>, on samples obtained from porcine or chicken brains (Weingarten <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0248">1975</xref>), the identification of the <italic>Mapt</italic> gene was initially achieved in mice (Lee <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0153">1988</xref>) and 1 year later in humans (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0079">1989</xref>). This bottom‐up approach has the obvious advantage of achieving a step‐wise mechanistic understanding, which is unattainable from studying the end‐stage of human disease in <italic>post‐mortem</italic> brain tissue. However, the knowledge obtained from non‐human samples or models provides the foundation for understanding the complexity of the interactions and functions of tau in both the healthy and diseased brain.</p>
<p>The first unambiguously characterized functional orthologue of the MAP2/tau‐family in the evolutionary chain was identified in the <italic>Caenorhabditis elegans</italic> worm model and termed Protein with tau‐like repeats‐1, Ptl‐1 (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0081">1996</xref>; McDermott <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0173">1996</xref>). <italic>C. elegans</italic> has a nervous system comprising 302 neurons and as such has been used extensively to model human neurodegenerative diseases (Calahorro and Ruiz‐Rubio <xref ref-type="ref" rid="jnc13600-bib-0032">2011</xref>). Ptl‐1 presents with a 50% similarity to its mammalian homologue and has two alternatively spliced forms, Ptl‐1A and Ptl‐1B, with four or five microtubule‐repeat domains respectively. Ptl‐1 is neuronally expressed and associates with homologues of the motor proteins kinesin and dynein (Tien <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0234">2011</xref>). Interestingly, a knock‐out (ko) of Ptl‐1 does not affect tubulin organization (Gordon <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0086">2008</xref>), but induces neuronal ageing and a shorter lifespan because of oxidative stress‐related mechanisms (Chew <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0039">2013</xref>, <xref ref-type="ref" rid="jnc13600-bib-0040">2015</xref>) or altered O‐linked N‐acetylglucosamine (O‐GlcNAc) cycling (Hanover and Wang <xref ref-type="ref" rid="jnc13600-bib-0096">2013</xref>). Pan‐neuronal <italic>unc‐119</italic> promoter‐driven expression of different tau species, such as human 0N3R or 0N4R isoforms, or only the 0N, 3R or 4R domains of tau, as well as MAP2, induced neurotoxicity in <italic>C. elegans</italic> (Xie <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0255">2014</xref>). The same study reported a higher toxicity of 4R compared to 3R tau in the absence of aggregate formation (Xie <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0255">2014</xref>).</p>
<p>The initial paper describing tau in the fly <italic>Drosophila melanogaster</italic> (dTau) reported an endogenous protein with five microtubule‐binding domains resembling those found in mammalian MAP2/tau, and a 66% similarity to the corresponding human tau homologue (Heidary and Fortini <xref ref-type="ref" rid="jnc13600-bib-0102">2001</xref>). However, this is only the longest, most frequent and most studied of the dTau isoforms. Two other isoforms are characterized by alterations in the C‐terminal region, whereas yet another isoform was found to be entirely absent from adult females (Bouleau and Tricoire <xref ref-type="ref" rid="jnc13600-bib-0023">2015</xref>). Initially, no obvious morphological or behavioural defects were described in dTau null flies (Doerflinger <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0056">2003</xref>), however, a more recent study re‐examined these flies and observed the presence of isoforms generated from additional internal transcriptional start sites that were not excised in the previous ko approach, thereby explaining the described lack of phenotype (Bolkan and Kretzschmar <xref ref-type="ref" rid="jnc13600-bib-0022">2014</xref>). Complete elimination of all dTau isoforms resulted in developmental lethality, whereas a knock‐down approach led to progressive eye and central nervous system degeneration (Bolkan and Kretzschmar <xref ref-type="ref" rid="jnc13600-bib-0022">2014</xref>). Moreover, a partial compensatory effect of Map1b was demonstrated in the dTau knock‐down flies, which was rescued when human tau was expressed (Bolkan and Kretzschmar <xref ref-type="ref" rid="jnc13600-bib-0022">2014</xref>). A shorter lifespan and neurodegenerative vacuolization in the absence of neuronal tau aggregates were reported in flies expressing human tau (Wittmann <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0252">2001</xref>). Over‐expression of a single copy of dTau or human tau in <italic>D. melanogaster</italic> led to a rough eye phenotype (Chen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0037">2007</xref>), indicative of impaired cell proliferation, growth, cell determination or differentiation during eye development (Gonzalez <xref ref-type="ref" rid="jnc13600-bib-0085">2013</xref>). Moreover, introduction of additional tau copies resulted in a gradually increased neurotoxicity in the same model (Chen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0037">2007</xref>). This could indicate that tau levels need to be balanced to prevent neurodegeneration. On the other hand, in the absence of time‐dependent vacuolization of the optic lobes and loss of photoreceptors, these findings could simply reflect a tau‐related developmental deficit (Sun and Chen <xref ref-type="ref" rid="jnc13600-bib-0223">2015</xref>). To add to this complexity, Kosmidis and colleagues described ablation of the mushroom bodies after pan‐neuronal accumulation of either 0N4R or 2N4R human Tau, but no effect on the mushroom bodies when dTau, bovine tau or 0N3R human tau were expressed, even though deficits of learning and memory were present (Kosmidis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0143">2010</xref>). Together, these data support both a structural and a functional similarity between human tau and dTau; they also suggest the presence of species‐specific features that cannot be compensated by homologous molecules.</p>
<p>Zebrafish (<italic>Danio rerio</italic>) has not been widely used to investigate tau‐related functions or tauopathies. Only recently, tau homologues were analysed in zebrafish, revealing the presence of two <italic>MAPT</italic> paralogues, <italic>mapta</italic> and <italic>maptb</italic>, resulting from the duplication of an ancestral teleost <italic>MAPT</italic> orthologue (Chen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0038">2009</xref>). Interestingly, <italic>mapta</italic> leads to splice variants that have either four or six microtubule‐binding repeats, whereas <italic>maptb</italic> is mainly spliced into a 3R isoform (Chen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0038">2009</xref>). The first tau zebrafish model expressed human 4R tau fused to green fluorescent protein under a neuron‐specific variant of the <italic>gata2</italic> promoter (Tomasiewicz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0235">2002</xref>). The model was characterized by cytoskeletal disruptions and alterations in tau trafficking, with tau accumulating in the cell body (Tomasiewicz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0235">2002</xref>). A subsequent study expressed human 4R tau in zebrafish under the transcriptional control of the <italic>eno2</italic> promoter, reporting a widespread expression of tau throughout the brain, although it was confined to axons and cell bodies (Bai <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0014">2007</xref>).</p>
<p>With no doubt, rodents (mice, <italic>Mus musculus</italic>, or rats, <italic>Rattus norvegicus</italic>) represent the most widely used <italic>in vivo</italic> models of neurodegeneration. The murine tau sequence is 89% identical and 92% similar to that of humans (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0184">2015</xref>). Seminal studies have shown that, as in humans, foetal brains of both mice and rats express the shortest tau isoform, 0N3R, but, unlike humans, the adult rodent brain predominantly expresses 4R tau (Kosik <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0142">1989</xref>; Kampers <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0130">1999</xref>; Liu and Götz <xref ref-type="ref" rid="jnc13600-bib-0166">2013</xref>). Mouse studies have demonstrated the presence of tau compartmentalization in neurons, with a high concentration of tau in axons (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>; Zempel and Mandelkow <xref ref-type="ref" rid="jnc13600-bib-0263">2014</xref>; Xia <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0254">2015</xref>). Moreover, as revealed in murine neurons, there is an additional intraneuronal compartmentalization: 0N isoforms are mainly found in cell bodies and axons and at lower levels in nuclei and dendrites; 1N isoforms are enriched in the soluble nuclear fraction, although they are also found in cell bodies and dendrites, but not axons, and 2N isoforms are highly expressed in axons and in cell bodies, at a lower level in dendrites and with only a very slight expression in nuclei (Liu and Götz <xref ref-type="ref" rid="jnc13600-bib-0166">2013</xref>). Furthermore, murine tau shows a higher degree of polymorphism in the N‐terminal domain in comparison with human tau, whereas the C‐terminal domain and its binding regions are almost identical, except for three amino acid residues (Kampers <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0130">1999</xref>). As in humans, ‘big tau’ isoforms have been found in the peripheral nerves of both mice (Couchie <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0045">1992</xref>) and rats (Boyne <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0024">1995</xref>).</p>
<p>In primary neuronal cultures from rat, blocking tau expression with antisense oligonucleotides suppresses axonal elongation (Caceres and Kosik <xref ref-type="ref" rid="jnc13600-bib-0030">1990</xref>). In 1994, the first tau ko mouse was generated by replacing the first coding exon of tau with a neomycin selection cassette (Harada <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0097">1994</xref>). In these mice, no overt phenotype was encountered, neither <italic>in vivo</italic> nor <italic>in vitro</italic>, possibly because of a compensatory increase in <italic>Map1a</italic> expression (Harada <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0097">1994</xref>). However, when both tau and Map1b were knocked out, this resulted in defects in axonal elongation and neuronal migration (Takei <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0227">2000</xref>). In the following decade, additional tau ko strains were generated by conventional techniques, all of which were phenotypically normal up to 7–8 months of age, generally with a compensatory increase in Map1a around birth that decreased with age (Dawson <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0050">2001</xref>; Tucker <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0238">2001</xref>). Studies of some of these ko strains revealed both behavioural changes and motor deficits with advanced age (Ikegami <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0114">2000</xref>; Lei <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0157">2012</xref>; Ma <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0168">2014</xref>), proving that even when compensatory mechanism were able to maintain normal brain development, they could not substitute for all tau‐specific functions throughout the entire lifespan. Interestingly, the tau ko mice generated by Dawson and colleagues, kept on a C57BL/6/SV129 mixed genetic background, showed reductions in dopaminergic neurons (Lei <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0157">2012</xref>), suggesting that the absence of tau or its dysfunction can act as a neurodegenerative trigger for this particularly sensitive neuronal population (Lannuzel <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0150">2003</xref>; Bodea <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0020">2014</xref>). However, a subsequent study of the same mouse line kept on the original background found normal age‐related cognition and only subtle dopamine‐independent motor deficits (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0183">2013</xref>). Another study found increased levels of Map1a, Map1b and Map2 in 8–9 month‐old tau ko animals, followed by a loss of Map1b and Map2 in 19–20‐month‐old mice (Ma <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0168">2014</xref>). Moreover, at 19–20 months, but not at a young age, these mice presented memory deficits and loss of acetylated α‐tubulin in the hippocampus, together with the loss of excitatory synaptic proteins (Ma <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0168">2014</xref>). Behavioural studies reported increased wakefulness and decreased non‐rapid eye movement sleep time, a higher number of state transitions between non‐rapid eye movement and wakefulness, and shortened sleep bouts, linking tau to the regulation of the sleep‐wake cycle (Cantero <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0033">2010a</xref>). Moreover, electrophysiology revealed anomalies characteristic of dysfunctional neuronal networks in the Dawson tau ko strain, suggesting a role for tau in forming collective neural responses during the generation of the hippocampal theta rhythm, as well as in the formation of functional circuits between the frontal cortex and other brain regions through gamma oscillations (Cantero <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0034">2011</xref>).</p>
<p>Another study using murine tau ko cultures showed impaired neuronal maturation, confirming previous reports (Caceres and Kosik <xref ref-type="ref" rid="jnc13600-bib-0030">1990</xref>), and observed that the phenotype was rescued by expressing human tau (Dawson <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0050">2001</xref>). Using a knock‐in approach, Sennvik and colleagues were able to introduce human 2N4R tau into the endogenous tau locus in mice (Sennvik <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0214">2007</xref>). These mice presented enlarged hippocampi because of increased neurogenesis, mirrored by an improved performance in the novel object recognition task. Primary neuronal cultures from these animals also displayed a delayed maturation, suggesting that human tau is not able to substitute for endogenous tau at early stages of brain development.</p>
<p>To study how tau regulates the attachment or detachment of motors involved in the microtubule‐dependent transport of single molecules, cells were stably transfected with tau constructs containing the microtubule‐binding domain, with or without the projection domain (Trinczek <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0236">1999</xref>). It was found that tau perturbed the balance of the bidirectional motion of vesicles by decreasing the reversal frequency from minus‐end‐ to plus‐end‐directed transport. These observations suggested that tau does not affect motor activity itself, but rather acts as a ‘speed bump’, that halts or diverts transport, and as an inhibitor of motor attachment which preferentially affects kinesin (Trinczek <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0236">1999</xref>). In subsequent studies, even though tau was found to be involved in microtubule assembly, the velocity of axonal transport seemed not to be altered in the tau ko mice generated by Tucker and colleagues compared to wild‐type controls (Yuan <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0259">2008</xref>). However, in an elegant <italic>in vitro</italic> study it was revealed that motor proteins involved in cargo transport are dependent on the presence of a tau concentration gradient (Dixit <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0055">2008</xref>). Thus, at the lower levels of tau, as found in the neuronal cell body and proximal parts of the axon, kinesin efficiently binds to microtubules and initiates anterograde transport of cargos, whereas the release of cargos is facilitated at the distal synapse, where a higher tau concentration is present (Dixit <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0055">2008</xref>). In contrast, dynein‐driven retrograde transport away from the distal axon would not be impeded because of dynein's lower sensitivity to tau (Dixit <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0055">2008</xref>).</p>
<p>Taken together, studies in animal models have led to a better understanding of the structure and function of tau, providing insight into tau‐dependent pathogenesis.</p>
</sec>
<sec id="jnc13600-sec-0005">
<title>Tau‐driven pathological mechanisms</title>
<p>Tau phosphorylation has been implicated in the pathogenesis of FTLD and other tauopathies during the 1980s (Grundke‐Iqbal <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0094">1986</xref>). In the following decade, pathogenic mutations in the <italic>MAPT</italic> gene were discovered in familial cases of FTLD (Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Poorkaj <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0194">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0220">1998b</xref>). These mutations either alter the physical properties of tau or its 3R/4R isoform ratio. Moreover, extracellular factors impact on tau pathology, as is evident in AD, where extracellular amyloid beta (Aβ) deposits trigger intraneuronal tau‐dependent pathological processes (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>). In fact, a significant fraction of the knowledge on tau pathomechanisms is derived from studies in AD models, and it is becoming increasingly clear that tau pathology is highly complex and dynamic. Moreover, even under physiological conditions and in addition to phosphorylation, tau can undergo post‐translational modifications that include ubiquitination, nitration, acetylation, oxidation and others (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0184">2015</xref>). How these post‐translational modifications affect tau function is still incompletely understood.</p>
</sec>
<sec id="jnc13600-sec-0006">
<title>Tau phosphorylation and neurofibrillary tangle formation</title>
<p>Tau phosphorylation is pronounced in the developing brain and reduced in the healthy adult brain (Morishima‐Kawashima <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0181">1995</xref>). However, even though many of its phosphorylation sites that are affected in both tauopathies and relevant animal models are known today (for an exhaustive list, see the online resources of Dr Diane Hanger's laboratory at <ext-link ext-link-type="uri" xlink:href="http://cnr.iop.kcl.ac.uk/hangerlab/tautable/">http://cnr.iop.kcl.ac.uk/hangerlab/tautable/</ext-link>), little is known about the actual role of distinct phosphorylation events under physiological conditions. Initially, it was observed in cell lines that tau phosphorylation leads to its detachment from microtubules (Trinczek <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0236">1999</xref>), which was explained as either leading to the neutralization of the positive charge of the microtubule‐binding domain as shown <italic>in silico</italic> (Jho <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0128">2010</xref>), conformational changes in the same domain following phosphorylation as shown biochemically (Fischer <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0067">2009</xref>), or a combination of both. Besides its obvious role in microtubule dynamics, phosphorylation of tau seems to have additional roles, as revealed in a study in rats and mice, in which tau phosphorylation enabled neurons to escape from acute apoptotic death through the stabilization of β‐catenin (Li <italic>et al</italic>., <xref ref-type="ref" rid="jnc13600-bib-0500">2007</xref>). It is also worth mentioning that, besides neuronal pathology, in both familial and sporadic cases of FTLD‐tau, tau inclusions have also been reported in glia (LoPresti <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0167">1995</xref>; Klein <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0137">2002</xref>; Kovacs <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0145">2008</xref>). Glial tau pathology is prominent and it can be more pronounced than neuronal pathology, a fact that is often overlooked.</p>
<p>It has been hypothesized that tau in its normal phosphorylated state contributes to microtubule recycling or other cellular functions, whereas hyperphosphorylation sequesters tau, leading to conformational changes and ultimately, aggregation (Fig. <xref ref-type="fig" rid="jnc13600-fig-0002">2</xref>). Even though it is acknowledged that hyperphosphorylated tau is found accumulated in deposits (Grundke‐Iqbal <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0094">1986</xref>; Bancher <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0017">1989</xref>), the mechanisms responsible for this tau aggregation are not fully understood. The formation of NFTs is thought to be a gradual process, starting with the oligomerization of non‐bound hyperphosphorylated tau into pretangles, with a change in β‐sheet conformation, building up filaments such as the paired helical filaments (PHFs) and, finally, leading to assembly into NFTs (Ballatore <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0016">2007</xref>). The role that different forms of tau aggregates have in disease has been reviewed recently, indicating that hyperphosphorylated oligomeric tau is involved in synaptic loss, whereas granular tau oligomers seem to be responsible for neuronal loss (Takashima <xref ref-type="ref" rid="jnc13600-bib-0226">2013</xref>). To address this, the development of antibodies that can discriminate these different assemblies is currently in high demand. In addition to PHFs, straight and narrow‐twisted filaments have also been described in tauopathies (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0078">1988</xref>; Wischik <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0251">1988</xref>).</p>
<p>Tau has 45 serine, 35 threonine and 5 tyrosine residues in the longest 2N4R isoform that can be potentially phosphorylated (Goedert <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0079">1989</xref>). It is thought that one reason for the abnormal increase in tau phosphorylation might be an imbalance in the activity or regulation of kinases and phosphatases. Among the kinases, glycogen synthase‐3 (GSK3), cyclin‐dependent kinase 5, the MAPK family composed of p38, extracellular‐regulated kinase and c‐Jun N‐terminal kinase, and microtubule‐affinity regulating kinase (MARK) have been shown to have a role and are considered as candidates for therapy (reviewed in Lee <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0156">2011</xref>; Tell and Hilgeroth <xref ref-type="ref" rid="jnc13600-bib-0232">2013</xref>; Medina and Avila <xref ref-type="ref" rid="jnc13600-bib-0174">2015</xref>). Interestingly, tau phosphorylation pathways seem to be evolutionarily conserved, as revealed by a study of 2N4R human tau over‐expression in <italic>Drosophila</italic>, that described tau hyperphosphorylation via the involvement of the GSK3 homologue shaggy or Sgg (Jackson <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0125">2002</xref>). Generating tau mutants in flies that are resistant to phosphorylation suggested that no specific residue plays a leading role in controlling a tau‐related pathology; rather serine‐/threonine‐proline sites work together towards neurodegeneration (Steinhilb <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0222">2007</xref>). However, in other <italic>Drosophila</italic> studies, the protease‐activated receptor 1, the homologue of MARK, was shown to play an important role in initiating tau phosphorylation (Nishimura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0188">2004</xref>). Moreover, Sgg seems to be more potent than protease‐activated receptor 1 in phosphorylating tau (Chatterjee <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0035">2008</xref>), suggesting the presence of an hierarchy of tau kinases.</p>
<p>Phosphorylation of tau can be decreased by phosphatases, in particular PP2A and PP2B (Gong <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0084">2000</xref>). PP2A is the major brain phosphatase of tau (Gong <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0084">2000</xref>), and reduced PP2A activity was found to cause hyperphosphorylation and compartmentalization of tau in mice (Kins <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0136">2001</xref>). However, therapeutic modulation of PP2A is challenging because of its multimeric structure and the different intracellular signalling pathways in which it has a role (Kamat <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0129">2014</xref>; Medina and Avila <xref ref-type="ref" rid="jnc13600-bib-0174">2015</xref>).</p>
<p>The extent to which NFTs contribute to neuropathology is not fully resolved, and recent findings point towards a neurotoxic role of less studied intermediate forms of hyperphosphorylated oligomeric tau (Iqbal <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0115">2010</xref>; Kumar <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0148">2014</xref>). This is because neuronal loss precedes or is independent of NFT formation (Gómez‐Isla <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0083">1997</xref>), with NFT‐positive neurons being claimed to survive for an extended period of time (Morsch <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0185">1999</xref>). Interestingly, during the hibernation‐wake cycle of the European ground squirrel (<italic>Spermophilus citellus</italic>), the formation of PHF‐like structures, in the absence of NFT formation, is a fully reversible process associated with hippocampal neuronal plasticity (Arendt <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0010">2003</xref>). Hyperphosphorylated tau has been found in several species including the spectacled bear, bison, guanaco, Campbell's guenon, rabbit, reindeer, baboon and rhesus monkey, with the two primate species also displaying NFTs (Härtig <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0100">2000</xref>; Schultz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0211">2000</xref>). However, the more widely used experimental animal models (such as mice and rats) do not show pathological accumulations of tau, even at old age. Nevertheless, models of endogenous tau hyperphosphorylation have been achieved by various techniques, ranging from the use of specific phosphorylation‐inducing chemicals, to the generation of transgenic mice that are characterized by hyperphosphorylated tau aggregates.</p>
<p>Several studies reduced the activity of PP2A chemically, by okadaic acid application (reviewed by Medina <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0175">2013</xref>). In an <italic>in vitro</italic> study, the usage of okadaic acid revealed that tau phosphorylation can actually regulate sequestration of tau within the axon (Li <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0161">2011</xref>). The study explained this observation by the presence of a retrograde barrier mechanism localized at the boundary between the neuronal soma and the axon, at the so‐called axonal initial segment (Li <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0161">2011</xref>). This semi‐permissive barrier allows tau to enter the axon, but prevents it from flowing back into the somato‐dendritic compartment, unless it is phosphorylated at specific sites (Li <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0161">2011</xref>). Human brain slices incubated in the presence of okadaic acid developed PHFs (Harris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0098">1993</xref>), and injection into the sheep cortex induced immunoreactive dystrophic neurites (Nelson and Saper <xref ref-type="ref" rid="jnc13600-bib-0187">1996</xref>). Whereas intracerebral injection in rats induced pathological tau phosphorylation (Gärtner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0072">1998</xref>), intrahippocampal injection led to spatial cognitive deficits and astrogliosis (Costa <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0044">2012</xref>).</p>
<p>Interestingly, alterations in the normal production and/or function of tau can also drive an imbalance in the ratio of normal and hyperphosphorylated forms of tau. This became also evident when the first tau transgenic mouse was generated (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0089">1995</xref>). In this model, the expression of the longest human tau isoform (2N4R) driven by the neuron‐specific promoter mThy1 was able to recapitulate key features of tauopathies, such as the presence of hyperphosphorylated tau mislocalized to neuronal cell bodies and dendrites (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0089">1995</xref>). However, NFTs were not detected. Similar findings were obtained in a more advanced model, ALZ17, where the expression of human 2N4R under the control of the stronger hThy1.2 promoter led to signs of Wallerian degeneration and neurogenic muscle atrophy (Probst <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0196">2000</xref>).</p>
<p>The expression of the shortest form of tau (0N3R), this time under the control of the prion protein promoter (PrP), resulted in an age‐dependent pathology as evident by hyperphosphorylated tau inclusions in the cortex and brain stem, gliosis and a generally more aggressive phenotype in the spinal cord (Ishihara <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0118">1999</xref>, <xref ref-type="ref" rid="jnc13600-bib-0120">2001b</xref>). This model was used by the same group to investigate a possible contribution of neurofilaments to the formation of NFTs by crossing the mice with lines that lack neurofilaments (Ishihara <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0119">2001a</xref>). The resulting cross revealed an attenuated neurodegenerative phenotype in the presence of tau over‐expression, leading to the conclusion that neurofilaments might act as chaperones in the formation of NFTs (Ishihara <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0119">2001a</xref>).</p>
<p>Endogenous murine tau seems to protect from human tau‐induced pathology, suggesting a dominant function of this form of tau in mice. This hypothesis was confirmed by over‐expressing 3R human tau driven by the tubulin‐α1 promoter in the tau ko mice generated by Dawson and colleagues, shifting the accumulation of abnormal tau aggregates into astrocytes and oligodendrocytes, but not neurons, together with a loss of both glial cells and neurons and progressive motor disturbances such as weakness and dystonia (Higuchi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0104">2002</xref>). Although, tau‐related glial pathology has been described in tauopathies such as PSP, CBD and PiD (Feany and Dickson <xref ref-type="ref" rid="jnc13600-bib-0066">1995</xref>; Kovacs <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0145">2008</xref>), what causes cell‐specific accumulation is not known. Generating mice with a P1‐derived artificial chromosome containing the coding sequence, intronic regions and regulatory regions of the human tau gene resulted in the expression of all six human tau isoforms in the mouse brain, in the absence of an overt neuropathology (Duff <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0060">2000</xref>). Interestingly, after breeding these P1‐derived artificial chromosome tau transgenic mice onto a tau ko background, tau hyperphosphorylation and translocation in the somato‐dendritic compartment were achieved as early as 2 months of age (Andorfer <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0009">2003</xref>), resulting in neuronal loss together with ventricle enlargement and reduced cortical thickness (Andorfer <xref ref-type="ref" rid="jnc13600-bib-0008">2005</xref>), memory deficits and perturbed long‐term potentiation at older age (Polydoro <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0193">2009</xref>).</p>
<p>Intraperitoneal injection of mice with recombinant human tau protein led to NFT formation in both neurons and glia, accompanied by clinical symptoms reminiscent of induced experimental autoimmune encephalomyelitis, i.e. neurologic deficits and mononuclear infiltration (Rosenmann <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0202">2006</xref>). However, this particular study focused on the effects of active tau immunization that used complete Freund's adjuvant together with pertussis toxin in the injection mix. In a more recent study addressing the safety profile of clinical trials, an increased encephalitogenic effect of repeated vaccinations with phosphorylated tau was revealed (Rozenstein‐Tsalkovich <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0203">2013</xref>), establishing a possible correlation with the increased neurodegeneration and tau aggregation. Indeed, a neuroinflammatory influence on the development of tauopathy was revealed by Krstic and colleagues using an entirely new approach, which achieved altered tau phosphorylation and mislocalization after intravenous application of virus‐mimicking polyriboinosinic‐polyribocytidilic acid (PolyI:C) either prenatally or into adult mice (Krstic <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0147">2012</xref>). This would suggest that chronic inflammatory conditions could contribute to the development of tauopathy.</p>
<p>Subcortical stereotaxic injections of full‐length human tau in oligomeric, but not fibrillar or monomer form were also found to be neurotoxic, leading to synaptic and mitochondrial dysfunction, neuronal loss and cognitive decline (Lasagna‐Reeves <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0151">2011</xref>). A study in which human 2N4R tau fibrils were injected into C57BL/6 brain revealed that negatively charged extracellular heparan sulphate proteoglycans might be involved in the uptake of fibrils and the initiation of intracellular tau hyperphosphorylation (Holmes <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0107">2013</xref>).</p>
</sec>
<sec id="jnc13600-sec-0007">
<title>MAPT mutations</title>
<p>In addition to the knowledge obtained from studying cases of sporadic FTLD brains and animal models, much about tau physiology and its associated pathology has been derived from observing alterations resulting from <italic>MAPT</italic> gene mutations (for an exhaustive list, see the online resource: <ext-link ext-link-type="uri" xlink:href="http://www.molgen.ua.ac.be/ADMutations/">http://www.molgen.ua.ac.be/ADMutations/</ext-link>). To date, 53 pathogenic <italic>MAPT</italic> mutations have been reported in approximately 150 families (van der Zee and Van <xref ref-type="ref" rid="jnc13600-bib-0262">2014</xref>). Exonic mutations of <italic>MAPT</italic> almost exclusively affect exons 9–13, with only two mutations being found in exon 1. The majority of the intronic mutations are clustered in the intron following exon 10, which encodes part of the microtubule‐binding region. Mutations in this hotspot of alternative mRNA splicing have been shown to lead to an increase in 4R tau translation, modifying the physiological 3R/4R ratio and affecting microtubule dynamics and other cellular functions (Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0220">1998b</xref>).</p>
<p>Based on the identification of pathogenic <italic>MAPT</italic> mutations, novel NFT‐forming models were successfully generated, mostly by introducing P301L, P301S, N279K, V337M or R406W mutations (for a more extensive review of the corresponding mouse strains see Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0093">2011</xref>; Dujardin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0061">2015</xref>; Ballatore <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0016">2007</xref>). Unlike wild‐type tau transgenic animals, most of the models expressing <italic>MAPT</italic> mutations form NFTs within 3–9 months. In 2000, the JNPL3 transgenic strain was generated by expressing the human 0N4R tau isoform bearing the P301L tau mutation under control of the PrP promoter (Lewis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0159">2000</xref>). The P301L mutation has previously been associated with FTLD‐tau presenting with the classic hallmark of tauopathy – intracytoplasmic hyperphosphorylated tau in multiple brain regions, including the hippocampus, neocortex and substantia nigra (Dumanchin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0062">1998</xref>; Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0219">1998a</xref>). The JNPL3 strain represented the first mouse model that expressed a mutant form of tau which led to NFT formation at around 4–5 months of age, and progressed to motor dysfunction, neuronal loss and astrogliosis by 10 months (Lewis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0159">2000</xref>). By expressing the human 2N4R tau isoform bearing the P301L mutation under control of the neuron‐specific promoter mThy1.2, another line, pR5, recapitulated the hallmarks of tauopathy (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0090">2001a</xref>). Unlike the mouse line generated by the same group that expressed wild‐type human 2N4R (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0089">1995</xref>), the pR5 mice developed NFTs (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0090">2001a</xref>). The P301L tau mutation eventually became widely expressed in many tauopathy studies, with similar results recapitulated in other organisms. By expressing this mutant form in <italic>D. rerio</italic>, it was possible to visualize early‐stage tau‐associated pathology, including disease‐specific hyperphosphorylation and conformational changes in tau, as well as neuronal and behavioural abnormalities (Paquet <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0190">2009</xref>). Intriguingly, the larvae developed substantial neurodegeneration within a few days, with a much more rapid progression than observed in the corresponding mouse models (Paquet <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0190">2009</xref>). In <italic>C. elegans</italic>, expressing wild‐type human 1N4R tau together with the P301L or V377M mutation caused progressive uncoordinated locomotion indicative of neuronal dysfunction, as well as hyperphosphorylated tau and neuronal loss enhanced by the presence of mutant tau (Kraemer <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0146">2003</xref>). Interestingly, the uncoordinated locomotion phenotype preceded the peak in tau hyperphosphorylation and neuronal loss, being caused by a pre‐synaptic defect (Kraemer <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0146">2003</xref>). This supports the hypothesis of a more powerful neurotoxic effect of oligomeric tau that could affect axonal transport leading to pre‐synaptic pathological alterations. A more aggressive phenotype was observed in a mouse line expressing P301L mutant human 0N4R tau in the forebrain under the control of a tetracycline‐inducible CamKII‐tTA promoter (Santacruz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0207">2005</xref>). Analysis of this model revealed NFT formation that was directly dependent on the level of tau expression, with the highest levels found in the Tg4510 mouse line that presented a 13‐fold level of transgenic tau expression compared with endogenous tau (Santacruz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0207">2005</xref>). The mice displayed mature NFTs starting as early as 2.5 months of age and behavioural alterations were recovered after doxycycline‐induced suppression of transgene expression, even though, surprisingly, NFTs continued to accumulate, suggesting a tau‐associated toxic effect independent of NFT formation (Santacruz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0207">2005</xref>).</p>
<p>The amino acid residue mutated in tau seems to dictate disease severity, onset and duration. This was observed by comparing human brains with the less severe P301L tau mutation with those carrying the P301S mutation (Sperfeld <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0217">1999</xref>; Allen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0003">2002</xref>). The mouse models expressing P301S were generated to either express human 1N4R tau in the so‐called PS19 model (Yoshiyama <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0258">2007</xref>) or 0N4R tau (Allen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0003">2002</xref>), the latter model presenting an enhanced NFT pathology when compared with the P301L‐expressing models generated earlier (Lewis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0159">2000</xref>; Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0090">2001a</xref>). Although both models are characterized by insoluble tau aggregates, neuronal loss and motor and cognitive deficits, they present with different pathological onsets, with the PS19 line being more severe, most likely because of PrP‐promoter‐mediated higher levels of expression (Allen <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0003">2002</xref>; Yoshiyama <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0258">2007</xref>; Scattoni <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0210">2010</xref>; Takeuchi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0228">2011</xref>).</p>
<p>Confirming the dominant function of tau, pan‐neuronal expression of wild‐type human tau or tau variants carrying the FTLD‐associated mutation R406W were found to cause retinal degeneration in <italic>Drosophila</italic>, with the mutant forms enhancing the severity of the effects (Wittmann <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0252">2001</xref>). In mice expressing R406W on a human 2N4R tau backbone (RW mouse line), widespread insoluble filamentous tau aggregates were found in neuronal perikarya within the cerebral cortex, hippocampus, cerebellum and spinal cord, correlating with impaired axonal transport (Zhang <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0264">2004</xref>). Interestingly, however, even though the RW mice were expressing mutant tau driven by the mouse PrP promoter and expression levels were 8–10 times higher than endogenous tau, pathology was only initiated at 12 months of age (Zhang <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0264">2004</xref>). An even more delayed pathology was described in another mouse model of R406W expression under the CamKII promoter, in which hyperphosphorylated tau deposits were only observed at 18 months of age (Tatebayashi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0231">2002</xref>). However, in a mouse model expressing the human R406W mutation, but driven by the Syrian hamster PrP promoter and expressing tau levels equivalent to the endogenous one, the age of hippocampal lesions onset was 6 months (Ikeda <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0113">2005</xref>). In addition, micro‐ and astrogliosis was reported at 10 months, suggesting the possibility of a strain‐related effect resulting in a different age of pathological onset. Intriguingly, an <italic>in vitro</italic> study suggested that the effect of the R406W mutation is not because of the impaired binding of tau to microtubules, but is rather caused by impaired membrane binding, which involves a functional interaction with annexin A2 as a membrane–cytoskeleton linker (Gauthier‐Kemper <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0073">2011</xref>).</p>
<p>Another FTLD‐related mutation, V337M (Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0219">1998a</xref>), was introduced into the human 2N4R tau backbone and expressed in mice under control of the platelet‐derived growth factor β‐chain promoter (Tanemura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0230">2001</xref>). The resulting Tg214 mouse line expressed the transgene at ten times lower levels than endogenous tau, but NFTs still developed by 11 months of age (Tanemura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0230">2001</xref>). The FTLD‐related G272V mutant tau (Hutton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0111">1998</xref>; Spillantini <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0219">1998a</xref>) was also introduced into mice under the PrP‐driven transactivator, leading to accumulation of filamentous tau in oligodendrocytes (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0092">2001c</xref>).</p>
<p>Tau accumulation in glial cells has been reported in many tauopathies, such as PSP, CBD, PiD or FTDP‐17 with <italic>MAPT</italic> mutations (Kouri <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0144">2011</xref>; Spillantini and Goedert <xref ref-type="ref" rid="jnc13600-bib-0218">2013</xref>; Yoshida <xref ref-type="ref" rid="jnc13600-bib-0257">2014</xref>; Irwin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0116">2015</xref>), or is even as specific marker in the case of globular glial tauopathies (Ahmed <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0001">2013</xref>). However, modelling of these diseases was achieved only in a handful of studies. Specific expression of P301L mutant 1N4R human tau in murine oligodendrocytes was achieved using the 2′,3′‐cyclic nucleotide 3′‐phosphodiesterase promoter, leading to structural disruption of myelin and axons that preceded the emergence of tau inclusions in oligodendrocytes (Higuchi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0105">2005</xref>). By using the glial fibrillary acidic protein promoter, P301L 1N4R human tau was specifically expressed in mouse astrocytes, resulting in an age‐dependent accumulation of tau inclusions, accompanied by compromised motor functions correlating with an altered expression of the glial glutamate‐aspartate transporter before development of tau pathology (Dabir <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0048">2006</xref>).</p>
<p>Many additional transgenic models carrying FTLD mutations in <italic>MAPT</italic> have been generated (for an extensive review see Götz and Ittner <xref ref-type="ref" rid="jnc13600-bib-0088">2008</xref>; Dujardin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0061">2015</xref>; Ballatore <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0016">2007</xref>). By combining mutations, it was possible to obtain an enhanced pathology and/or a decreased age of onset of pathology, as in the case of a P301L/G272V/R406W triple mutation introduced into the 2N4R tau backbone under the Thy1 promoter that led to tau pathology as early as 1.5 months of age together with aberrant lysosomal morphology (Lim <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0164">2001</xref>). In another approach, P301L tau transgenic mice were crossed with a PP2A dominant negative strain, resulting in double‐mutant mice with an accelerated NFT pathology, thereby proving the possibility of genetically modulating tau phosphorylation (Deters <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0053">2009</xref>). Advanced AD models have also provided tools to study the complex interaction or involvement of tau in other pathologies. For example the JNPL3 tau mouse line, when crossed with the Tg2576 mouse line that expresses the human amyloid precursor protein gene together with the so‐called Swedish mutation found in familial cases of AD (APP<sup>sw</sup> mouse line), developed an enhanced neurofibrillary degeneration, demonstrating a cross‐talk of tau and Aβ in neurodegeneration (Lewis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0160">2001</xref>). Moreover, by injecting preparations of the Aβ peptide into brains of pR5 mice, the downstream position of tau in a pathological cascade of AD development was revealed (Götz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0091">2001b</xref>). APP<sub>OSK</sub>‐Tg mice, which carry the E693Δ (Osaka) mutation in <italic>APP</italic> and accumulate Aβ oligomers without forming plaques, exhibited tau hyperphosphorylation at 8 months, but failed to develop NFTs even at 24 months of age (Umeda <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0240">2014</xref>). The same study reported an accelerated NFT formation at 18 months, by cross‐breeding the mice with a second tau mouse line, tau 264, that expressed human tau at low levels and in the absence of any pathology (Umeda <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0239">2013</xref>). Moreover, synapse loss and memory impairment were accelerated in the newly generated line, suggesting that the presence of tau in its human form is critical for NFT formation (Umeda <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0240">2014</xref>)<bold>.</bold> Interestingly, breeding APP mutant APP23 mice with P301L tau mutant mice led to accelerated mortality in offsprings, possibly because of increased excitotoxicity (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>). The 3xTg‐AD model was generated by combining three mutations, APP<sup>swe</sup>, P301L tau and the M146V mutation in the <italic>PSEN1</italic> gene (that encodes a component of the γ‐secretase complex involved in APP processing), with the resulting mouse model closely recapitulating human AD pathology by forming both Aβ plaques and NFTs (Oddo <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0189">2003</xref>; Rhein <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0199">2009</xref>).</p>
<p>In another line of research, human tau was delivered to mice using viral vectors. When adeno‐associated viral vectors (AAVs) of serotype 1/2 encoding human 2N4R tau were applied diffusely into the hippocampus of wild‐type mice, a dramatic degeneration of pyramidal neurons of the hippocampal CA1/2 region and the cortex was obtained within weeks, in the absence of NFT formation (Jaworski <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0127">2009</xref>). In contrast, injection of serotype 2 AAVs encoding the P301L form of 2N4R tau into Sprague–Dawley rats induced NFT formation 4 months after the injection (Klein <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0138">2004</xref>).</p>
<p>Taken together, these investigations produced different and, at times, even contradictory results, which might be explained by the limitation inherent to each model. However, the transgenic models support the notion that FTLD‐related mutations of <italic>MAPT</italic> enhance tau phosphorylation and cause tau aggregation leading to impaired memory functions and neurodegeneration.</p>
</sec>
<sec id="jnc13600-sec-0008">
<title>Other post‐translational modifications of tau</title>
<p>The majority of studies on post‐translational modifications of tau have focused on phosphorylation. However, there are also additional post‐translational modifications of tau that can induce misfolding and subsequent aggregation, thereby affecting normal cellular physiology.</p>
<p>O‐glycosylation has been described as a major form of post‐translational modification that is highly dynamic and responsive to cellular stimuli in a fashion similar to phosphorylation. It is characterized by the addition of an O‐GlcNAc residue on serines or threonines in the proximity of proline residues (Haltiwanger <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0095">1992</xref>; Varki <xref ref-type="ref" rid="jnc13600-bib-0242">2007</xref>). Given that tau is highly enriched in these amino acid residues, it was expected that it would also be found in an O‐GlcNAc form (Arnold <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0011">1996</xref>), and moreover, that O‐GlcNAcylation might modulate tau function and play a role in its subcellular localization and degradation (Arnold <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0011">1996</xref>). However, more recently, this hypothesis was challenged, as it was found that the number of O‐GlcNAc sites on tau might actually be reduced to just three in the rat brain: T123, S400 and a third which might be either S409, S412 or S413 (Yuzwa <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0260">2011</xref>). Another study of rat tau reduced this number even further, identifying only S400 of tau as being O‐GlcNAc‐modified (Wang <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0244">2010</xref>). This result was subsequently confirmed in mice, although only wild‐type animals were assessed (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0184">2015</xref>). Increasing the level of O‐GlcNAc tau, by using OGAse inhibitors in JNPL3 hemizygous mice, resulted in a decrease in tau aggregates and neuronal loss, in the absence of alterations in tau phosphorylation, indicating that phosphorylation and O‐GlcNAcylation might not be linked (Yuzwa <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0261">2012</xref>). More recently, interaction of the O‐GlcNAc form of tau with β‐catenin was revealed using a FLIM/FRET‐based imaging approach (Lin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0165">2015</xref>).</p>
<p>Glycation, also known as ‘non‐enzymatic glycosylation’ or ‘Maillard reaction’, is a process by which sugar molecules are covalently bound to proteins or lipids in a slow process of rearrangements and additions that initially form early glycation adducts, followed by advanced glycation end (AGE) products that are irreversibly modified and tend to aggregate. Tau can suffer glycation reactions in the microtubule‐binding site, which then induces oxidative stress (Ledesma <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0152">1995</xref>). Interestingly, many molecules implicated in AD are associated with or sensitive to binding AGE products (reviewed in Li <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0162">2012a</xref>) and these products were shown to induce tau hyperphosphorylation, resulting in impairments in synapse function and memory in rats (Li <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0163">2012b</xref>).</p>
<p>Ubiquitination, acetylation and methylation are enzyme‐mediated processes. Ubiquitination tags proteins by the addition of ubiquitin, whereas acetylation and methylation are processes by which an acetyl or methyl group, respectively, are transferred from one molecule to another. Thus, the modified proteins become equipped with a signal‐code for protein interaction and an altered intracellular localization, as well as degradation. All these modifications have been identified in tau aggregates obtained from diseased or transgenic brains (Cripps <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0046">2006</xref>; Min <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0178">2010</xref>; Funk <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0071">2014</xref>) and, interestingly, they share a common set of lysine residues concentrated mostly around the microtubule‐binding domains (Morris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0184">2015</xref>), leading to the idea that there is a competitive cross‐talk between these modifications (Yang and Seto <xref ref-type="ref" rid="jnc13600-bib-0256">2008</xref>).</p>
<p>Sumoylation is a process that tags proteins with small ubiquitin‐related modifiers, in a process similar to ubiquitination, but without ending in protein degradation. Sumoylation regulates various functional properties of many proteins, including tau. An <italic>in vitro</italic> study suggested that free tau is more accessible to sumoylation (Dorval and Fraser <xref ref-type="ref" rid="jnc13600-bib-0057">2006</xref>). Although in Tg2576 mice small ubiquitin‐related modifiers and tau colocalize (Takahashi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0225">2008</xref>), tau lesions in affected human brains show low levels of sumoylated tau (Pountney <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0195">2003</xref>), perhaps resulting from proteasome failure and increased tau ubiquitination (Dorval and Fraser <xref ref-type="ref" rid="jnc13600-bib-0057">2006</xref>).</p>
<p>Oxidative stress can contribute to tauopathy as revealed by studies of pathological tau modifications caused by the formation of intermolecular bridges between cysteine residues (Schweers <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0212">1995</xref>) or by nitration of tyrosines (Reyes <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0198">2012</xref>). Moreover, reactive oxygen species (ROS) are highly reactive molecules that are intracellularly produced even under physiological conditions, by specialized organelles such as mitochondria, peroxisomes or the endoplasmic reticulum. Oxidative stress markers, together with ROS production, are acknowledged as signs of a possible evolution of tauopathy in both humans and animal models (Alavi Naini and Soussi‐Yanicostas <xref ref-type="ref" rid="jnc13600-bib-0002">2015</xref>). Although tyrosine nitration has been observed in AD‐, CBD‐ and PiD‐affected brains (Horiguchi <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0109">2003</xref>), the mechanisms that generate nitrated tau are still debated. In older studies, it was suggested that tau nitration is a random process resulting from the generation of free radicals during neurodegeneration (Ischiropoulos and Al‐Mehdi <xref ref-type="ref" rid="jnc13600-bib-0117">1995</xref>), whereas more recently, tau nitration was suggested to be a highly regulated, lesion‐specific process (Reyes <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0198">2012</xref>).</p>
<p>It is not entirely clear whether these alterations in tau structure represent an upstream event in tau pathology, whether tau is able to induce certain pathological cascades on its own, or whether a combination of both occurs. For example there might be a feedback loop by which pathological tau interferes with mitochondrial function and induces oxidative stress, which in turn pathologically alters tau structure (Alavi Naini and Soussi‐Yanicostas <xref ref-type="ref" rid="jnc13600-bib-0002">2015</xref>).</p>
</sec>
<sec id="jnc13600-sec-0009">
<title>Cell cycle and epigenetics in tauopathies</title>
<p>Aberrant cell cycle activation in neurons has been reported in both tauopathies and animal models, providing a possible explanation for the generally late onset of neurodegenerative diseases (Herrup and Yang <xref ref-type="ref" rid="jnc13600-bib-0103">2007</xref>). In aged mice expressing wild‐type 2N4R human tau in the absence of mouse tau, re‐expression of cell‐cycle regulatory proteins and DNA synthesis was induced, demonstrating that wild‐type tau pathology and neurodegeneration may be linked via abnormal, incomplete cell‐cycle re‐entry (Andorfer <xref ref-type="ref" rid="jnc13600-bib-0008">2005</xref>). In a <italic>Drosophila</italic> tauopathy study, a neuroprotective role because of the induction of DNA damage checkpoint molecules has been suggested (Khurana <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0133">2012</xref>). Based on serial analysis of gene expression of amygdala samples from pR5 mice, 29 differentially enriched transcripts were identified, including <italic>Sfpq</italic> that encodes a nuclear factor implicated in the splicing and regulation of gene expression (Ke <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0132">2012</xref>). Furthermore, by analysing human AD and PiD brain samples, translocation of splicing factor proline/glutamine‐rich from the nucleus to the cytoplasm was observed in neurons and astrocytes, highlighting nucleo‐cytoplasmic redistribution of transcription factors as a pathomechanism in tauopathies (Ke <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0132">2012</xref>). Tau‐related chromatin relaxation was observed in a study encompassing human R406W tau <italic>Drosophila</italic> and JNPL3 mouse models of tauopathy, as well as AD brain samples (Frost <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0069">2014</xref>). Interestingly, in the <italic>Drosophila</italic> model, genetic manipulation of the genes related to heterochromatin reorganization resulted in a phenotypic rescue. These studies suggest a tauopathy‐related induction of gene expression of molecules implicated in neuronal dedifferentiation and re‐entry into a non‐appropriate cell cycle, correlated with chromatin restructuring and aberrant translocation of nuclear factors, which together leads to neurodegeneration and cellular loss.</p>
</sec>
<sec id="jnc13600-sec-0010">
<title>Role of tau in dendritic spines and synaptic impairment</title>
<p>Studies into how Aβ induces synaptic dysfunction have helped to understand how tau impairs synaptic function on its own. This is because how Aβ interacts with tau in causing synaptic dysfunction is, to some degree, understood although there are still major gaps to be filled (Tu <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0237">2014</xref>). Aβ has been found to interact in its oligomeric and possibly fibrillar form with various synaptic and extra‐synaptic receptors, thereby triggering a series of toxic events. Specifically the activation of the N‐methyl‐D‐aspartate (NMDA) receptor, both directly and indirectly, together with increased calcium influx, has several downstream consequences, including hyperphosphorylation of tau and depolymerization of F‐actin, which ultimately results in synaptic dysfunction and cognitive impairment (Tu <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0237">2014</xref>). Tau has a critical role in mediating the toxicity of Aβ in the synapse (Roberson <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0200">2007</xref>; Vossel <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0243">2010</xref>; Leroy <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0158">2012</xref>). More specifically, it has been found that tau is required to target the Src kinase Fyn to the post‐synapse, where it phosphorylates NMDA receptor subunits which then recruit the adaptor protein PSD‐95 to facilitate the formation of an excitotoxic protein complex (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>). Furthermore, using hippocampal slice cultures, it was found that chemically inducing long‐term depression activated the NMDA receptor, together with reversible tau phosphorylation at several pathological epitopes (Mondragón‐Rodríguez <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0179">2012</xref>).</p>
<p>Tau‐dependent synaptic dysfunction involves Fyn kinase (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>). This kinase contains an amino‐terminal Src‐homology (SH) region with acylation sites, a unique domain, an SH3 domain (with which it interacts with the PXXP motifs found in the proline‐rich region of tau) (Fig. <xref ref-type="fig" rid="jnc13600-fig-0001">1</xref>b), an SH2 domain (with which it interacts with tau phosphorylated at residue Y18), an SH1/kinase domain and a carboxy‐terminal regulatory tail (Brandt <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0026">1995</xref>; Lee <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0154">1998</xref>). It has been shown that pseudophosphorylated tau binds Fyn more tightly than wild‐type tau, thereby increasing Fyn activity and synaptic damage (Bhaskar <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0018">2005</xref>). Using real‐time surface plasmon resonance studies, it was further found that the interaction between the SH3 domain of Fyn and 3R‐tau was 20‐fold higher than that with 4R‐tau, and that the affinity between 4R‐tau and Fyn SH3 was 25–45‐fold increased in the presence of P301L tau (Bhaskar <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0018">2005</xref>).</p>
<p>In V337M mutant mice, mutant tau depleted PSD‐95, which resulted in smaller post‐synaptic densities, impaired synaptic localization of NMDA receptors, and reduced firing of striatal neuron (Warmus <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0245">2014</xref>). The NMDA receptor hypofunction contrasts with the hyperfunction and excitotoxicity caused by Aβ. In this context, a recent review discusses the possibility of sequential activation of Fyn, followed by its inactivating phosphatase, striatal‐enriched protein tyrosine phosphatase, in the regulation of the NMDA receptor, synaptic plasticity and the induction of synaptic depression, suggesting hyperfunction followed by hypofunction (Boehm <xref ref-type="ref" rid="jnc13600-bib-0021">2013</xref>).</p>
<p>It is also important to highlight again that, although tau is conventionally perceived as an axonal protein, it is found in the dendrite, albeit at lower levels, and, to an even lesser extent, in dendritic spines (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0122">2010</xref>). The latter are present on pyramidal neurons where they represent the main post‐synaptic elements of cortical excitatory synapses. Spine localization is massively augmented by the presence of pathogenic tau mutations such as P301L, as well as when tau is pseudophosphorylated, whereas replacing critical phosphorylation sites with alanine abrogates spine localization (Hoover <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0108">2010</xref>; Xia <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0254">2015</xref>). When full‐length tau containing up to 20 phosphate residues (i.e. being more phosphorylated than tau in human FTLD‐tau brains) was generated in Sf9 cells and then purified, it readily formed oligomers, whereas fibrils were only rarely observed. Exposure of primary neurons to these tau preparations caused a reduction in spine density without affecting overall cell viability (Tepper <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0233">2014</xref>).</p>
<p>Increased concentrations of phosphorylated tau produce a range of effects on synapses. These include the induction of synaptic dysfunction by impairing the surface expression of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors as well as a reduction in synaptic transmission (Hoover <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0108">2010</xref>). Consistent with these findings, tau deletion or inhibition of tau hyperphosphorylation using a GSK‐3β inhibitor can prevent Aβ‐induced impairment of long‐term potentiation, a long‐lasting strengthening of the response of a post‐synaptic neuron to stimulation that occurs with repeated stimulation and has been linked to learning and long‐term memory (Shipton <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0216">2011</xref>). The inducible Tg4510 mouse model expressing P301L tau was used to examine the effects of tau pathology on hippocampal glutamate regulation (Hunsberger <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0110">2015</xref>). This study reported a 40% increase in hippocampal vesicular glutamate transporters which package glutamate into vesicles, and a 40% decrease in hippocampal glutamate transporter 1, the major transporter responsible for removing glutamate from the extracellular space. P301L tau expression resulted in an up to 7‐fold increase in potassium‐evoked glutamate release in the hippocampus and a significantly decreased glutamate clearance, correlated with memory impairments, suggesting a mechanism by which tau might mediate hyperexcitability (Hunsberger <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0110">2015</xref>).</p>
<p>To clarify the relationship between tau aggregation and the loss of synapses and neurons, two lines of mice expressing human tau with or without P301L mutation were compared (Kimura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0135">2010</xref>). Interestingly, P301L tau transgenic mice exhibited neuronal loss and produced insoluble tau with advanced age but not synaptic loss or memory impairment. In contrast, wild‐type tau‐expressing mice neither exhibited neuronal loss nor produced insoluble tau but did exhibit synaptic loss and memory impairment. Moreover, P301L tau was less phosphorylated than wild‐type human tau, suggesting that tau phosphorylation is involved in synaptic loss, whereas tau aggregation is more involved in neuronal loss (Kimura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0135">2010</xref>).</p>
<p>Tau localization to spines has further been found to depend on neuronal activity, implying that tau serves a physiological function in spines, and that disease processes that impact on its spine localization will cause an impairment in synaptic function (Frandemiche <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0068">2014</xref>). In the context of AD, exposing cortical cultures to synthetic preparations of Aβ oligomers was found to induce mislocalization of tau into spines under resting conditions, abrogating subsequent activity‐dependent synaptic tau translocation (Frandemiche <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0068">2014</xref>). In another study, P301L mutant tau expression was targeted predominantly to layer II and III neurons of the entorhinal cortex, leading to ultrastructural synaptic alterations in hippocampal circuits, in the absence of robust cognitive deficits (Harris <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0099">2012</xref>).</p>
<p>The role of Aβ in synapse loss is reasonably well established, but despite data linking tau to synaptic function, the latter's role in synapse loss remains largely undetermined. To address age‐dependent synaptic loss and dysfunction in P301L tau‐over‐expressing rTg4510 mice, multiphoton <italic>in vivo</italic> imaging was used to reveal an approximately 30% loss of apical dendritic spines in individual pyramidal neurons, suggesting selective vulnerability to tau‐induced degeneration. The data further indicated that the tau‐induced loss of a subset of synapses may be accompanied by compensatory increases in other synaptic subtypes, thereby preserving overall synapse density. Synaptosomal fractionation showed a significant decrease in the expression of several synaptic proteins, suggesting a functional deficit of the remaining synapses in the rTg4510 brain (Kopeikina <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0140">2013</xref>). What dictates the underlying selective vulnerability is not understood.</p>
<p>Based on the reconstruction of almost 20 000 dendritic spines in fixed hippocampal tissue from AD patients by intracellular injections of Lucifer yellow and staining with specific anti‐tau phosphorylated antibodies, it was revealed that the diffuse accumulation of phosphorylated tau in a putative pre‐NFT state did not induce changes in the dendrites of pyramidal neurons, whereas the presence of tau aggregates forming intraneuronal NFTs was associated with progressive loss of dendritic spines and changes in their morphology (Merino‐Serrais <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0176">2013</xref>). Although these findings differ from those of the P301L mouse study discussed above (Kimura <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0135">2010</xref>), they have obvious implications for therapeutic interventions.</p>
<p>Connectivity changes induced by pathological tau have also been reported. The stratum lacunosum moleculare is a structure that serves as a connection hub between the entorhinal cortex and hippocampus, two brain regions that are particularly vulnerable in AD. A detailed structural study in P301L mutant mice revealed an impaired functional and structural organization of the entorhinal‐hippocampal complex, in particular of the synapses and myelinated axons in the stratum lacunosum moleculare, with the authors concluding that white matter pathology deserves further attention in tauopathy (Maurin <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0172">2014</xref>). It is also known that sleep disturbances are frequent in AD. When 3xTg mice were subjected to sleep deprivation, there was a significant increase in the insoluble fraction of tau, and a reduction in PSD‐95 (Di <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0054">2014</xref>). To the best of our knowledge, whether such changes are also found in pure tauopathy models has not been reported. Synaptic changes have not been extensively addressed in invertebrate models. A recent study in <italic>Drosophila</italic> expressing R406W tau identified 62 genes that, when silenced by RNAi, specifically modified tau‐induced toxicity. Among these were three subunits of the dynein/dynactin motor complex. In the course of a phenotypic analysis, owing to strong pathological changes in the axon, but not the synapse, the authors concluded that tau‐induced detrimental effects have an axonal rather than synaptic origin (Butzlaff <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0029">2015</xref>).</p>
<p>Finally, the fact that homeostasis of tau levels is critical for neuronal functions is not only evident from FTLD‐tau cases, where an altered ratio of tau isoforms can cause neurodegeneration and cognitive decline, but also from the analysis of the <italic>MAPT</italic> locus for which microdeletions have been reported that may have a role in intellectual disability. Interestingly, by reducing tau levels in mice neuronal development or migration was inhibited (Caceres and Kosik <xref ref-type="ref" rid="jnc13600-bib-0030">1990</xref>; Takei <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0227">2000</xref>). In support, a more recent study observed that in the early postnatal brain, a number of neurons with reduced tau levels that reached the cortical plate exhibited underdeveloped dendrites and a striking reduction in connectivity as evidenced by the size of their boutons (Sapir <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0209">2012</xref>). The authors concluded that <italic>MAPT</italic> may be a dosage‐sensitive gene involved in intellectual disability. Together, these findings indicate that tau has a role in the synapse and that the accumulation of hyperphosphorylated forms of tau, particularly in the spine, causes functional impairments and synaptic degeneration.</p>
</sec>
<sec id="jnc13600-sec-0011">
<title>Spreading of tau pathology</title>
<p>Tau aggregates appear to spread along neuronal pathways from one brain region to another. This aspect has been characterized extensively in AD, where tau accumulation is initiated in the locus coeruleus of the brainstem, before appearing in transentorhinal and entorhinal regions of the temporal lobe, followed by inclusions in the hippocampus and parts of the neocortex and, in the most severe cases, affecting almost the entire neocortex (reviewed in (Braak and Tredici <xref ref-type="ref" rid="jnc13600-bib-0025">2011</xref>; Brettschneider <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0027">2015</xref>). However, in FTLD‐tau, the aspect of this apparent tau spreading is less well characterized. A study focussing on the dynamics of tau deposition in PSP reported an initial pallido‐luyso‐nigral stage of tau deposition, progressing to a gradually increasing involvement of the basal ganglia, the pontine and dentate nuclei, and the frontal and parietal lobe (Williams <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0250">2007</xref>). In AGD, on the other hand, the initial sites of deposition were found to be the ambient gyrus, the CA1 region of the hippocampus and the basolateral nucleus of the amygdala, then the entire amygdala, along with the involvement of the posterior transentorhinal cortex and the subiculum, and the anterior medial temporal lobe, whereas in the final stage of the disease, argyrophilic grains are also found in the insular cortex, the anterior cingulate gyrus, the nucleus accumbens, the septal nucleus, the hypothalamus and the gyri recti beyond the boundary of the temporal lobe (Saito <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0204">2004</xref>). These data point towards a high level of heterogeneity in tau spreading. This difference in the pattern of spreading between AD and FTLD or even within FTLD‐tau may be explained by different triggers of the tau pathology. Moreover, it seems that AD requires abundant tau inclusions as well as Aβ deposits in the neocortex to trigger the disease clinically, whereas initial tau deposition appears to be insufficient for disease development (Jack <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0124">2013</xref>; Duyckaerts <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0063">2015</xref>). Overlapping the models of a gradual distribution with the connectivity maps of the brain led to the formulation of different spreading hypotheses, the most appealing of which is currently a ‘prion‐like model of propagation’ (Sanders <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0206">2014</xref>; Goedert <xref ref-type="ref" rid="jnc13600-bib-0076">2015</xref>). However, this model has been contested or at least modified in a recent study (Wegmann <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0246">2015</xref>, commented further by Polanco and Götz <xref ref-type="ref" rid="jnc13600-bib-0192">2015</xref>). Tau aggregation has been described as a heterogeneous nucleation reaction, whereby exogenous effectors, tau gene mutations or other modifications that stabilize assembly competent conformations of tau act to trigger the fibrillization reaction (Kuret <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0149">2005</xref>). This concept has been strengthened by both <italic>in vitro</italic> and <italic>in vivo</italic> studies that used chemicals to induce tau phosphorylation and aggregation, such as in the case of okadaic acid mentioned earlier. In this regard, a recent study proposed the use of microfluidic chambers to study the spread of okadaic acid‐triggered tau phosphorylation in primary cultures containing healthy and diseased neurons (Kunze <italic>et al</italic>., <xref ref-type="ref" rid="jnc13600-bib-1048">2011</xref>). However, the mechanisms leading to progressive tau phosphorylation remain elusive.</p>
<p>By injecting brain lysates from transgenic NFT‐forming P301S mice into pre‐symptomatic ALZ17 mice, filamentous and hyperphosphorylated tau species were detected at the injection site and in closely connected regions 6 months after injection, suggesting transmissibility of tau pathology (Clavaguera <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0041">2009</xref>). This contributed to the application of the prion hypothesis to tau, in which pathologically altered tau protein strains recruit native tau, converting it into pathological species. To verify this hypothesis, human brain lysates from various human tauopathies were injected into ALZ17 brains, resulting in brain lesions, including NFTs, argyrophilic grains and Pick bodies using samples originating from AD, AGD and PiD cases respectively (Clavaguera <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0042">2013</xref>). To understand which molecular species are responsible for the induction of tau phosphorylation, recombinant fibrils were injected into wild‐type mouse brains, revealing that only aggregated tau is capable of recruiting endogenous tau in a process mediated by extracellular heparin sulphate (Holmes <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0107">2013</xref>). In another study, injection of recombinant tau fibrils into PS19 mice decreased the onset of NFT formation, suggesting that preformed synthetic fibrils are capable of inducing NFT‐like tau aggregates and initiating the spread of tau pathology (Iba <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0112">2013</xref>). Intriguingly, increased tau phosphorylation was also detected after intraperitoneal application of lysates from transgenic P301S mice into heterozygous mice of the same line (Clavaguera <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0043">2014</xref>).</p>
<p>However, it is not yet entirely understood what induces a self‐feeding mechanism of propagation, or whether there is another mechanism that responds to the injection of a mixture of not fully characterized foreign material into the brain. In support of this, two papers have highlighted a potential involvement of microglia in enhancing tau pathology and spreading of pathological tau in the brain, even though the mechanistic picture in not entirely clear. The first of these is based on the observation that mice lacking the microglial fractalkine receptor (Cx3cr1) crossed with those over‐expressing human 2N4R tau (Andorfer <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0009">2003</xref>) present tau hyperphosphorylation and aggregation as early as 2 months of age, together with the spread of tau pathology to anatomically connected regions within the hippocampus (Maphis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0171">2015</xref>). Moreover, adoptive transfer of purified microglia from hTau/Cx3cr1<sup>−/−</sup> mice induced tau hyperphosphorylation in non‐transgenic animals (Maphis <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0171">2015</xref>). In another study, tau propagation was halted when microglia were depleted from the brain, suggesting their involvement in tau propagation supposedly mediated by exosome secretion (Asai <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0012">2015</xref>). Recently, however, the prion model of tau spreading was contested or at least modified in a study that showed that pathological tau can propagate across neural systems in the absence of a templated misfolding and that the absence of endogenous tau greatly decreases its toxicity (Wegmann <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0246">2015</xref>).</p>
</sec>
<sec id="jnc13600-sec-0012">
<title>Other tau‐related cellular dysfunctions</title>
<p>Steric hindrance of molecular function as well as possible organelle trapping because of sequestration of tau into the cytosolic pool have been hypothesized as factors that affect normal cellular function. In the 1970s, it was observed that tau contributes to microtubule stabilization (Weingarten <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0248">1975</xref>), and it was shown subsequently that hyperphosphorylated tau sequesters normal tau into NFTs, thereby leading to microtubule disassembly (Alonso <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0004">1996</xref>). Increased levels of unbound tau can also contribute to neuronal dysfunction even prior to the formation of detectable levels of tau deposits as shown in the Tg4510 mouse model (Santacruz <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0207">2005</xref>).</p>
<p>It has been demonstrated that tau can interact with actin at a physiological pH, inducing actin filament bundles by interactions mediated by the microtubule‐binding domains (Moraga <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0180">1993</xref>), or via its proline‐rich domain (He <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0101">2009</xref>). An <italic>in vitro</italic> study revealed that over‐expression of different forms of tau can inhibit the plus‐end‐directed transport of vesicles along microtubules by kinesin such that the minus‐end‐directed transport by dynein becomes more dominant (Ebneth <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0064">1998</xref>). As a consequence, exocytosis slows down and affects the distribution of mitochondria which become clustered near the microtubule‐organizing centre (Ebneth <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0064">1998</xref>).</p>
<p>In <italic>Drosophila</italic>, R406W tau‐mediated actin stabilization inhibits the association of the fission protein dynamin‐related 1 with mitochondria, causing a shift in mitochondrial dynamics towards elongation and production of ROS, with some of these aspects being confirmed in tau transgenic mouse models (DuBoff <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0059">2012</xref>). Pathological tau‐related mitochondrial dysfunction, including impaired oxidative phosphorylation, has been revealed by a proteomic and functional analysis of pR5 mice (David <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0049">2005</xref>; Rhein <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0199">2009</xref>). Interestingly, neuronal quality control of microglia is affected by a truncated form of human 2N4R tau (Amadoro <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0007">2014</xref>). This study specifically revealed that early neuronal death correlated with dystrophic mitochondria dynamics, selective autophagic clearance, fragmentation and perinuclear mislocalization of small and dense mitochondria (Amadoro <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0007">2014</xref>). Together, these studies highlight the critical role of mitochondrial turnover and function in FTLD pathology.</p>
<p>Alterations of normal actin dynamics will, however, also affect other cellular functions, such as the transport of membrane organelles via myosin‐dependent mechanics, an aspect that has been observed in models of tauopathies (Semenova <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0213">2008</xref>). K369I mutant tau transgenic K3 mice are characterized by impaired axonal transport because of a tau‐dependent cargo‐selective impairment of kinesin‐driven axonal anterograde transport (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0121">2009</xref>). A more in‐depth analysis of these mice revealed that hyperphosphorylated tau interacts with c‐Jun N‐terminal kinase‐interacting protein 1 (JIP1), which becomes trapped in the soma and is not efficiently available to associate with the kinesin motor protein complex, thereby causing impaired axonal transport of defined cargoes (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0121">2009</xref>).</p>
</sec>
<sec id="jnc13600-sec-0013">
<title>Conclusions and perspectives</title>
<p>Since the discovery of tau, many aspects of its physiology and pathology have been clarified, particularly with the development of improved <italic>in vitro</italic> and <italic>in vivo</italic> models (Fig. <xref ref-type="fig" rid="jnc13600-fig-0003">3</xref>). Human neurons derived from embryonic stem cells or the more recently developed induced pluripotent stem cells (iPSCs) are now being explored to study tau‐associated pathomechanisms. In one study, the generation of neuroepithelial embryonic stem cells cultures was combined with lentiviral expression of 2N4R human tau or a pseudophosphorylated form of tau driven by the elongation factor 1α promoter (Mertens <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0177">2013</xref>). Cells expressing the altered form of tau recapitulated the tau pathology seen in transgenic animals, together with degeneration and an increased rate of neuronal cell death. Moreover, these cellular studies confirmed the causative link between tau phosphorylation and conformation, microtubule‐based transport and the vulnerability of human neurons to oxidative stress (Mertens <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0177">2013</xref>). In another study supporting prior findings in transgenic mouse models, it was revealed that seeding iPSCs with oligomeric, but not monomeric tau caused an increase in aggregated and pathologically phosphorylated tau, together with neurite retraction, loss of synapses, aberrant calcium homeostasis and an imbalance in neurotransmitter release (Usenovic <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0241">2015</xref>). Recently, a 3D human cell culture system based on neuroprogenitor cells was used to model AD, successfully recapitulating both the extracellular aggregation of Aβ and an intracellular accumulation of hyperphosphorylated tau, opening the door to new technical possibilities for studying tauopathies <italic>in vitro</italic> (Kim <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0134">2015</xref>).</p>
<fig fig-type="Figure" id="jnc13600-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Tau‐mediated cellular functions under healthy and pathological conditions. In healthy neurons (top), tau molecules are found in a specific localization, with the highest concentrations being found within the distal part of the axon. Cargo molecules are particularly sensitive to the presence of a tau gradient within the axon. Disequilibrium of tau distribution (bottom), as found in frontotemporal lobar degeneration (<styled-content style="fixed-case">FTLD</styled-content>)‐tau, has severe consequence for cellular physiology. Under these conditions, tau accumulates in the neuronal soma and dendrites, leading to microtubule depolymerization and affecting axonal transport. Mitochondrial impairments increase the production of toxic reactive oxygen species (<styled-content style="fixed-case">ROS</styled-content>). Intra‐cytoplasmatic hyperphosphorylated tau aggregates are sequestrating more molecules, stalling cellular physiology. In the nucleus, the ratio between eu‐ and hetero‐chromatin is altered and transcription factors [e.g. splicing factor proline/glutamine‐rich (<styled-content style="fixed-case">SFPQ</styled-content>)] can redistribute from the nucleus to the cytoplasm. Neuronal interconnectivity is lost as a result of a toxic accumulation of tau in dendritic spines, together with the loss of synaptic input.</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="JNC-138-71-g003"></graphic>
</fig>
<p>Animal models have pointed towards the fact that tau levels need to be balanced. FTLD‐tau seems to be characterized by both a gain‐of‐toxic‐function and a loss‐of‐physiological function that together cause disease. However, it is becoming increasingly clear that, despite their merits, the existing models have also intrinsic limitations (Ittner <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0123">2015</xref>). Based on the explosion of gene editing techniques, improved models of FTLD can be created, in the absence of the adverse effects inherent to protein over‐expression (Saito <italic>et al</italic>. <xref ref-type="ref" rid="jnc13600-bib-0205">2014</xref>). Whether endogenous levels of expression of mutated genes will be generally sufficient to achieve pathology within the lifespan of rodents remains to be determined. Nevertheless, deciphering the molecular pathogenesis of FTLD offers new perspectives for the development of therapies, which is critical to prevent or halt tauopathies. As novel interventions are being developed, the animal models will be instrumental in validating treatment options.</p>
</sec>
</body>
<back>
<ack id="jnc13600-sec-0014">
<title>Acknowledgements and conflict of interest disclosure</title>
<p>This study was supported by the Estate of Dr Clem Jones AO, the State Government of Queensland, the Federal Government of Australia (ACT900116), and by grants from the Australian Research Council [DP13300101932] and the National Health and Medical Research Council of Australia [APP1037746, APP1003150] to JG. LGB is supported by the Peter Hilton Fellowship. The authors declare that they have no conflicts of interest with the contents of this article.</p>
</ack>
<ref-list content-type="cited-references" id="jnc13600-bibl-0001">
<title>References</title>
<ref id="jnc13600-bib-0001">
<mixed-citation id="jnc13600-cit-0001" publication-type="journal">
<string-name>
<surname>Ahmed</surname>
<given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Bigio</surname>
<given-names>E. H.</given-names>
</string-name>, <string-name>
<surname>Budka</surname>
<given-names>H.</given-names>
</string-name>
<italic>et al</italic> (<year>2013</year>) <article-title>Globular glial tauopathies (GGT): consensus recommendations</article-title>. <source/>Acta Neuropathol.
<volume>126</volume>, <fpage>537</fpage>–<lpage>544</lpage>.<pub-id pub-id-type="pmid">23995422</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0002">
<mixed-citation id="jnc13600-cit-0002" publication-type="journal">
<string-name>
<surname>Alavi Naini</surname>
<given-names>S. M.</given-names>
</string-name> and <string-name>
<surname>Soussi‐Yanicostas</surname>
<given-names>N.</given-names>
</string-name> (<year>2015</year>) <article-title>Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?</article-title>. <source/>Oxid. Med. Cell. Longev.
<volume>2015</volume>, <fpage>151979</fpage>.<pub-id pub-id-type="pmid">26576216</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0003">
<mixed-citation id="jnc13600-cit-0003" publication-type="journal">
<string-name>
<surname>Allen</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Ingram</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Takao</surname>
<given-names>M.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein</article-title>. <source/>J. Neurosci.
<volume>22</volume>, <fpage>9340</fpage>–<lpage>9351</lpage>.<pub-id pub-id-type="pmid">12417659</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0004">
<mixed-citation id="jnc13600-cit-0004" publication-type="journal">
<string-name>
<surname>Alonso</surname>
<given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Grundke‐Iqbal</surname>
<given-names>I.</given-names>
</string-name> and <string-name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</string-name> (<year>1996</year>) <article-title>Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules</article-title>. <source/>Nat. Med.
<volume>2</volume>, <fpage>783</fpage>–<lpage>787</lpage>.<pub-id pub-id-type="pmid">8673924</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0005">
<mixed-citation id="jnc13600-cit-0005" publication-type="journal">
<string-name>
<surname>Alzheimer</surname>
<given-names>A.</given-names>
</string-name> (<year>1907</year>) <article-title>Über eine eigenartige Erkrankung der Hirnrinde</article-title>. <source/>Allg. Z Psychiat.
<volume>64</volume>, <fpage>146</fpage>–<lpage>148</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0006">
<mixed-citation id="jnc13600-cit-0006" publication-type="journal">
<string-name>
<surname>Alzheimer</surname>
<given-names>A.</given-names>
</string-name> (<year>1911</year>) <article-title>Über eigenartige Krankheitsfälle des späteren Alters</article-title>. <source/>Z ges Neurol Psychiat
<volume>4</volume>, <fpage>356</fpage>–<lpage>385</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0007">
<mixed-citation id="jnc13600-cit-0007" publication-type="journal">
<string-name>
<surname>Amadoro</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Corsetti</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Florenzano</surname>
<given-names>F.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>AD‐linked, toxic NH2 human tau affects the quality control of mitochondria in neurons</article-title>. <source/>Neurobiol. Dis.
<volume>62</volume>, <fpage>489</fpage>–<lpage>507</lpage>.<pub-id pub-id-type="pmid">24411077</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0008">
<mixed-citation id="jnc13600-cit-0008" publication-type="journal">
<string-name>
<surname>Andorfer</surname>
<given-names>C.</given-names>
</string-name> (<year>2005</year>) <article-title>Cell‐cycle reentry and cell death in transgenic mice expressing nonmutant human Tau isoforms</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>5446</fpage>–<lpage>5454</lpage>.<pub-id pub-id-type="pmid">15930395</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0009">
<mixed-citation id="jnc13600-cit-0009" publication-type="journal">
<string-name>
<surname>Andorfer</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Kress</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Espinoza</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>De Tucker</surname>
<given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Barde</surname>
<given-names>Y. A.</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Davies</surname>
<given-names>P.</given-names>
</string-name> (<year>2003</year>) <article-title>Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms</article-title>. <source/>J. Neurochem.
<volume>86</volume>, <fpage>582</fpage>–<lpage>590</lpage>.<pub-id pub-id-type="pmid">12859672</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0010">
<mixed-citation id="jnc13600-cit-0010" publication-type="journal">
<string-name>
<surname>Arendt</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Stieler</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Strijkstra</surname>
<given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Hut</surname>
<given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Rüdiger</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Van der Zee</surname>
<given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Harkany</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Holzer</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Härtig</surname>
<given-names>W.</given-names>
</string-name> (<year>2003</year>) <article-title>Reversible paired helical filament‐like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals</article-title>. <source/>J. Neurosci.
<volume>23</volume>, <fpage>6972</fpage>–<lpage>6981</lpage>.<pub-id pub-id-type="pmid">12904458</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0011">
<mixed-citation id="jnc13600-cit-0011" publication-type="journal">
<string-name>
<surname>Arnold</surname>
<given-names>C. S.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>G. V.</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>R. N.</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Hart</surname>
<given-names>G. W.</given-names>
</string-name> (<year>1996</year>) <article-title>The microtubule‐associated protein tau is extensively modified with O‐linked N‐acetylglucosamine</article-title>. <source/>J. Biol. Chem.
<volume>271</volume>, <fpage>28741</fpage>–<lpage>28744</lpage>.<pub-id pub-id-type="pmid">8910513</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0012">
<mixed-citation id="jnc13600-cit-0012" publication-type="journal">
<string-name>
<surname>Asai</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ikezu</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Tsunoda</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Medalla</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Luebke</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Haydar</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Wolozin</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Butovsky</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Kügler</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Ikezu</surname>
<given-names>T.</given-names>
</string-name> (<year>2015</year>) <article-title>Depletion of microglia and inhibition of exosome synthesis halt tau propagation</article-title>. <source/>Nat. Neurosci.
<volume>18</volume>, <fpage>1584</fpage>–<lpage>1593</lpage>.<pub-id pub-id-type="pmid">26436904</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0013">
<mixed-citation id="jnc13600-cit-0013" publication-type="journal">
<string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>2009</year>) <article-title>The tau code</article-title>. <source/>Front. Aging Neurosci.
<volume>1</volume>, <fpage>1</fpage>.<pub-id pub-id-type="pmid">20552052</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0014">
<mixed-citation id="jnc13600-cit-0014" publication-type="journal">
<string-name>
<surname>Bai</surname>
<given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Garver</surname>
<given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Hukriede</surname>
<given-names>N. A.</given-names>
</string-name> and <string-name>
<surname>Burton</surname>
<given-names>E. A.</given-names>
</string-name> (<year>2007</year>) <article-title>Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene</article-title>. <source/>Nucleic Acids Res.
<volume>35</volume>, <fpage>6501</fpage>–<lpage>6516</lpage>.<pub-id pub-id-type="pmid">17897967</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0015">
<mixed-citation id="jnc13600-cit-0015" publication-type="journal">
<string-name>
<surname>Baker</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Litvan</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Houlden</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Adamson</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Perez‐Tur</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lynch</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Bigio</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</string-name> (<year>1999</year>) <article-title>Association of an extended haplotype in the tau gene with progressive supranuclear palsy</article-title>. <source/>Hum. Mol. Genet.
<volume>8</volume>, <fpage>711</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">10072441</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0016">
<mixed-citation id="jnc13600-cit-0016" publication-type="journal">
<string-name>
<surname>Ballatore</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2007</year>) <article-title>Tau‐mediated neurodegeneration in Alzheimer's disease and related disorders</article-title>. <source/>Nat. Rev. Neurosci.
<volume>8</volume>, <fpage>663</fpage>–<lpage>672</lpage>.<pub-id pub-id-type="pmid">17684513</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0017">
<mixed-citation id="jnc13600-cit-0017" publication-type="journal">
<string-name>
<surname>Bancher</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Brunner</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lassmann</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Budka</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Jellinger</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Wiche</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Seitelberger</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Grundke‐Iqbal</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Wisniewski</surname>
<given-names>H. M.</given-names>
</string-name> (<year>1989</year>) <article-title>Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease</article-title>. <source/>Brain Res.
<volume>477</volume>, <fpage>90</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">2495152</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0018">
<mixed-citation id="jnc13600-cit-0018" publication-type="journal">
<string-name>
<surname>Bhaskar</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>S.‐H.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>G.</given-names>
</string-name> (<year>2005</year>) <article-title>Disease‐related modifications in tau affect the interaction between Fyn and tau</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>35119</fpage>–<lpage>35125</lpage>.<pub-id pub-id-type="pmid">16115884</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0019">
<mixed-citation id="jnc13600-cit-0019" publication-type="journal">
<string-name>
<surname>Black</surname>
<given-names>M. M.</given-names>
</string-name>, <string-name>
<surname>Slaughter</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Moshiach</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Obrocka</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Fischer</surname>
<given-names>I.</given-names>
</string-name> (<year>1996</year>) <article-title>Tau is enriched on dynamic microtubules in the distal region of growing axons</article-title>. <source/>J. Neurosci.
<volume>16</volume>, <fpage>3601</fpage>–<lpage>3619</lpage>.<pub-id pub-id-type="pmid">8642405</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0020">
<mixed-citation id="jnc13600-cit-0020" publication-type="journal">
<string-name>
<surname>Bodea</surname>
<given-names>L.‐G.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Linnartz‐Gerlach</surname>
<given-names>B.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>Neurodegeneration by activation of the microglial complement‐phagosome pathway</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>8546</fpage>–<lpage>8556</lpage>.<pub-id pub-id-type="pmid">24948809</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0021">
<mixed-citation id="jnc13600-cit-0021" publication-type="journal">
<string-name>
<surname>Boehm</surname>
<given-names>J.</given-names>
</string-name> (<year>2013</year>) <article-title>A “danse macabre”: tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity</article-title>. <source/>Eur. J. Neurosci.
<volume>37</volume>, <fpage>1925</fpage>–<lpage>1930</lpage>.<pub-id pub-id-type="pmid">23773061</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0022">
<mixed-citation id="jnc13600-cit-0022" publication-type="journal">
<string-name>
<surname>Bolkan</surname>
<given-names>B. J.</given-names>
</string-name> and <string-name>
<surname>Kretzschmar</surname>
<given-names>D.</given-names>
</string-name> (<year>2014</year>) <article-title>Loss of tau results in defects in photoreceptor development and progressive neuronal degeneration in drosophila</article-title>. <source/>Dev. Neurobiol.
<volume>74</volume>, <fpage>1210</fpage>–<lpage>1225</lpage>.<pub-id pub-id-type="pmid">24909306</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0023">
<mixed-citation id="jnc13600-cit-0023" publication-type="journal">
<string-name>
<surname>Bouleau</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Tricoire</surname>
<given-names>H.</given-names>
</string-name> (<year>2015</year>) <article-title>Drosophila models of Alzheimer's disease: advances, limits, and perspectives</article-title>. <source/>J. Alzheimers Dis.
<volume>45</volume>, <fpage>1015</fpage>–<lpage>1038</lpage>.<pub-id pub-id-type="pmid">25697708</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0024">
<mixed-citation id="jnc13600-cit-0024" publication-type="journal">
<string-name>
<surname>Boyne</surname>
<given-names>L. J.</given-names>
</string-name>, <string-name>
<surname>Tessler</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Fischer</surname>
<given-names>I.</given-names>
</string-name> (<year>1995</year>) <article-title>Distribution of Big tau in the central nervous system of the adult and developing rat</article-title>. <source/>J. Comp. Neurol.
<volume>358</volume>, <fpage>279</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">7560287</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0025">
<mixed-citation id="jnc13600-cit-0025" publication-type="journal">
<string-name>
<surname>Braak</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Del Tredici</surname>
<given-names>K.</given-names>
</string-name>(<year>2011</year>) <article-title>Alzheimer's pathogenesis: is there neuron‐to‐neuron propagation?</article-title>
<source/>Acta Neuropathol.
<volume>121</volume>, <fpage>589</fpage>–<lpage>595</lpage>.<pub-id pub-id-type="pmid">21516512</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0026">
<mixed-citation id="jnc13600-cit-0026" publication-type="journal">
<string-name>
<surname>Brandt</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Léger</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>G.</given-names>
</string-name> (<year>1995</year>) <article-title>Interaction of tau with the neural plasma membrane mediated by tau's amino‐terminal projection domain</article-title>. <source/>J. Cell Biol.
<volume>131</volume>, <fpage>1327</fpage>–<lpage>1340</lpage>.<pub-id pub-id-type="pmid">8522593</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0027">
<mixed-citation id="jnc13600-cit-0027" publication-type="journal">
<string-name>
<surname>Brettschneider</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Tredici</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Del Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2015</year>) <article-title>Spreading of pathology in neurodegenerative diseases: a focus on human studies</article-title>. <source/>Nat. Rev. Neurosci.
<volume>16</volume>, <fpage>109</fpage>–<lpage>120</lpage>.<pub-id pub-id-type="pmid">25588378</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0028">
<mixed-citation id="jnc13600-cit-0028" publication-type="journal">
<string-name>
<surname>Buée</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Bussière</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Buée‐Scherrer</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Delacourte</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Hof</surname>
<given-names>P. R.</given-names>
</string-name> (<year>2000</year>) <article-title>Tau protein isoforms, phosphorylation and role in neurodegenerative disorders</article-title>. <source/>Brain Res. Brain Res. Rev.
<volume>33</volume>, <fpage>95</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">10967355</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0029">
<mixed-citation id="jnc13600-cit-0029" publication-type="journal">
<string-name>
<surname>Butzlaff</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hannan</surname>
<given-names>S. B.</given-names>
</string-name>, <string-name>
<surname>Karsten</surname>
<given-names>P.</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau‐induced toxicity</article-title>. <source/>Hum. Mol. Genet.
<volume>24</volume>, <fpage>3623</fpage>–<lpage>3637</lpage>.<pub-id pub-id-type="pmid">25794683</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0030">
<mixed-citation id="jnc13600-cit-0030" publication-type="journal">
<string-name>
<surname>Caceres</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Kosik</surname>
<given-names>K. S.</given-names>
</string-name> (<year>1990</year>) <article-title>Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons</article-title>. <source/>Nature
<volume>343</volume>, <fpage>461</fpage>–<lpage>463</lpage>.<pub-id pub-id-type="pmid">2105469</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0031">
<mixed-citation id="jnc13600-cit-0031" publication-type="journal">
<string-name>
<surname>Cairns</surname>
<given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Bigio</surname>
<given-names>E. H.</given-names>
</string-name>, <string-name>
<surname>Mackenzie</surname>
<given-names>I. R. A.</given-names>
</string-name>
<italic>et al</italic> (<year>2007</year>) <article-title>Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration</article-title>. <source/>Acta Neuropathol.
<volume>114</volume>, <fpage>5</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">17579875</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0032">
<mixed-citation id="jnc13600-cit-0032" publication-type="journal">
<string-name>
<surname>Calahorro</surname>
<given-names>F.</given-names>
</string-name> and <string-name>
<surname>Ruiz‐Rubio</surname>
<given-names>M.</given-names>
</string-name> (<year>2011</year>) <article-title>Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder</article-title>. <source/>Invertebr. Neurosci.
<volume>11</volume>, <fpage>73</fpage>–<lpage>83</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0033">
<mixed-citation id="jnc13600-cit-0033" publication-type="journal">
<string-name>
<surname>Cantero</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Hita‐Yañez</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Moreno‐Lopez</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Portillo</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Rubio</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>2010a</year>) <article-title>Tau protein role in sleep‐wake cycle</article-title>. <source/>J. Alzheimers Dis.
<volume>21</volume>, <fpage>411</fpage>–<lpage>421</lpage>.<pub-id pub-id-type="pmid">20555133</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0034">
<mixed-citation id="jnc13600-cit-0034" publication-type="journal">
<string-name>
<surname>Cantero</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Moreno‐Lopez</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Portillo</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Rubio</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hita‐Yañez</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>2011</year>) <article-title>Role of tau protein on neocortical and hippocampal oscillatory patterns</article-title>. <source/>Hippocampus
<volume>21</volume>, <fpage>827</fpage>–<lpage>834</lpage>.<pub-id pub-id-type="pmid">20607795</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0035">
<mixed-citation id="jnc13600-cit-0035" publication-type="journal">
<string-name>
<surname>Chatterjee</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Sang</surname>
<given-names>T.‐K.</given-names>
</string-name>, <string-name>
<surname>Lawless</surname>
<given-names>G. M.</given-names>
</string-name> and <string-name>
<surname>Jackson</surname>
<given-names>G. R.</given-names>
</string-name> (<year>2008</year>) <article-title>Dissociation of tau toxicity and phosphorylation: role of GSK‐3, MARK and Cdk5 in a Drosophila model</article-title>. <source/>Hum. Mol. Genet.
<volume>18</volume>, <fpage>164</fpage>–<lpage>177</lpage>.<pub-id pub-id-type="pmid">18930955</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0036">
<mixed-citation id="jnc13600-cit-0036" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kanai</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Cowan</surname>
<given-names>N. J.</given-names>
</string-name> and <string-name>
<surname>Hirokawa</surname>
<given-names>N.</given-names>
</string-name> (<year>1992</year>) <article-title>Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons</article-title>. <source/>Nature
<volume>360</volume>, <fpage>674</fpage>–<lpage>677</lpage>.<pub-id pub-id-type="pmid">1465130</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0037">
<mixed-citation id="jnc13600-cit-0037" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>W.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Guo</surname>
<given-names>A.</given-names>
</string-name> (<year>2007</year>) <article-title>Study of tauopathies by comparing Drosophila and human tau in Drosophila</article-title>. <source/>Cell Tissue Res.
<volume>329</volume>, <fpage>169</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">17406902</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0038">
<mixed-citation id="jnc13600-cit-0038" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Martins</surname>
<given-names>R. N.</given-names>
</string-name> and <string-name>
<surname>Lardelli</surname>
<given-names>M.</given-names>
</string-name> (<year>2009</year>) <article-title>Complex splicing and neural expression of duplicated tau genes in zebrafish embryos</article-title>. <source/>J. Alzheimers Dis.
<volume>18</volume>, <fpage>305</fpage>–<lpage>317</lpage>.<pub-id pub-id-type="pmid">19584432</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0039">
<mixed-citation id="jnc13600-cit-0039" publication-type="journal">
<string-name>
<surname>Chew</surname>
<given-names>Y. L.</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Nicholas</surname>
<given-names>H. R.</given-names>
</string-name> (<year>2013</year>) <article-title>PTL‐1 regulates neuronal integrity and lifespan in C. elegans</article-title>. <source/>J. Cell Sci.
<volume>126</volume>, <fpage>2079</fpage>–<lpage>2091</lpage>.<pub-id pub-id-type="pmid">23525010</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0040">
<mixed-citation id="jnc13600-cit-0040" publication-type="journal">
<string-name>
<surname>Chew</surname>
<given-names>Y. L.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Nicholas</surname>
<given-names>H. R.</given-names>
</string-name> (<year>2015</year>) <article-title>Neuronal protein with tau‐like repeats (PTL‐1) regulates intestinal SKN‐1 nuclear accumulation in response to oxidative stress</article-title>. <source/>Aging Cell
<volume>14</volume>, <fpage>148</fpage>–<lpage>151</lpage>.<pub-id pub-id-type="pmid">25399685</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0041">
<mixed-citation id="jnc13600-cit-0041" publication-type="journal">
<string-name>
<surname>Clavaguera</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Bolmont</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Crowther</surname>
<given-names>R. A.</given-names>
</string-name>
<italic>et al</italic> (<year>2009</year>) <article-title>Transmission and spreading of tauopathy in transgenic mouse brain</article-title>. <source/>Nat. Cell Biol.
<volume>11</volume>, <fpage>909</fpage>–<lpage>913</lpage>.<pub-id pub-id-type="pmid">19503072</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0042">
<mixed-citation id="jnc13600-cit-0042" publication-type="journal">
<string-name>
<surname>Clavaguera</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Akatsu</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>G.</given-names>
</string-name>
<italic>et al</italic> (<year>2013</year>) <article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title>. <source/>Proc. Natl Acad. Sci.
<volume>110</volume>, <fpage>9535</fpage>–<lpage>9540</lpage>.<pub-id pub-id-type="pmid">23690619</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0043">
<mixed-citation id="jnc13600-cit-0043" publication-type="journal">
<string-name>
<surname>Clavaguera</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Hench</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lavenir</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Schweighauser</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Tolnay</surname>
<given-names>M.</given-names>
</string-name> (<year>2014</year>) <article-title>Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice</article-title>. <source/>Acta Neuropathol.
<volume>127</volume>, <fpage>299</fpage>–<lpage>301</lpage>.<pub-id pub-id-type="pmid">24362441</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0044">
<mixed-citation id="jnc13600-cit-0044" publication-type="journal">
<string-name>
<surname>Costa</surname>
<given-names>A. P.</given-names>
</string-name>, <string-name>
<surname>Tramontina</surname>
<given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Biasibetti</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Batassini</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>M. W.</given-names>
</string-name>, <string-name>
<surname>Wartchow</surname>
<given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Bernardi</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Tortorelli</surname>
<given-names>L. S.</given-names>
</string-name>, <string-name>
<surname>Leal</surname>
<given-names>R. B.</given-names>
</string-name> and <string-name>
<surname>Gonçalves</surname>
<given-names>C.‐A.</given-names>
</string-name> (<year>2012</year>) <article-title>Neuroglial alterations in rats submitted to the okadaic acid‐induced model of dementia</article-title>. <source/>Behav. Brain Res.
<volume>226</volume>, <fpage>420</fpage>–<lpage>427</lpage>.<pub-id pub-id-type="pmid">21982813</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0045">
<mixed-citation id="jnc13600-cit-0045" publication-type="journal">
<string-name>
<surname>Couchie</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Mavilia</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Georgieff</surname>
<given-names>I. S.</given-names>
</string-name>, <string-name>
<surname>Liem</surname>
<given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Shelanski</surname>
<given-names>M. L.</given-names>
</string-name> and <string-name>
<surname>Nunez</surname>
<given-names>J.</given-names>
</string-name> (<year>1992</year>) <article-title>Primary structure of high molecular weight tau present in the peripheral nervous system</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>89</volume>, <fpage>4378</fpage>–<lpage>4381</lpage>.<pub-id pub-id-type="pmid">1374898</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0046">
<mixed-citation id="jnc13600-cit-0046" publication-type="journal">
<string-name>
<surname>Cripps</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>S. N.</given-names>
</string-name>, <string-name>
<surname>Jeng</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>P.</given-names>
</string-name> and <string-name>
<surname>Yang</surname>
<given-names>A. J.</given-names>
</string-name> (<year>2006</year>) <article-title>Alzheimer disease‐specific conformation of hyperphosphorylated paired helical filament‐tau is polyubiquitinated through Lys‐48, Lys‐11, and Lys‐6 ubiquitin conjugation</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>10825</fpage>–<lpage>10838</lpage>.<pub-id pub-id-type="pmid">16443603</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0047">
<mixed-citation id="jnc13600-cit-0047" publication-type="journal">
<string-name>
<surname>Cruchaga</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Vidal‐Taboada</surname>
<given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Ezquerra</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lorenzo</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Martinez‐Lage</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Blazquez</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tolosa</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Pastor</surname>
<given-names>P.</given-names>
</string-name> (<year>2009</year>) <article-title>5’‐Upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration</article-title>. <source/>Neurobiol. Dis.
<volume>33</volume>, <fpage>164</fpage>–<lpage>170</lpage>.<pub-id pub-id-type="pmid">19022385</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0048">
<mixed-citation id="jnc13600-cit-0048" publication-type="journal">
<string-name>
<surname>Dabir</surname>
<given-names>D. V.</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>M. B.</given-names>
</string-name>, <string-name>
<surname>Swanson</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> and <string-name>
<surname>Forman</surname>
<given-names>M. S.</given-names>
</string-name> (<year>2006</year>) <article-title>Impaired glutamate transport in a mouse model of tau pathology in astrocytes</article-title>. <source/>J. Neurosci.
<volume>26</volume>, <fpage>644</fpage>–<lpage>654</lpage>.<pub-id pub-id-type="pmid">16407562</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0049">
<mixed-citation id="jnc13600-cit-0049" publication-type="journal">
<string-name>
<surname>David</surname>
<given-names>D. C.</given-names>
</string-name>, <string-name>
<surname>Hauptmann</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Scherping</surname>
<given-names>I.</given-names>
</string-name>
<italic>et al</italic> (<year>2005</year>) <article-title>Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>23802</fpage>–<lpage>23814</lpage>.<pub-id pub-id-type="pmid">15831501</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0050">
<mixed-citation id="jnc13600-cit-0050" publication-type="journal">
<string-name>
<surname>Dawson</surname>
<given-names>H. N.</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>a.</given-names>
</string-name>, <string-name>
<surname>Eyster</surname>
<given-names>M. V.</given-names>
</string-name>, <string-name>
<surname>Ghoshal</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Binder</surname>
<given-names>L. I.</given-names>
</string-name> and <string-name>
<surname>Vitek</surname>
<given-names>M. P.</given-names>
</string-name> (<year>2001</year>) <article-title>Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice</article-title>. <source/>J. Cell Sci.
<volume>114</volume>, <fpage>1179</fpage>–<lpage>1187</lpage>.<pub-id pub-id-type="pmid">11228161</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0051">
<mixed-citation id="jnc13600-cit-0051" publication-type="journal">
<string-name>
<surname>Dehmelt</surname>
<given-names>L.</given-names>
</string-name> and <string-name>
<surname>Halpain</surname>
<given-names>S.</given-names>
</string-name> (<year>2005</year>) <article-title>The MAP2/tau family of microtubule‐associated proteins</article-title>. <source/>Genome Biol.
<volume>6</volume>, <fpage>204</fpage>.<pub-id pub-id-type="pmid">15642108</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0052">
<mixed-citation id="jnc13600-cit-0052" publication-type="journal">
<string-name>
<surname>Delay</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Brion</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Escourolle</surname>
<given-names>R.</given-names>
</string-name> (<year>1957</year>) <article-title>L'opposition anatomo‐clinique des maladies de Pick et d'Alzheimer: Etude de 38 cas</article-title>. <source/>Presse Med.
<volume>65</volume>, <fpage>1495</fpage>–<lpage>1497</lpage>.<pub-id pub-id-type="pmid">13484841</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0053">
<mixed-citation id="jnc13600-cit-0053" publication-type="journal">
<string-name>
<surname>Deters</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2009</year>) <article-title>Substrate‐specific reduction of PP2A activity exaggerates tau pathology</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>379</volume>, <fpage>400</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">19126401</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0054">
<mixed-citation id="jnc13600-cit-0054" publication-type="journal">
<string-name>
<surname>Di Meco</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Joshi</surname>
<given-names>Y. B.</given-names>
</string-name> and <string-name>
<surname>Praticò</surname>
<given-names>D.</given-names>
</string-name> (<year>2014</year>) <article-title>Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles</article-title>. <source/>Neurobiol. Aging
<volume>35</volume>, <fpage>1813</fpage>–<lpage>1820</lpage>.<pub-id pub-id-type="pmid">24629673</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0055">
<mixed-citation id="jnc13600-cit-0055" publication-type="journal">
<string-name>
<surname>Dixit</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>Y. E.</given-names>
</string-name> and <string-name>
<surname>Holzbaur</surname>
<given-names>E. L. F.</given-names>
</string-name> (<year>2008</year>) <article-title>Differential regulation of dynein and kinesin motor proteins by tau</article-title>. <source/>Science (80‐.), <volume>319</volume>, 1086–1089.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0056">
<mixed-citation id="jnc13600-cit-0056" publication-type="journal">
<string-name>
<surname>Doerflinger</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Benton</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>
<given-names>J. M.</given-names>
</string-name> and <string-name>
<surname>Johnston St</surname>
<given-names>D.</given-names>
</string-name> (<year>2003</year>) <article-title>The role of PAR‐1 in regulating the polarised microtubule cytoskeleton in the Drosophila follicular epithelium</article-title>. <source/>Development
<volume>130</volume>, <fpage>3965</fpage>–<lpage>3975</lpage>.<pub-id pub-id-type="pmid">12874119</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0057">
<mixed-citation id="jnc13600-cit-0057" publication-type="journal">
<string-name>
<surname>Dorval</surname>
<given-names>V.</given-names>
</string-name> and <string-name>
<surname>Fraser</surname>
<given-names>P. E.</given-names>
</string-name> (<year>2006</year>) <article-title>Small ubiquitin‐like modifier (SUMO) modification of natively unfolded proteins tau and α‐synuclein</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>9919</fpage>–<lpage>9924</lpage>.<pub-id pub-id-type="pmid">16464864</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0058">
<mixed-citation id="jnc13600-cit-0058" publication-type="journal">
<string-name>
<surname>Drubin</surname>
<given-names>D. G.</given-names>
</string-name>, <string-name>
<surname>Caput</surname>
<given-names>D.</given-names>
</string-name> and <string-name>
<surname>Kirschner</surname>
<given-names>M. W.</given-names>
</string-name> (<year>1984</year>) <article-title>Studies on the expression of the microtubule‐associated protein, tau, during mouse brain development, with newly isolated complementary DNA probes</article-title>. <source/>J. Cell Biol.
<volume>98</volume>, <fpage>1090</fpage>–<lpage>1097</lpage>.<pub-id pub-id-type="pmid">6421824</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0059">
<mixed-citation id="jnc13600-cit-0059" publication-type="journal">
<string-name>
<surname>DuBoff</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2012</year>) <article-title>Tau promotes neurodegeneration via DRP1 mislocalization in vivo</article-title>. <source/>Neuron
<volume>75</volume>, <fpage>618</fpage>–<lpage>632</lpage>.<pub-id pub-id-type="pmid">22920254</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0060">
<mixed-citation id="jnc13600-cit-0060" publication-type="journal">
<string-name>
<surname>Duff</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Refolo</surname>
<given-names>L. M.</given-names>
</string-name>
<italic>et al</italic> (<year>2000</year>) <article-title>Characterization of pathology in transgenic mice over‐expressing human genomic and cDNA tau transgenes</article-title>. <source/>Neurobiol. Dis.
<volume>7</volume>, <fpage>87</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">10783293</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0061">
<mixed-citation id="jnc13600-cit-0061" publication-type="journal">
<string-name>
<surname>Dujardin</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Colin</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Buée</surname>
<given-names>L.</given-names>
</string-name> (<year>2015</year>) <article-title>Invited review: animal models of tauopathies and their implications for research/translation into the clinic</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>41</volume>, <fpage>59</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">25428793</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0062">
<mixed-citation id="jnc13600-cit-0062" publication-type="journal">
<string-name>
<surname>Dumanchin</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Camuzat</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Campion</surname>
<given-names>D.</given-names>
</string-name>
<italic>et al</italic> (<year>1998</year>) <article-title>Segregation of a missense mutation in the microtubule‐associated protein tau gene with familial frontotemporal dementia and parkinsonism</article-title>. <source/>Hum. Mol. Genet.
<volume>7</volume>, <fpage>1825</fpage>–<lpage>1829</lpage>.<pub-id pub-id-type="pmid">9736786</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0063">
<mixed-citation id="jnc13600-cit-0063" publication-type="journal">
<string-name>
<surname>Duyckaerts</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Brion</surname>
<given-names>J.‐P.</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>PART is part of Alzheimer disease</article-title>. <source/>Acta Neuropathol.
<volume>129</volume>, <fpage>749</fpage>–<lpage>756</lpage>.<pub-id pub-id-type="pmid">25628035</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0064">
<mixed-citation id="jnc13600-cit-0064" publication-type="journal">
<string-name>
<surname>Ebneth</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Godemann</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Stamer</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Illenberger</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Trinczek</surname>
<given-names>B.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>1998</year>) <article-title>Overexpression of tau protein inhibits kinesin‐dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease</article-title>. <source/>J. Cell Biol.
<volume>143</volume>, <fpage>777</fpage>–<lpage>794</lpage>.<pub-id pub-id-type="pmid">9813097</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0065">
<mixed-citation id="jnc13600-cit-0065" publication-type="journal">
<string-name>
<surname>Fanara</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>K. H.</given-names>
</string-name>, <string-name>
<surname>Selle</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>P.‐Y. A. P.</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>R.</given-names>
</string-name> and <string-name>
<surname>Hellerstein</surname>
<given-names>M. K.</given-names>
</string-name> (<year>2010</year>) <article-title>Changes in microtubule turnover accompany synaptic plasticity and memory formation in response to contextual fear conditioning in mice</article-title>. <source/>Neuroscience
<volume>168</volume>, <fpage>167</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">20332016</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0066">
<mixed-citation id="jnc13600-cit-0066" publication-type="journal">
<string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> and <string-name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</string-name> (<year>1995</year>) <article-title>Widespread cytoskeletal pathology characterizes corticobasal degeneration</article-title>. <source/>Am. J. Pathol.
<volume>146</volume>, <fpage>1388</fpage>–<lpage>1396</lpage>.<pub-id pub-id-type="pmid">7778678</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0067">
<mixed-citation id="jnc13600-cit-0067" publication-type="journal">
<string-name>
<surname>Fischer</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Mukrasch</surname>
<given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Biernat</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bibow</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Blackledge</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Zweckstetter</surname>
<given-names>M.</given-names>
</string-name> (<year>2009</year>) <article-title>Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules</article-title>. <source/>Biochemistry
<volume>48</volume>, <fpage>10047</fpage>–<lpage>10055</lpage>.<pub-id pub-id-type="pmid">19769346</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0068">
<mixed-citation id="jnc13600-cit-0068" publication-type="journal">
<string-name>
<surname>Frandemiche</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Seranno</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>Rush. T.</given-names>
</string-name>, <string-name>
<surname>Borel</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Elie</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Arnal</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Lanté</surname>
<given-names>F.</given-names>
</string-name> and <string-name>
<surname>Buisson</surname>
<given-names>A.</given-names>
</string-name> (<year>2014</year>) <article-title>Activity‐dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid‐beta oligomers</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>6084</fpage>–<lpage>6097</lpage>.<pub-id pub-id-type="pmid">24760868</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0069">
<mixed-citation id="jnc13600-cit-0069" publication-type="journal">
<string-name>
<surname>Frost</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Hemberg</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2014</year>) <article-title>Tau promotes neurodegeneration through global chromatin relaxation</article-title>. <source/>Nat. Neurosci.
<volume>17</volume>, <fpage>357</fpage>–<lpage>366</lpage>.<pub-id pub-id-type="pmid">24464041</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0070">
<mixed-citation id="jnc13600-cit-0070" publication-type="journal">
<string-name>
<surname>Fulga</surname>
<given-names>T. A.</given-names>
</string-name>, <string-name>
<surname>Elson‐Schwab</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Khurana</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Steinhilb</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Spires</surname>
<given-names>T. L.</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>B. T.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2007</year>) <article-title>Abnormal bundling and accumulation of F‐actin mediates tau‐induced neuronal degeneration in vivo</article-title>. <source/>Nat. Cell Biol.
<volume>9</volume>, <fpage>139</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">17187063</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0071">
<mixed-citation id="jnc13600-cit-0071" publication-type="journal">
<string-name>
<surname>Funk</surname>
<given-names>K. E.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>S. N.</given-names>
</string-name>, <string-name>
<surname>Schafer</surname>
<given-names>K. N.</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>G. L.</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>D. J.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>A. J.</given-names>
</string-name> and <string-name>
<surname>Kuret</surname>
<given-names>J.</given-names>
</string-name> (<year>2014</year>) <article-title>Lysine methylation is an endogenous post‐translational modification of tau protein in human brain and a modulator of aggregation propensity</article-title>. <source/>Biochem. J.
<volume>462</volume>, <fpage>77</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">24869773</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0072">
<mixed-citation id="jnc13600-cit-0072" publication-type="journal">
<string-name>
<surname>Gärtner</surname>
<given-names>U.</given-names>
</string-name>, <string-name>
<surname>Janke</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Holzer</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Vanmechelen</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Arendt</surname>
<given-names>T.</given-names>
</string-name> (<year>1998</year>) <article-title>Postmortem changes in the phosphorylation state of tau‐protein in the rat brain</article-title>. <source/>Neurobiol. Aging
<volume>19</volume>, <fpage>535</fpage>–<lpage>543</lpage>.<pub-id pub-id-type="pmid">10192212</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0073">
<mixed-citation id="jnc13600-cit-0073" publication-type="journal">
<string-name>
<surname>Gauthier‐Kemper</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Weissmann</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Golovyashkina</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Sebo‐Lemke</surname>
<given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Drewes</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Gerke</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Heinisch</surname>
<given-names>J. J.</given-names>
</string-name> and <string-name>
<surname>Brandt</surname>
<given-names>R.</given-names>
</string-name> (<year>2011</year>) <article-title>The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2‐dependent manner</article-title>. <source/>J. Cell Biol.
<volume>192</volume>, <fpage>647</fpage>–<lpage>661</lpage>.<pub-id pub-id-type="pmid">21339331</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0074">
<mixed-citation id="jnc13600-cit-0074" publication-type="journal">
<string-name>
<surname>Georgieff</surname>
<given-names>I. S.</given-names>
</string-name>, <string-name>
<surname>Liem</surname>
<given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Couchie</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Mavilia</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Nunez</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Shelanski</surname>
<given-names>M. L.</given-names>
</string-name> (<year>1993</year>) <article-title>Expression of high molecular weight tau in the central and peripheral nervous systems</article-title>. <source/>J. Cell Sci.
<volume>105</volume> (Pt 3, <fpage>729</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">8408300</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0075">
<mixed-citation id="jnc13600-cit-0075" publication-type="journal">
<string-name>
<surname>Ghetti</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Oblak</surname>
<given-names>A. L.</given-names>
</string-name>, <string-name>
<surname>Boeve</surname>
<given-names>B. F.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Dickerson</surname>
<given-names>B. C.</given-names>
</string-name> and <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> (<year>2015</year>) <article-title>Invited review: frontotemporal dementia caused by <italic>microtubule‐associated protein tau</italic> gene (<italic>MAPT</italic>) mutations: a chameleon for neuropathology and neuroimaging</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>41</volume>, <fpage>24</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">25556536</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0076">
<mixed-citation id="jnc13600-cit-0076" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> (<year>2015</year>) <article-title>Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α‐synuclein</article-title>. <source/>Science
<volume>349</volume>, <fpage>1255555</fpage>.<pub-id pub-id-type="pmid">26250687</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0077">
<mixed-citation id="jnc13600-cit-0077" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Jakes</surname>
<given-names>R.</given-names>
</string-name> (<year>1990</year>) <article-title>Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization</article-title>. <source/>EMBO J.
<volume>9</volume>, <fpage>4225</fpage>–<lpage>4230</lpage>.<pub-id pub-id-type="pmid">2124967</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0078">
<mixed-citation id="jnc13600-cit-0078" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wischik</surname>
<given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Crowther</surname>
<given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>J. E.</given-names>
</string-name> and <string-name>
<surname>Klug</surname>
<given-names>A.</given-names>
</string-name> (<year>1988</year>) <article-title>Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule‐associated protein tau</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>85</volume>, <fpage>4051</fpage>–<lpage>4055</lpage>.<pub-id pub-id-type="pmid">3131773</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0079">
<mixed-citation id="jnc13600-cit-0079" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Potier</surname>
<given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Ulrich</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Crowther</surname>
<given-names>R. A.</given-names>
</string-name> (<year>1989</year>) <article-title>Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain</article-title>. <source/>EMBO J.
<volume>8</volume>, <fpage>393</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">2498079</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0080">
<mixed-citation id="jnc13600-cit-0080" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Cairns</surname>
<given-names>N. J.</given-names>
</string-name> and <string-name>
<surname>Crowther</surname>
<given-names>R. A.</given-names>
</string-name> (<year>1992</year>) <article-title>Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms</article-title>. <source/>Neuron
<volume>8</volume>, <fpage>159</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">1530909</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0081">
<mixed-citation id="jnc13600-cit-0081" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Baur</surname>
<given-names>C. P.</given-names>
</string-name>, <string-name>
<surname>Ahringer</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Jakes</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>M. J.</given-names>
</string-name> and <string-name>
<surname>Hill</surname>
<given-names>F.</given-names>
</string-name> (<year>1996</year>) <article-title>PTL‐1, a microtubule‐associated protein with tau‐like repeats from the nematode Caenorhabditis elegans</article-title>. <source/>J. Cell Sci.
<volume>109</volume> (Pt 1, <fpage>2661</fpage>–<lpage>2672</lpage>.<pub-id pub-id-type="pmid">8937984</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0082">
<mixed-citation id="jnc13600-cit-0082" publication-type="journal">
<string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ghetti</surname>
<given-names>B.</given-names>
</string-name> and <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name> (<year>2012</year>) <article-title>Frontotemporal dementia: implications for understanding Alzheimer disease</article-title>. <source/>Cold Spring Harb. Perspect Med.
<volume>2</volume>, <fpage>a006254</fpage>.<pub-id pub-id-type="pmid">22355793</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0083">
<mixed-citation id="jnc13600-cit-0083" publication-type="journal">
<string-name>
<surname>Gómez‐Isla</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hollister</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>West</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mui</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Growdon</surname>
<given-names>J. H.</given-names>
</string-name>, <string-name>
<surname>Petersen</surname>
<given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Parisi</surname>
<given-names>J. E.</given-names>
</string-name> and <string-name>
<surname>Hyman</surname>
<given-names>B. T.</given-names>
</string-name> (<year>1997</year>) <article-title>Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease</article-title>. <source/>Ann. Neurol.
<volume>41</volume>, <fpage>17</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">9005861</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0084">
<mixed-citation id="jnc13600-cit-0084" publication-type="journal">
<string-name>
<surname>Gong</surname>
<given-names>C. X.</given-names>
</string-name>, <string-name>
<surname>Lidsky</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Wegiel</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zuck</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Grundke‐Iqbal</surname>
<given-names>I.</given-names>
</string-name> and <string-name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</string-name> (<year>2000</year>) <article-title>Phosphorylation of microtubule‐associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>5535</fpage>–<lpage>5544</lpage>.<pub-id pub-id-type="pmid">10681533</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0085">
<mixed-citation id="jnc13600-cit-0085" publication-type="journal">
<string-name>
<surname>Gonzalez</surname>
<given-names>C.</given-names>
</string-name> (<year>2013</year>) <article-title>Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics</article-title>. <source/>Nat. Rev. Cancer
<volume>13</volume>, <fpage>172</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">23388617</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0086">
<mixed-citation id="jnc13600-cit-0086" publication-type="journal">
<string-name>
<surname>Gordon</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hingula</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Krasny</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Swienckowski</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Pokrywka</surname>
<given-names>N. J.</given-names>
</string-name> and <string-name>
<surname>Raley‐Susman</surname>
<given-names>K. M.</given-names>
</string-name> (<year>2008</year>) <article-title>The invertebrate microtubule‐associated protein PTL‐1 functions in mechanosensation and development in Caenorhabditis elegans</article-title>. <source/>Dev. Genes. Evol.
<volume>218</volume>, <fpage>541</fpage>–<lpage>551</lpage>.<pub-id pub-id-type="pmid">18807071</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0087">
<mixed-citation id="jnc13600-cit-0087" publication-type="journal">
<string-name>
<surname>Gorno‐Tempini</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Hillis</surname>
<given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Weintraub</surname>
<given-names>S.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Classification of primary progressive aphasia and its variants</article-title>. <source/>Neurology
<volume>76</volume>, <fpage>1006</fpage>–<lpage>1014</lpage>.<pub-id pub-id-type="pmid">21325651</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0088">
<mixed-citation id="jnc13600-cit-0088" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name> (<year>2008</year>) <article-title>Animal models of Alzheimer's disease and frontotemporal dementia</article-title>. <source/>Nat. Rev. Neurosci.
<volume>9</volume>, <fpage>532</fpage>–<lpage>544</lpage>.<pub-id pub-id-type="pmid">18568014</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0089">
<mixed-citation id="jnc13600-cit-0089" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Probst</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Schäfer</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Jakes</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bürki</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> (<year>1995</year>) <article-title>Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform</article-title>. <source/>EMBO J.
<volume>14</volume>, <fpage>1304</fpage>–<lpage>1313</lpage>.<pub-id pub-id-type="pmid">7729409</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0090">
<mixed-citation id="jnc13600-cit-0090" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Barmettler</surname>
<given-names>R.</given-names>
</string-name> and <string-name>
<surname>Nitsch</surname>
<given-names>R. M.</given-names>
</string-name> (<year>2001a</year>) <article-title>Tau filament formation in transgenic mice expressing P301L tau</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>529</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">11013246</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0091">
<mixed-citation id="jnc13600-cit-0091" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F.</given-names>
</string-name>, <string-name>van<surname>Dorpe</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Nitsch</surname>
<given-names>R. M.</given-names>
</string-name> (<year>2001b</year>) <article-title>Formation of neurofibrillary tangles in P301 l tau transgenic mice induced by Abeta 42 fibrils</article-title>. <source/>Science
<volume>293</volume>, <fpage>1491</fpage>–<lpage>1495</lpage>.<pub-id pub-id-type="pmid">11520988</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0092">
<mixed-citation id="jnc13600-cit-0092" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Tolnay</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Barmettler</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Probst</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Nitsch</surname>
<given-names>R. M.</given-names>
</string-name> (<year>2001c</year>) <article-title>Oligodendroglial tau filament formation in transgenic mice expressing G272V tau</article-title>. <source/>Eur. J. Neurosci.
<volume>13</volume>, <fpage>2131</fpage>–<lpage>2140</lpage>.<pub-id pub-id-type="pmid">11422454</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0093">
<mixed-citation id="jnc13600-cit-0093" publication-type="journal">
<string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Eckert</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Matamales</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name> and <string-name>
<surname>Liu</surname>
<given-names>X.</given-names>
</string-name> (<year>2011</year>) <article-title>Modes of Aβ toxicity in Alzheimer's disease</article-title>. <source/>Cell. Mol. Life Sci.
<volume>68</volume>, <fpage>3359</fpage>–<lpage>3375</lpage>.<pub-id pub-id-type="pmid">21706148</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0094">
<mixed-citation id="jnc13600-cit-0094" publication-type="journal">
<string-name>
<surname>Grundke‐Iqbal</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tung</surname>
<given-names>Y. C.</given-names>
</string-name>, <string-name>
<surname>Quinlan</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wisniewski</surname>
<given-names>H. M.</given-names>
</string-name> and <string-name>
<surname>Binder</surname>
<given-names>L. I.</given-names>
</string-name> (<year>1986</year>) <article-title>Abnormal phosphorylation of the microtubule‐associated protein tau (tau) in Alzheimer cytoskeletal pathology</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>83</volume>, <fpage>4913</fpage>–<lpage>4917</lpage>.<pub-id pub-id-type="pmid">3088567</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0095">
<mixed-citation id="jnc13600-cit-0095" publication-type="journal">
<string-name>
<surname>Haltiwanger</surname>
<given-names>R. S.</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>W. G.</given-names>
</string-name>, <string-name>
<surname>Roquemore</surname>
<given-names>E. P.</given-names>
</string-name>, <string-name>
<surname>Blomberg</surname>
<given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kreppel</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>T. Y.</given-names>
</string-name> and <string-name>
<surname>Hart</surname>
<given-names>G. W.</given-names>
</string-name> (<year>1992</year>) <article-title>Glycosylation of nuclear and cytoplasmic proteins is ubiquitous and dynamic</article-title>. <source/>Biochem. Soc. Trans.
<volume>20</volume>, <fpage>264</fpage>–<lpage>269</lpage>.<pub-id pub-id-type="pmid">1397609</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0096">
<mixed-citation id="jnc13600-cit-0096" publication-type="journal">
<string-name>
<surname>Hanover</surname>
<given-names>J. A.</given-names>
</string-name> and <string-name>
<surname>Wang</surname>
<given-names>P.</given-names>
</string-name> (<year>2013</year>) <article-title>O‐GlcNAc cycling shows neuroprotective potential in C. elegans models of neurodegenerative disease</article-title>. <source/>Worm
<volume>2</volume>, <fpage>e27043</fpage>.<pub-id pub-id-type="pmid">24744983</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0097">
<mixed-citation id="jnc13600-cit-0097" publication-type="journal">
<string-name>
<surname>Harada</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Oguchi</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kuno</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Terada</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ohshima</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Sato‐Yoshitake</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Takei</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>T.</given-names>
</string-name> and <string-name>
<surname>Hirokawa</surname>
<given-names>N.</given-names>
</string-name> (<year>1994</year>) <article-title>Altered microtubule organization in small‐calibre axons of mice lacking tau protein</article-title>. <source/>Nature
<volume>369</volume>, <fpage>488</fpage>–<lpage>491</lpage>.<pub-id pub-id-type="pmid">8202139</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0098">
<mixed-citation id="jnc13600-cit-0098" publication-type="journal">
<string-name>
<surname>Harris</surname>
<given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Oyler</surname>
<given-names>G. A.</given-names>
</string-name>, <string-name>
<surname>Doolittle</surname>
<given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Lehman</surname>
<given-names>R. A. W.</given-names>
</string-name>, <string-name>
<surname>Kincaid</surname>
<given-names>R. L.</given-names>
</string-name> and <string-name>
<surname>Billingsley</surname>
<given-names>M. L.</given-names>
</string-name> (<year>1993</year>) <article-title>Okadiac acid induces hyperphosphorylated forms of tau protein in human brain slices</article-title>. <source/>Ann. Neurol.
<volume>33</volume>, <fpage>77</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">8494335</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0099">
<mixed-citation id="jnc13600-cit-0099" publication-type="journal">
<string-name>
<surname>Harris</surname>
<given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Koyama</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Devidze</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Dubal</surname>
<given-names>D. B.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>G.‐Q.</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2012</year>) <article-title>Human P301L‐mutant tau expression in mouse entorhinal‐hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits</article-title>. <source/>PLoS ONE
<volume>7</volume>, <fpage>e45881</fpage>.<pub-id pub-id-type="pmid">23029293</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0100">
<mixed-citation id="jnc13600-cit-0100" publication-type="journal">
<string-name>
<surname>Härtig</surname>
<given-names>W.</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Brauer</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Schüppel</surname>
<given-names>K. F.</given-names>
</string-name>, <string-name>
<surname>Arendt</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Brückner</surname>
<given-names>G.</given-names>
</string-name> and <string-name>
<surname>Bigl</surname>
<given-names>V.</given-names>
</string-name> (<year>2000</year>) <article-title>Abnormally phosphorylated protein tau in the cortex of aged individuals of various mammalian orders</article-title>. <source/>Acta Neuropathol.
<volume>100</volume>, <fpage>305</fpage>–<lpage>312</lpage>.<pub-id pub-id-type="pmid">10965801</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0101">
<mixed-citation id="jnc13600-cit-0101" publication-type="journal">
<string-name>
<surname>He</surname>
<given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X. S.</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>M. N.</given-names>
</string-name> and <string-name>
<surname>He</surname>
<given-names>R. Q.</given-names>
</string-name> (<year>2009</year>) <article-title>The proline‐rich domain of tau plays a role in interactions with actin</article-title>. <source/>BMC Cell Biol.
<volume>10</volume>, <fpage>81</fpage>.<pub-id pub-id-type="pmid">19895707</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0102">
<mixed-citation id="jnc13600-cit-0102" publication-type="journal">
<string-name>
<surname>Heidary</surname>
<given-names>G.</given-names>
</string-name> and <string-name>
<surname>Fortini</surname>
<given-names>M. E.</given-names>
</string-name> (<year>2001</year>) <article-title>Identification and characterization of the Drosophila tau homolog</article-title>. <source/>Mech. Dev.
<volume>108</volume>, <fpage>171</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">11578871</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0103">
<mixed-citation id="jnc13600-cit-0103" publication-type="journal">
<string-name>
<surname>Herrup</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</string-name> (<year>2007</year>) <article-title>Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?</article-title>
<source/>Nat. Rev. Neurosci.
<volume>8</volume>, <fpage>368</fpage>–<lpage>378</lpage>.<pub-id pub-id-type="pmid">17453017</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0104">
<mixed-citation id="jnc13600-cit-0104" publication-type="journal">
<string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Andreadis</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> (<year>2002</year>) <article-title>Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration</article-title>. <source/>Neuron
<volume>35</volume>, <fpage>433</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">12165467</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0105">
<mixed-citation id="jnc13600-cit-0105" publication-type="journal">
<string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Yoshiyama</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> (<year>2005</year>) <article-title>Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies</article-title>. <source/>J. Neurosci.
<volume>25</volume>, <fpage>9434</fpage>–<lpage>9443</lpage>.<pub-id pub-id-type="pmid">16221853</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0106">
<mixed-citation id="jnc13600-cit-0106" publication-type="journal">
<string-name>
<surname>Höglinger</surname>
<given-names>G. U.</given-names>
</string-name>, <string-name>
<surname>Melhem</surname>
<given-names>N. M.</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy</article-title>. <source/>Nat. Genet.
<volume>43</volume>, <fpage>699</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">21685912</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0107">
<mixed-citation id="jnc13600-cit-0107" publication-type="journal">
<string-name>
<surname>Holmes</surname>
<given-names>B. B.</given-names>
</string-name>, <string-name>
<surname>DeVos</surname>
<given-names>S. L.</given-names>
</string-name>, <string-name>
<surname>Kfoury</surname>
<given-names>N.</given-names>
</string-name>
<italic>et al</italic> (<year>2013</year>) <article-title>Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds</article-title>. <source/>Proc. Natl Acad. Sci.
<volume>110</volume>, <fpage>E3138</fpage>–<lpage>E3147</lpage>.<pub-id pub-id-type="pmid">23898162</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0108">
<mixed-citation id="jnc13600-cit-0108" publication-type="journal">
<string-name>
<surname>Hoover</surname>
<given-names>B. R.</given-names>
</string-name>, <string-name>
<surname>Reed</surname>
<given-names>M. N.</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>J.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration</article-title>. <source/>Neuron
<volume>68</volume>, <fpage>1067</fpage>–<lpage>1081</lpage>.<pub-id pub-id-type="pmid">21172610</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0109">
<mixed-citation id="jnc13600-cit-0109" publication-type="journal">
<string-name>
<surname>Horiguchi</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Uryu</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Giasson</surname>
<given-names>B. I.</given-names>
</string-name>, <string-name>
<surname>Ischiropoulos</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>LightFoot</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bellmann</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Richter‐Landsberg</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2003</year>) <article-title>Nitration of tau protein is linked to neurodegeneration in tauopathies</article-title>. <source/>Am. J. Pathol.
<volume>163</volume>, <fpage>1021</fpage>–<lpage>1031</lpage>.<pub-id pub-id-type="pmid">12937143</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0110">
<mixed-citation id="jnc13600-cit-0110" publication-type="journal">
<string-name>
<surname>Hunsberger</surname>
<given-names>H. C.</given-names>
</string-name>, <string-name>
<surname>Rudy</surname>
<given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Batten</surname>
<given-names>S. R.</given-names>
</string-name>, <string-name>
<surname>Gerhardt</surname>
<given-names>G. A.</given-names>
</string-name> and <string-name>
<surname>Reed</surname>
<given-names>M. N.</given-names>
</string-name> (<year>2015</year>) <article-title>P301L tau expression affects glutamate release and clearance in the hippocampal trisynaptic pathway</article-title>. <source/>J. Neurochem.
<volume>132</volume>, <fpage>169</fpage>–<lpage>182</lpage>.<pub-id pub-id-type="pmid">25319522</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0111">
<mixed-citation id="jnc13600-cit-0111" publication-type="journal">
<string-name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lendon</surname>
<given-names>C. L.</given-names>
</string-name>, <string-name>
<surname>Rizzu</surname>
<given-names>P.</given-names>
</string-name>
<italic>et al</italic> (<year>1998</year>) <article-title>Association of missense and 5’‐splice‐site mutations in tau with the inherited dementia FTDP‐17</article-title>. <source/>Nature
<volume>393</volume>, <fpage>702</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">9641683</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0112">
<mixed-citation id="jnc13600-cit-0112" publication-type="journal">
<string-name>
<surname>Iba</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> (<year>2013</year>) <article-title>Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic Mouse model of Alzheimer's‐like tauopathy</article-title>. <source/>J. Neurosci.
<volume>33</volume>, <fpage>1024</fpage>–<lpage>1037</lpage>.<pub-id pub-id-type="pmid">23325240</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0113">
<mixed-citation id="jnc13600-cit-0113" publication-type="journal">
<string-name>
<surname>Ikeda</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kawarai</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kawarabayashi</surname>
<given-names>T.</given-names>
</string-name>
<italic>et al</italic> (<year>2005</year>) <article-title>Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice</article-title>. <source/>Am. J. Pathol.
<volume>166</volume>, <fpage>521</fpage>–<lpage>531</lpage>.<pub-id pub-id-type="pmid">15681835</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0114">
<mixed-citation id="jnc13600-cit-0114" publication-type="journal">
<string-name>
<surname>Ikegami</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Hirokawa</surname>
<given-names>N.</given-names>
</string-name> (<year>2000</year>) <article-title>Muscle weakness, hyperactivity, and impairment in fear conditioning in tau‐deficient mice</article-title>. <source/>Neurosci. Lett.
<volume>279</volume>, <fpage>129</fpage>–<lpage>132</lpage>.<pub-id pub-id-type="pmid">10688046</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0115">
<mixed-citation id="jnc13600-cit-0115" publication-type="journal">
<string-name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Blanchard</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>C.‐X.</given-names>
</string-name> and <string-name>
<surname>Grundke‐Iqbal</surname>
<given-names>I.</given-names>
</string-name> (<year>2010</year>) <article-title>Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial</article-title>. <source/>Biochem. Soc. Trans.
<volume>38</volume>, <fpage>962</fpage>–<lpage>966</lpage>.<pub-id pub-id-type="pmid">20658985</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0116">
<mixed-citation id="jnc13600-cit-0116" publication-type="journal">
<string-name>
<surname>Irwin</surname>
<given-names>D. J.</given-names>
</string-name>, <string-name>
<surname>Cairns</surname>
<given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>McMillan</surname>
<given-names>C. T.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>E. B.</given-names>
</string-name>, <string-name>
<surname>Deerlin</surname>
<given-names>V. M.</given-names>
</string-name>, <string-name>
<surname>Van</surname>
<given-names>Lee. V. M.‐Y.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2015</year>) <article-title>Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine</article-title>. <source/>Acta Neuropathol.
<volume>129</volume>, <fpage>469</fpage>–<lpage>491</lpage>.<pub-id pub-id-type="pmid">25549971</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0117">
<mixed-citation id="jnc13600-cit-0117" publication-type="journal">
<string-name>
<surname>Ischiropoulos</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Al‐Mehdi</surname>
<given-names>A. B.</given-names>
</string-name> (<year>1995</year>) <article-title>Peroxynitrite‐mediated oxidative protein modifications</article-title>. <source/>FEBS Lett.
<volume>364</volume>, <fpage>279</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">7758583</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0118">
<mixed-citation id="jnc13600-cit-0118" publication-type="journal">
<string-name>
<surname>Ishihara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>M. K.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.</given-names>
</string-name> (<year>1999</year>) <article-title>Age‐dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform</article-title>. <source/>Neuron
<volume>24</volume>, <fpage>751</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">10595524</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0119">
<mixed-citation id="jnc13600-cit-0119" publication-type="journal">
<string-name>
<surname>Ishihara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Yoshiyama</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.</given-names>
</string-name> (<year>2001a</year>) <article-title>Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments</article-title>. <source/>J. Neurosci.
<volume>21</volume>, <fpage>6026</fpage>–<lpage>6035</lpage>.<pub-id pub-id-type="pmid">11487626</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0120">
<mixed-citation id="jnc13600-cit-0120" publication-type="journal">
<string-name>
<surname>Ishihara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yoshiyama</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.</given-names>
</string-name> (<year>2001b</year>) <article-title>Age‐dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice</article-title>. <source/>Am. J. Pathol.
<volume>158</volume>, <fpage>555</fpage>–<lpage>562</lpage>.<pub-id pub-id-type="pmid">11159192</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0121">
<mixed-citation id="jnc13600-cit-0121" publication-type="journal">
<string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Ke</surname>
<given-names>Y. D.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2009</year>) <article-title>Phosphorylated tau interacts with c‐Jun N‐terminal kinase‐interacting protein 1 (JIP1) in Alzheimer disease</article-title>. <source/>J. Biol. Chem.
<volume>284</volume>, <fpage>20909</fpage>–<lpage>20916</lpage>.<pub-id pub-id-type="pmid">19491104</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0122">
<mixed-citation id="jnc13600-cit-0122" publication-type="journal">
<string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Ke</surname>
<given-names>Y. D.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Dendritic function of tau mediates amyloid‐beta toxicity in Alzheimer's disease mouse models</article-title>. <source/>Cell
<volume>142</volume>, <fpage>387</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">20655099</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0123">
<mixed-citation id="jnc13600-cit-0123" publication-type="journal">
<string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Kril</surname>
<given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hodges</surname>
<given-names>J. R.</given-names>
</string-name> and <string-name>
<surname>Kiernan</surname>
<given-names>M. C.</given-names>
</string-name> (<year>2015</year>) <article-title>FTD and ALS—translating mouse studies into clinical trials</article-title>. <source/>Nat. Rev. Neurol.
<volume>11</volume>, <fpage>360</fpage>–<lpage>366</lpage>.<pub-id pub-id-type="pmid">25939274</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0124">
<mixed-citation id="jnc13600-cit-0124" publication-type="journal">
<string-name>
<surname>Jack</surname>
<given-names>C. R.</given-names>
</string-name>, <string-name>
<surname>Knopman</surname>
<given-names>D. S.</given-names>
</string-name>, <string-name>
<surname>Jagust</surname>
<given-names>W. J.</given-names>
</string-name>
<italic>et al</italic> (<year>2013</year>) <article-title>Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers</article-title>. <source/>Lancet Neurol.
<volume>12</volume>, <fpage>207</fpage>–<lpage>216</lpage>.<pub-id pub-id-type="pmid">23332364</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0125">
<mixed-citation id="jnc13600-cit-0125" publication-type="journal">
<string-name>
<surname>Jackson</surname>
<given-names>G. R.</given-names>
</string-name>, <string-name>
<surname>Wiedau‐Pazos</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sang</surname>
<given-names>T. K.</given-names>
</string-name>, <string-name>
<surname>Wagle</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>C. a.</given-names>
</string-name>, <string-name>
<surname>Massachi</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Geschwind</surname>
<given-names>D. H.</given-names>
</string-name> (<year>2002</year>) <article-title>Human wild‐type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila</article-title>. <source/>Neuron
<volume>34</volume>, <fpage>509</fpage>–<lpage>519</lpage>.<pub-id pub-id-type="pmid">12062036</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0126">
<mixed-citation id="jnc13600-cit-0126" publication-type="journal">
<string-name>
<surname>Janning</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Igaev</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sündermann</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Brühmann</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Beutel</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Heinisch</surname>
<given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Bakota</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Piehler</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Junge</surname>
<given-names>W.</given-names>
</string-name> and <string-name>
<surname>Brandt</surname>
<given-names>R.</given-names>
</string-name> (<year>2014</year>) <article-title>Single‐molecule tracking of tau reveals fast kiss‐and‐hop interaction with microtubules in living neurons</article-title>. <source/>Mol. Biol. Cell
<volume>25</volume>, <fpage>3541</fpage>–<lpage>3551</lpage>.<pub-id pub-id-type="pmid">25165145</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0127">
<mixed-citation id="jnc13600-cit-0127" publication-type="journal">
<string-name>
<surname>Jaworski</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Dewachter</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Lechat</surname>
<given-names>B.</given-names>
</string-name>
<italic>et al</italic> (<year>2009</year>) <article-title>AAV‐tau mediates pyramidal neurodegeneration by cell‐cycle re‐entry without neurofibrillary tangle formation in wild‐type mice</article-title>. <source/>PLoS ONE
<volume>4</volume>, <fpage>e7280</fpage>.<pub-id pub-id-type="pmid">19794916</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0128">
<mixed-citation id="jnc13600-cit-0128" publication-type="journal">
<string-name>
<surname>Jho</surname>
<given-names>Y. S.</given-names>
</string-name>, <string-name>
<surname>Zhulina</surname>
<given-names>E. B.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>M. W.</given-names>
</string-name> and <string-name>
<surname>Pincus</surname>
<given-names>P. A.</given-names>
</string-name> (<year>2010</year>) <article-title>Monte carlo simulations of tau proteins: effect of phosphorylation</article-title>. <source/>Biophys. J .
<volume>99</volume>, <fpage>2387</fpage>–<lpage>2397</lpage>.<pub-id pub-id-type="pmid">20959078</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0129">
<mixed-citation id="jnc13600-cit-0129" publication-type="journal">
<string-name>
<surname>Kamat</surname>
<given-names>P. K.</given-names>
</string-name>, <string-name>
<surname>Rai</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Swarnkar</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Shukla</surname>
<given-names>R.</given-names>
</string-name> and <string-name>
<surname>Nath</surname>
<given-names>C.</given-names>
</string-name> (<year>2014</year>) <article-title>Molecular and cellular mechanism of okadaic acid (OKA)‐induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application</article-title>. <source/>Mol. Neurobiol.
<volume>50</volume>, <fpage>852</fpage>–<lpage>865</lpage>.<pub-id pub-id-type="pmid">24710687</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0130">
<mixed-citation id="jnc13600-cit-0130" publication-type="journal">
<string-name>
<surname>Kampers</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Pangalos</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Geerts</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Wiech</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>1999</year>) <article-title>Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease</article-title>. <source/>FEBS Lett.
<volume>451</volume>, <fpage>39</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">10356980</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0131">
<mixed-citation id="jnc13600-cit-0131" publication-type="journal">
<string-name>
<surname>Kar</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Amos</surname>
<given-names>L. A.</given-names>
</string-name> (<year>2003</year>) <article-title>Repeat motifs of tau bind to the insides of microtubules in the absence of taxol</article-title>. <source/>EMBO J.
<volume>22</volume>, <fpage>70</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">12505985</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0132">
<mixed-citation id="jnc13600-cit-0132" publication-type="journal">
<string-name>
<surname>Ke</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Dramiga</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schütz</surname>
<given-names>U.</given-names>
</string-name>, <string-name>
<surname>Kril</surname>
<given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Ittner</surname>
<given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Schröder</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2012</year>) <article-title>Tau‐mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease</article-title>. <source/>PLoS ONE
<volume>7</volume>, <fpage>e35678</fpage>.<pub-id pub-id-type="pmid">22558197</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0133">
<mixed-citation id="jnc13600-cit-0133" publication-type="journal">
<string-name>
<surname>Khurana</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Merlo</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Duboff</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Fulga</surname>
<given-names>T. a.</given-names>
</string-name>, <string-name>
<surname>Sharp</surname>
<given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>S. D.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2012</year>) <article-title>A neuroprotective role for the DNA damage checkpoint in tauopathy</article-title>. <source/>Aging Cell
<volume>11</volume>, <fpage>360</fpage>–<lpage>362</lpage>.<pub-id pub-id-type="pmid">22181010</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0134">
<mixed-citation id="jnc13600-cit-0134" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>Y. H.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>S. H.</given-names>
</string-name>, <string-name>
<surname>D'Avanzo</surname>
<given-names>C.</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>A 3D human neural cell culture system for modeling Alzheimer's disease</article-title>. <source/>Nat. Protoc.
<volume>10</volume>, <fpage>985</fpage>–<lpage>1006</lpage>.<pub-id pub-id-type="pmid">26068894</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0135">
<mixed-citation id="jnc13600-cit-0135" publication-type="journal">
<string-name>
<surname>Kimura</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Fukuda</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Sahara</surname>
<given-names>N.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Aggregation of detergent‐insoluble tau is involved in neuronal loss but not in synaptic loss</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>38692</fpage>–<lpage>38699</lpage>.<pub-id pub-id-type="pmid">20921222</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0136">
<mixed-citation id="jnc13600-cit-0136" publication-type="journal">
<string-name>
<surname>Kins</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Crameri</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>D. R. H.</given-names>
</string-name>, <string-name>
<surname>Hemmings</surname>
<given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Nitsch</surname>
<given-names>R. M.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2001</year>) <article-title>Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>38193</fpage>–<lpage>38200</lpage>.<pub-id pub-id-type="pmid">11473109</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0137">
<mixed-citation id="jnc13600-cit-0137" publication-type="journal">
<string-name>
<surname>Klein</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>E.‐M.</given-names>
</string-name>, <string-name>
<surname>Cardine</surname>
<given-names>A.‐M.</given-names>
</string-name>, <string-name>
<surname>Schraven</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>R.</given-names>
</string-name> and <string-name>
<surname>Trotter</surname>
<given-names>J.</given-names>
</string-name> (<year>2002</year>) <article-title>Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau</article-title>. <source/>J. Neurosci.
<volume>22</volume>, <fpage>698</fpage>–<lpage>707</lpage>.<pub-id pub-id-type="pmid">11826099</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0138">
<mixed-citation id="jnc13600-cit-0138" publication-type="journal">
<string-name>
<surname>Klein</surname>
<given-names>R. L.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>W.‐L.</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>E. M.</given-names>
</string-name> and <string-name>
<surname>King</surname>
<given-names>M. A.</given-names>
</string-name> (<year>2004</year>) <article-title>Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau</article-title>. <source/>Am. J. Pathol.
<volume>164</volume>, <fpage>347</fpage>–<lpage>353</lpage>.<pub-id pub-id-type="pmid">14695347</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0139">
<mixed-citation id="jnc13600-cit-0139" publication-type="journal">
<string-name>
<surname>Konzack</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Thies</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Marx</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.‐M.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2007</year>) <article-title>Swimming against the tide: mobility of the microtubule‐associated protein tau in neurons</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>9916</fpage>–<lpage>9927</lpage>.<pub-id pub-id-type="pmid">17855606</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0140">
<mixed-citation id="jnc13600-cit-0140" publication-type="journal">
<string-name>
<surname>Kopeikina</surname>
<given-names>K. J.</given-names>
</string-name>, <string-name>
<surname>Polydoro</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tai</surname>
<given-names>H. C.</given-names>
</string-name>, <string-name>
<surname>Yaeger</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>G. a.</given-names>
</string-name>, <string-name>
<surname>Pitstick</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>B. T.</given-names>
</string-name> and <string-name>
<surname>Spires‐Jones</surname>
<given-names>T. L.</given-names>
</string-name> (<year>2013</year>) <article-title>Synaptic alterations in the rTg4510 mouse model of tauopathy</article-title>. <source/>J. Comp. Neurol.
<volume>521</volume>, <fpage>1334</fpage>–<lpage>1353</lpage>.<pub-id pub-id-type="pmid">23047530</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0141">
<mixed-citation id="jnc13600-cit-0141" publication-type="journal">
<string-name>
<surname>Kosik</surname>
<given-names>K. S.</given-names>
</string-name>, <string-name>
<surname>Joachim</surname>
<given-names>C. L.</given-names>
</string-name> and <string-name>
<surname>Selkoe</surname>
<given-names>D. J.</given-names>
</string-name> (<year>1986</year>) <article-title>Microtubule‐associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>83</volume>, <fpage>4044</fpage>–<lpage>4048</lpage>.<pub-id pub-id-type="pmid">2424016</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0142">
<mixed-citation id="jnc13600-cit-0142" publication-type="journal">
<string-name>
<surname>Kosik</surname>
<given-names>K. S.</given-names>
</string-name>, <string-name>
<surname>Orecchio</surname>
<given-names>L. D.</given-names>
</string-name>, <string-name>
<surname>Bakalis</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Neve</surname>
<given-names>R. L.</given-names>
</string-name> (<year>1989</year>) <article-title>Developmentally regulated expression of specific tau sequences</article-title>. <source/>Neuron
<volume>2</volume>, <fpage>1389</fpage>–<lpage>1397</lpage>.<pub-id pub-id-type="pmid">2560640</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0143">
<mixed-citation id="jnc13600-cit-0143" publication-type="journal">
<string-name>
<surname>Kosmidis</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Grammenoudi</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Papanikolopoulou</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Skoulakis</surname>
<given-names>E. M. C.</given-names>
</string-name> (<year>2010</year>) <article-title>Differential effects of tau on the integrity and function of neurons essential for learning in drosophila</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>464</fpage>–<lpage>477</lpage>.<pub-id pub-id-type="pmid">20071510</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0144">
<mixed-citation id="jnc13600-cit-0144" publication-type="journal">
<string-name>
<surname>Kouri</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Whitwell</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Josephs</surname>
<given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Rademakers</surname>
<given-names>R.</given-names>
</string-name> and <string-name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</string-name> (<year>2011</year>) <article-title>Corticobasal degeneration: a pathologically distinct 4R tauopathy</article-title>. <source/>Nat. Rev. Neurol.
<volume>7</volume>, <fpage>263</fpage>–<lpage>272</lpage>.<pub-id pub-id-type="pmid">21487420</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0145">
<mixed-citation id="jnc13600-cit-0145" publication-type="journal">
<string-name>
<surname>Kovacs</surname>
<given-names>G. G.</given-names>
</string-name>, <string-name>
<surname>Majtenyi</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Spina</surname>
<given-names>S.</given-names>
</string-name>
<italic>et al</italic> (<year>2008</year>) <article-title>White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>67</volume>, <fpage>963</fpage>–<lpage>975</lpage>.<pub-id pub-id-type="pmid">18800011</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0146">
<mixed-citation id="jnc13600-cit-0146" publication-type="journal">
<string-name>
<surname>Kraemer</surname>
<given-names>B. C.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Leverenz</surname>
<given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>J. H.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Schellenberg</surname>
<given-names>G. D.</given-names>
</string-name> (<year>2003</year>) <article-title>Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>100</volume>, <fpage>9980</fpage>–<lpage>9985</lpage>.<pub-id pub-id-type="pmid">12872001</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0147">
<mixed-citation id="jnc13600-cit-0147" publication-type="journal">
<string-name>
<surname>Krstic</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Madhusudan</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Doehner</surname>
<given-names>J.</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Systemic immune challenges trigger and drive Alzheimer‐like neuropathology in mice</article-title>. <source/>J. Neuroinflammation
<volume>9</volume>, <fpage>151</fpage>.<pub-id pub-id-type="pmid">22747753</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0148">
<mixed-citation id="jnc13600-cit-0148" publication-type="journal">
<string-name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Tepper</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Kaniyappan</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Biernat</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wegmann</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Müller</surname>
<given-names>D. J.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2014</year>) <article-title>Stages and conformations of the tau repeat domain during aggregation and its effect on neuronal toxicity</article-title>. <source/>J. Biol. Chem.
<volume>289</volume>, <fpage>20318</fpage>–<lpage>20332</lpage>.<pub-id pub-id-type="pmid">24825901</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-1048">
<mixed-citation id="jnc13600-cit-1048" publication-type="journal">
<string-name>
<surname>Kunze</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Meissner</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Brando</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Renaud</surname>
<given-names>P.</given-names>
</string-name> (<year>2011</year>) <article-title>Co‐pathological connected primary neurons in a microfluidic device for Alzheimer studies</article-title>. <source/>Biotechnol. Bioeng.
<volume>108</volume>, <fpage>2241</fpage>–<lpage>2245</lpage>.<pub-id pub-id-type="pmid">21391208</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0149">
<mixed-citation id="jnc13600-cit-0149" publication-type="journal">
<string-name>
<surname>Kuret</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Congdon</surname>
<given-names>E. E.</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>X.</given-names>
</string-name> and <string-name>
<surname>Zhong</surname>
<given-names>Q.</given-names>
</string-name> (<year>2005</year>) <article-title>Evaluating triggers and enhancers of tau fibrillization</article-title>. <source/>Microsc. Res. Tech.
<volume>67</volume>, <fpage>141</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">16103995</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0150">
<mixed-citation id="jnc13600-cit-0150" publication-type="journal">
<string-name>
<surname>Lannuzel</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Höglinger</surname>
<given-names>G.</given-names>
</string-name> and <string-name>
<surname>Champy</surname>
<given-names>P.</given-names>
</string-name> (<year>2003</year>) <article-title>The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism</article-title>. <source/>Neuroscience
<volume>121</volume>, <fpage>287</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">14521988</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0151">
<mixed-citation id="jnc13600-cit-0151" publication-type="journal">
<string-name>
<surname>Lasagna‐Reeves</surname>
<given-names>C. A.</given-names>
</string-name>, <string-name>
<surname>Castillo‐Carranza</surname>
<given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>U.</given-names>
</string-name>, <string-name>
<surname>Clos</surname>
<given-names>A. L.</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>G. R.</given-names>
</string-name> and <string-name>
<surname>Kayed</surname>
<given-names>R.</given-names>
</string-name> (<year>2011</year>) <article-title>Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild‐type mice</article-title>. <source/>Mol. Neurodegener.
<volume>6</volume>, <fpage>39</fpage>.<pub-id pub-id-type="pmid">21645391</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0152">
<mixed-citation id="jnc13600-cit-0152" publication-type="journal">
<string-name>
<surname>Ledesma</surname>
<given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Bonay</surname>
<given-names>P.</given-names>
</string-name> and <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>1995</year>) <article-title>Tau protein from Alzheimer's disease patients is glycated at its tubulin‐binding domain</article-title>. <source/>J. Neurochem.
<volume>65</volume>, <fpage>1658</fpage>–<lpage>1664</lpage>.<pub-id pub-id-type="pmid">7561862</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0153">
<mixed-citation id="jnc13600-cit-0153" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Cowan</surname>
<given-names>N.</given-names>
</string-name> and <string-name>
<surname>Kirschner</surname>
<given-names>M.</given-names>
</string-name> (<year>1988</year>) <article-title>The primary structure and heterogeneity of tau protein from mouse brain</article-title>. <source/>Science
<volume>239</volume>, <fpage>285</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">3122323</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0154">
<mixed-citation id="jnc13600-cit-0154" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Newman</surname>
<given-names>S. T.</given-names>
</string-name>, <string-name>
<surname>Gard</surname>
<given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Band</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Panchamoorthy</surname>
<given-names>G.</given-names>
</string-name> (<year>1998</year>) <article-title>Tau interacts with src‐family non‐receptor tyrosine kinases</article-title>. <source/>J. Cell Sci.
<volume>111</volume> (Pt 2, <fpage>3167</fpage>–<lpage>3177</lpage>.<pub-id pub-id-type="pmid">9763511</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0155">
<mixed-citation id="jnc13600-cit-0155" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>V. M.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2001</year>) <article-title>Neurodegenerative auopathies</article-title>. <source/>Annu. Rev. Neurosci.
<volume>24</volume>, <fpage>1121</fpage>–<lpage>1159</lpage>.<pub-id pub-id-type="pmid">11520930</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0156">
<mixed-citation id="jnc13600-cit-0156" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name>, <string-name>
<surname>Brunden</surname>
<given-names>K. R.</given-names>
</string-name>, <string-name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> (<year>2011</year>) <article-title>Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets</article-title>. <source/>Cold Spring Harb. Perspect Med.
<volume>1</volume>, <fpage>a006437</fpage>.<pub-id pub-id-type="pmid">22229117</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0157">
<mixed-citation id="jnc13600-cit-0157" publication-type="journal">
<string-name>
<surname>Lei</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Ayton</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Finkelstein</surname>
<given-names>D. I.</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Tau deficiency induces parkinsonism with dementia by impairing APP‐mediated iron export</article-title>. <source/>Nat. Med.
<volume>18</volume>, <fpage>291</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">22286308</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0158">
<mixed-citation id="jnc13600-cit-0158" publication-type="journal">
<string-name>
<surname>Leroy</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ando</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Laporte</surname>
<given-names>V.</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice</article-title>. <source/>Am. J. Pathol.
<volume>181</volume>, <fpage>1928</fpage>–<lpage>1940</lpage>.<pub-id pub-id-type="pmid">23026200</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0159">
<mixed-citation id="jnc13600-cit-0159" publication-type="journal">
<string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>McGowan</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Rockwood</surname>
<given-names>J.</given-names>
</string-name>
<italic>et al</italic> (<year>2000</year>) <article-title>Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein</article-title>. <source/>Nat. Genet.
<volume>25</volume>, <fpage>402</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">10932182</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0160">
<mixed-citation id="jnc13600-cit-0160" publication-type="journal">
<string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Dickson</surname>
<given-names>D. W.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>W. L.</given-names>
</string-name>
<italic>et al</italic> (<year>2001</year>) <article-title>Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP</article-title>. <source/>Science
<volume>293</volume>, <fpage>1487</fpage>–<lpage>1491</lpage>.<pub-id pub-id-type="pmid">11520987</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0500">
<mixed-citation id="jnc13600-cit-0500" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>H.‐L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>H.‐H.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S.‐J.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>Y.‐Q.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y.‐J.</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X.‐C.</given-names>
</string-name>
<italic>et al</italic> (<year>2007</year>) <article-title>Phosphorylation of tau antagonizes apoptosis by stabilizing beta‐catenin, a mechanism involved in Alzheimer’s neurodegeneration</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>104</volume>, <fpage>3591</fpage>–<lpage>3596</lpage>.<pub-id pub-id-type="pmid">17360687</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0161">
<mixed-citation id="jnc13600-cit-0161" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zempel</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.‐M.</given-names>
</string-name>, <string-name>
<surname>Biernat</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2011</year>) <article-title>Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration</article-title>. <source/>EMBO J.
<volume>30</volume>, <fpage>4825</fpage>–<lpage>4837</lpage>.<pub-id pub-id-type="pmid">22009197</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0162">
<mixed-citation id="jnc13600-cit-0162" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</string-name> and <string-name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</string-name> (<year>2012a</year>) <article-title>Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective</article-title>. <source/>J. Neurol. Sci.
<volume>317</volume>, <fpage>1</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">22410257</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0163">
<mixed-citation id="jnc13600-cit-0163" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>X.‐H.</given-names>
</string-name>, <string-name>
<surname>Lv</surname>
<given-names>B.‐L.</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>J.‐Z.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>X.‐W.</given-names>
</string-name> and <string-name>
<surname>Wang</surname>
<given-names>J.‐Z.</given-names>
</string-name> (<year>2012b</year>) <article-title>AGEs induce Alzheimer‐like tau pathology and memory deficit via RAGE‐mediated GSK‐3 activation</article-title>. <source/>Neurobiol. Aging
<volume>33</volume>, <fpage>1400</fpage>–<lpage>1410</lpage>.<pub-id pub-id-type="pmid">21450369</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0164">
<mixed-citation id="jnc13600-cit-0164" publication-type="journal">
<string-name>
<surname>Lim</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Hernández</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>
<given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Gómez‐Ramos</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Morán</surname>
<given-names>M. a.</given-names>
</string-name> and <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>2001</year>) <article-title>FTDP‐17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain</article-title>. <source/>Mol. Cell Neurosci.
<volume>18</volume>, <fpage>702</fpage>–<lpage>714</lpage>.<pub-id pub-id-type="pmid">11749044</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0165">
<mixed-citation id="jnc13600-cit-0165" publication-type="journal">
<string-name>
<surname>Lin</surname>
<given-names>W.</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>L.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>
<given-names>X.</given-names>
</string-name> (<year>2015</year>) <article-title>Protein‐Specific Imaging of O‐GlcNAcylation in Single Cells</article-title>. <source/>Chem. Bio. Chem.
<volume>16</volume>, <fpage>2571</fpage>–<lpage>2575</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0166">
<mixed-citation id="jnc13600-cit-0166" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>C.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2013</year>) <article-title>Profiling murine tau with 0N, 1N and 2N isoform‐specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus</article-title>. <source/>PLoS ONE
<volume>8</volume>, <fpage>1</fpage>–<lpage>18</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0167">
<mixed-citation id="jnc13600-cit-0167" publication-type="journal">
<string-name>
<surname>LoPresti</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Szuchet</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Papasozomenos</surname>
<given-names>S. C.</given-names>
</string-name>, <string-name>
<surname>Zinkowski</surname>
<given-names>R. P.</given-names>
</string-name> and <string-name>
<surname>Binder</surname>
<given-names>L. I.</given-names>
</string-name> (<year>1995</year>) <article-title>Functional implications for the microtubule‐associated protein tau: localization in oligodendrocytes</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>92</volume>, <fpage>10369</fpage>–<lpage>10373</lpage>.<pub-id pub-id-type="pmid">7479786</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0168">
<mixed-citation id="jnc13600-cit-0168" publication-type="journal">
<string-name>
<surname>Ma</surname>
<given-names>Q.‐L.</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>F.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>7124</fpage>–<lpage>7136</lpage>.<pub-id pub-id-type="pmid">24849348</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0169">
<mixed-citation id="jnc13600-cit-0169" publication-type="journal">
<string-name>
<surname>Mackenzie</surname>
<given-names>I. R. A.</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Bigio</surname>
<given-names>E. H.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update</article-title>. <source/>Acta Neuropathol.
<volume>119</volume>, <fpage>1</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">19924424</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0170">
<mixed-citation id="jnc13600-cit-0170" publication-type="journal">
<string-name>
<surname>Mandelkow</surname>
<given-names>E.‐M.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2012</year>) <article-title>Biochemistry and cell biology of tau protein in neurofibrillary degeneration</article-title>. <source/>Cold Spring Harb. Perspect Med.
<volume>2</volume>, <fpage>a006247</fpage>.<pub-id pub-id-type="pmid">22762014</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0171">
<mixed-citation id="jnc13600-cit-0171" publication-type="journal">
<string-name>
<surname>Maphis</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Kokiko‐Cochran</surname>
<given-names>O. N.</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Cardona</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ransohoff</surname>
<given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Lamb</surname>
<given-names>B. T.</given-names>
</string-name> and <string-name>
<surname>Bhaskar</surname>
<given-names>K.</given-names>
</string-name> (<year>2015</year>) <article-title>Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain</article-title>. <source/>Brain
<volume>138</volume>, <fpage>1738</fpage>–<lpage>1755</lpage>.<pub-id pub-id-type="pmid">25833819</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0172">
<mixed-citation id="jnc13600-cit-0172" publication-type="journal">
<string-name>
<surname>Maurin</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Chong</surname>
<given-names>S.‐A.</given-names>
</string-name>, <string-name>
<surname>Kraev</surname>
<given-names>I.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e87605</fpage>.<pub-id pub-id-type="pmid">24498342</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0173">
<mixed-citation id="jnc13600-cit-0173" publication-type="journal">
<string-name>
<surname>McDermott</surname>
<given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Aamodt</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Aamodt</surname>
<given-names>E.</given-names>
</string-name> (<year>1996</year>) <article-title>ptl‐1, a Caenorhabditis elegans gene whose products are homologous to the tau microtubule‐associated proteins</article-title>. <source/>Biochemistry
<volume>35</volume>, <fpage>9415</fpage>–<lpage>9423</lpage>.<pub-id pub-id-type="pmid">8755720</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0174">
<mixed-citation id="jnc13600-cit-0174" publication-type="journal">
<string-name>
<surname>Medina</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> (<year>2015</year>) <article-title>Further understanding of tau phosphorylation: implications for therapy</article-title>. <source/>Expert Rev. Neurother.
<volume>15</volume>, <fpage>115</fpage>–<lpage>122</lpage>.<pub-id pub-id-type="pmid">25555397</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0175">
<mixed-citation id="jnc13600-cit-0175" publication-type="journal">
<string-name>
<surname>Medina</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Villanueva</surname>
<given-names>N.</given-names>
</string-name> (<year>2013</year>) <article-title>Use of okadaic acid to identify relevant phosphoepitopes in pathology: a focus on neurodegeneration</article-title>. <source/>Mar. Drugs
<volume>11</volume>, <fpage>1656</fpage>–<lpage>1668</lpage>.<pub-id pub-id-type="pmid">23697949</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0176">
<mixed-citation id="jnc13600-cit-0176" publication-type="journal">
<string-name>
<surname>Merino‐Serrais</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Benavides‐Piccione</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Blazquez‐Llorca</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kastanauskaite</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Rábano</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Avila</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>DeFelipe</surname>
<given-names>J.</given-names>
</string-name> (<year>2013</year>) <article-title>The influence of phospho‐τ on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease</article-title>. <source/>Brain
<volume>136</volume>, <fpage>1913</fpage>–<lpage>1928</lpage>.<pub-id pub-id-type="pmid">23715095</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0177">
<mixed-citation id="jnc13600-cit-0177" publication-type="journal">
<string-name>
<surname>Mertens</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Stüber</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Poppe</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Doerr</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ladewig</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Brüstle</surname>
<given-names>O.</given-names>
</string-name> and <string-name>
<surname>Koch</surname>
<given-names>P.</given-names>
</string-name> (<year>2013</year>) <article-title>Embryonic stem cell‐based modeling of tau pathology in human neurons</article-title>. <source/>Am. J. Pathol.
<volume>182</volume>, <fpage>1769</fpage>–<lpage>1779</lpage>.<pub-id pub-id-type="pmid">23499461</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0178">
<mixed-citation id="jnc13600-cit-0178" publication-type="journal">
<string-name>
<surname>Min</surname>
<given-names>S.‐W.</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>S.‐H.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</string-name>
<italic>et al</italic> (<year>2010</year>) <article-title>Acetylation of tau inhibits Its degradation and contributes to tauopathy</article-title>. <source/>Neuron
<volume>67</volume>, <fpage>953</fpage>–<lpage>966</lpage>.<pub-id pub-id-type="pmid">20869593</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0179">
<mixed-citation id="jnc13600-cit-0179" publication-type="journal">
<string-name>
<surname>Mondragón‐Rodríguez</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Trillaud‐Doppia</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Dudilot</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bourgeois</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lauzon</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Leclerc</surname>
<given-names>N.</given-names>
</string-name> and <string-name>
<surname>Boehm</surname>
<given-names>J.</given-names>
</string-name> (<year>2012</year>) <article-title>Interaction of endogenous tau protein with synaptic proteins is regulated by N‐methyl‐D‐aspartate receptor‐dependent tau phosphorylation</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>32040</fpage>–<lpage>32053</lpage>.<pub-id pub-id-type="pmid">22833681</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0180">
<mixed-citation id="jnc13600-cit-0180" publication-type="journal">
<string-name>
<surname>Moraga</surname>
<given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Nuñez</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Garrido</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Maccioni</surname>
<given-names>R. B.</given-names>
</string-name> (<year>1993</year>) <article-title>A tau fragment containing a repetitive sequence induces bundling of actin filaments</article-title>. <source/>J. Neurochem.
<volume>61</volume>, <fpage>979</fpage>–<lpage>986</lpage>.<pub-id pub-id-type="pmid">8360695</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0181">
<mixed-citation id="jnc13600-cit-0181" publication-type="journal">
<string-name>
<surname>Morishima‐Kawashima</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Takio</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Titani</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Ihara</surname>
<given-names>Y.</given-names>
</string-name> (<year>1995</year>) <article-title>Proline‐directed and non‐proline‐directed phosphorylation of PHF‐tau</article-title>. <source/>J. Biol. Chem.
<volume>270</volume>, <fpage>823</fpage>–<lpage>829</lpage>.<pub-id pub-id-type="pmid">7822317</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0182">
<mixed-citation id="jnc13600-cit-0182" publication-type="journal">
<string-name>
<surname>Morris</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Vossel</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2011</year>) <article-title>The many faces of tau</article-title>. <source/>Neuron
<volume>70</volume>, <fpage>410</fpage>–<lpage>426</lpage>.<pub-id pub-id-type="pmid">21555069</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0183">
<mixed-citation id="jnc13600-cit-0183" publication-type="journal">
<string-name>
<surname>Morris</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hamto</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Adame</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Devidze</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2013</year>) <article-title>Age‐appropriate cognition and subtle dopamine‐independent motor deficits in aged Tau knockout mice</article-title>. <source/>Neurobiol. Aging
<volume>34</volume>, <fpage>1523</fpage>–<lpage>1529</lpage>.<pub-id pub-id-type="pmid">23332171</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0184">
<mixed-citation id="jnc13600-cit-0184" publication-type="journal">
<string-name>
<surname>Morris</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Knudsen</surname>
<given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Trinidad</surname>
<given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Ioanoviciu</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Burlingame</surname>
<given-names>A. L.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2015</year>) <article-title>Tau post‐translational modifications in wild‐type and human amyloid precursor protein transgenic mice</article-title>. <source/>Nat. Neurosci.
<volume>18</volume>, <fpage>1183</fpage>–<lpage>1189</lpage>.<pub-id pub-id-type="pmid">26192747</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0185">
<mixed-citation id="jnc13600-cit-0185" publication-type="journal">
<string-name>
<surname>Morsch</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>W.</given-names>
</string-name> and <string-name>
<surname>Coleman</surname>
<given-names>P. D.</given-names>
</string-name> (<year>1999</year>) <article-title>Neurons may live for decades with neurofibrillary tangles</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>58</volume>, <fpage>188</fpage>–<lpage>197</lpage>.<pub-id pub-id-type="pmid">10029101</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0186">
<mixed-citation id="jnc13600-cit-0186" publication-type="journal">
<string-name>
<surname>Murrell</surname>
<given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Koller</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Foroud</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Edenberg</surname>
<given-names>H. J.</given-names>
</string-name>, <string-name>
<surname>Farlow</surname>
<given-names>M. R.</given-names>
</string-name> and <string-name>
<surname>Ghetti</surname>
<given-names>B.</given-names>
</string-name> (<year>1997</year>) <article-title>Familial multiple‐system tauopathy with presenile dementia is localized to chromosome 17</article-title>. <source/>Am. J. Hum. Genet.
<volume>61</volume>, <fpage>1131</fpage>–<lpage>1138</lpage>.<pub-id pub-id-type="pmid">9345089</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0187">
<mixed-citation id="jnc13600-cit-0187" publication-type="journal">
<string-name>
<surname>Nelson</surname>
<given-names>P. T.</given-names>
</string-name> and <string-name>
<surname>Saper</surname>
<given-names>C. B.</given-names>
</string-name> (<year>1996</year>) <article-title>Injections of okadaic acid, but not beta‐amyloid peptide, induce Alz‐50 immunoreactive dystrophic neurites in the cerebral cortex of sheep</article-title>. <source/>Neurosci. Lett.
<volume>208</volume>, <fpage>77</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">8859894</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0188">
<mixed-citation id="jnc13600-cit-0188" publication-type="journal">
<string-name>
<surname>Nishimura</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</string-name> and <string-name>
<surname>Lu</surname>
<given-names>B.</given-names>
</string-name> (<year>2004</year>) <article-title>PAR‐1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila</article-title>. <source/>Cell
<volume>116</volume>, <fpage>671</fpage>–<lpage>682</lpage>.<pub-id pub-id-type="pmid">15006350</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0189">
<mixed-citation id="jnc13600-cit-0189" publication-type="journal">
<string-name>
<surname>Oddo</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Caccamo</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>M. P.</given-names>
</string-name>, <string-name>
<surname>Golde</surname>
<given-names>T. E.</given-names>
</string-name>, <string-name>
<surname>Kayed</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Metherate</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mattson</surname>
<given-names>M. P.</given-names>
</string-name>, <string-name>
<surname>Akbari</surname>
<given-names>Y.</given-names>
</string-name> and <string-name>
<surname>LaFerla</surname>
<given-names>F. M.</given-names>
</string-name> (<year>2003</year>) <article-title>Triple‐transgenic model of Alzheimer's Disease with plaques and tangles: intracellular Aβ and synaptic dysfunction</article-title>. <source/>Neuron
<volume>39</volume>, <fpage>409</fpage>–<lpage>421</lpage>.<pub-id pub-id-type="pmid">12895417</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0190">
<mixed-citation id="jnc13600-cit-0190" publication-type="journal">
<string-name>
<surname>Paquet</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Bhat</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Sydow</surname>
<given-names>A.</given-names>
</string-name>
<italic>et al</italic> (<year>2009</year>) <article-title>Technical advance A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation</article-title>. <source/>J. Clin. Invest.
<volume>119</volume>, <fpage>1382</fpage>–<lpage>1395</lpage>.<pub-id pub-id-type="pmid">19363289</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0191">
<mixed-citation id="jnc13600-cit-0191" publication-type="journal">
<string-name>
<surname>Pick</surname>
<given-names>A.</given-names>
</string-name> (<year>1892</year>) <article-title>Ueber die Beziehungen der senilen Hirnatrophie zur Aphasie</article-title>. <source/>Prager med Wschr
<volume>17</volume>, <fpage>165</fpage>–<lpage>167</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0192">
<mixed-citation id="jnc13600-cit-0192" publication-type="journal">
<string-name>
<surname>Polanco</surname>
<given-names>J. C.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2015</year>) <article-title>No full admission for tau to the exclusive prion club yet</article-title>. <source/>EMBO J., <fpage>1</fpage>–<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="jnc13600-bib-0193">
<mixed-citation id="jnc13600-cit-0193" publication-type="journal">
<string-name>
<surname>Polydoro</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Acker</surname>
<given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Castillo</surname>
<given-names>P. E.</given-names>
</string-name> and <string-name>
<surname>Davies</surname>
<given-names>P.</given-names>
</string-name> (<year>2009</year>) <article-title>Age‐dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology</article-title>. <source/>J. Neurosci.
<volume>29</volume>, <fpage>10741</fpage>–<lpage>10749</lpage>.<pub-id pub-id-type="pmid">19710325</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0194">
<mixed-citation id="jnc13600-cit-0194" publication-type="journal">
<string-name>
<surname>Poorkaj</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Bird</surname>
<given-names>T. D.</given-names>
</string-name>, <string-name>
<surname>Wijsman</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Nemens</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Garruto</surname>
<given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Andreadis</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wiederholt</surname>
<given-names>W. C.</given-names>
</string-name>, <string-name>
<surname>Raskind</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Schellenberg</surname>
<given-names>G. D.</given-names>
</string-name> (<year>1998</year>) <article-title>Tau is a candidate gene for chromosome 17 frontotemporal dementia</article-title>. <source/>Ann. Neurol.
<volume>43</volume>, <fpage>815</fpage>–<lpage>825</lpage>.<pub-id pub-id-type="pmid">9629852</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0195">
<mixed-citation id="jnc13600-cit-0195" publication-type="journal">
<string-name>
<surname>Pountney</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Burns</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Haan</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Blumbergs</surname>
<given-names>P.</given-names>
</string-name> and <string-name>
<surname>Gai</surname>
<given-names>W.</given-names>
</string-name> (<year>2003</year>) <article-title>SUMO‐1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease</article-title>. <source/>Exp. Neurol.
<volume>184</volume>, <fpage>436</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">14637113</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0196">
<mixed-citation id="jnc13600-cit-0196" publication-type="journal">
<string-name>
<surname>Probst</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wiederhold</surname>
<given-names>K. H.</given-names>
</string-name>
<italic>et al</italic> (<year>2000</year>) <article-title>Axonopathy and amyotrophy in mice transgenic for human four‐repeat tau protein</article-title>. <source/>Acta Neuropathol.
<volume>99</volume>, <fpage>469</fpage>–<lpage>481</lpage>.<pub-id pub-id-type="pmid">10805089</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0197">
<mixed-citation id="jnc13600-cit-0197" publication-type="journal">
<string-name>
<surname>Rascovsky</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Hodges</surname>
<given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Knopman</surname>
<given-names>D.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title>. <source/>Brain
<volume>134</volume>, <fpage>2456</fpage>–<lpage>2477</lpage>.<pub-id pub-id-type="pmid">21810890</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0198">
<mixed-citation id="jnc13600-cit-0198" publication-type="journal">
<string-name>
<surname>Reyes</surname>
<given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>Geula</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Vana</surname>
<given-names>L.</given-names>
</string-name> and <string-name>
<surname>Binder</surname>
<given-names>L. I.</given-names>
</string-name> (<year>2012</year>) <article-title>Selective tau tyrosine nitration in non‐AD tauopathies</article-title>. <source/>Acta Neuropathol.
<volume>123</volume>, <fpage>119</fpage>–<lpage>132</lpage>.<pub-id pub-id-type="pmid">22057784</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0199">
<mixed-citation id="jnc13600-cit-0199" publication-type="journal">
<string-name>
<surname>Rhein</surname>
<given-names>V.</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Wiesner</surname>
<given-names>A.</given-names>
</string-name>
<italic>et al</italic> (<year>2009</year>) <article-title>Amyloid‐beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>20057</fpage>–<lpage>20062</lpage>.<pub-id pub-id-type="pmid">19897719</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0200">
<mixed-citation id="jnc13600-cit-0200" publication-type="journal">
<string-name>
<surname>Roberson</surname>
<given-names>E. D.</given-names>
</string-name>, <string-name>
<surname>Scearce‐Levie</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Palop</surname>
<given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>F.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>I. H.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Gerstein</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>G.‐Q.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2007</year>) <article-title>Reducing endogenous tau ameliorates amyloid beta‐induced deficits in an Alzheimer's disease mouse model</article-title>. <source/>Science
<volume>316</volume>, <fpage>750</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">17478722</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0201">
<mixed-citation id="jnc13600-cit-0201" publication-type="journal">
<string-name>
<surname>Rosenberg</surname>
<given-names>K. J.</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Feinstein</surname>
<given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Feinstein</surname>
<given-names>S. C.</given-names>
</string-name> and <string-name>
<surname>Israelachvili</surname>
<given-names>J.</given-names>
</string-name> (<year>2008</year>) <article-title>Complementary dimerization of microtubule‐associated tau protein: implications for microtubule bundling and tau‐mediated pathogenesis</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>105</volume>, <fpage>7445</fpage>–<lpage>7450</lpage>.<pub-id pub-id-type="pmid">18495933</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0202">
<mixed-citation id="jnc13600-cit-0202" publication-type="journal">
<string-name>
<surname>Rosenmann</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Grigoriadis</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Karussis</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Boimel</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Touloumi</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Ovadia</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Abramsky</surname>
<given-names>O.</given-names>
</string-name> (<year>2006</year>) <article-title>Tauopathy‐like abnormalities and neurologic deficits in mice immunized with neuronal tau protein</article-title>. <source/>Arch. Neurol.
<volume>63</volume>, <fpage>1459</fpage>–<lpage>1467</lpage>.<pub-id pub-id-type="pmid">17030663</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0203">
<mixed-citation id="jnc13600-cit-0203" publication-type="journal">
<string-name>
<surname>Rozenstein‐Tsalkovich</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Grigoriadis</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Lourbopoulos</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Nousiopoulou</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Kassis</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Abramsky</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Karussis</surname>
<given-names>D.</given-names>
</string-name> and <string-name>
<surname>Rosenmann</surname>
<given-names>H.</given-names>
</string-name> (<year>2013</year>) <article-title>Repeated immunization of mice with phosphorylated‐tau peptides causes neuroinflammation</article-title>. <source/>Exp. Neurol.
<volume>248</volume>, <fpage>451</fpage>–<lpage>456</lpage>.<pub-id pub-id-type="pmid">23876516</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0204">
<mixed-citation id="jnc13600-cit-0204" publication-type="journal">
<string-name>
<surname>Saito</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ruberu</surname>
<given-names>N. N.</given-names>
</string-name>, <string-name>
<surname>Sawabe</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Arai</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kakuta</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yamanouchi</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Murayama</surname>
<given-names>S.</given-names>
</string-name> (<year>2004</year>) <article-title>Staging of argyrophilic grains: an age‐associated tauopathy</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>63</volume>, <fpage>911</fpage>–<lpage>918</lpage>.<pub-id pub-id-type="pmid">15453090</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0205">
<mixed-citation id="jnc13600-cit-0205" publication-type="journal">
<string-name>
<surname>Saito</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Matsuba</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Mihira</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Takano</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Itohara</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Iwata</surname>
<given-names>N.</given-names>
</string-name> and <string-name>
<surname>Saido</surname>
<given-names>T. C.</given-names>
</string-name> (<year>2014</year>) <article-title>Single App knock‐in mouse models of Alzheimer's disease</article-title>. <source/>Nat. Neurosci.
<volume>17</volume>, <fpage>661</fpage>–<lpage>663</lpage>.<pub-id pub-id-type="pmid">24728269</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0206">
<mixed-citation id="jnc13600-cit-0206" publication-type="journal">
<string-name>
<surname>Sanders</surname>
<given-names>D. W.</given-names>
</string-name>, <string-name>
<surname>Kaufman</surname>
<given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>DeVos</surname>
<given-names>S. L.</given-names>
</string-name>
<italic>et al</italic> (<year>2014</year>) <article-title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</article-title>. <source/>Neuron
<volume>82</volume>, <fpage>1271</fpage>–<lpage>1288</lpage>.<pub-id pub-id-type="pmid">24857020</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0207">
<mixed-citation id="jnc13600-cit-0207" publication-type="journal">
<string-name>
<surname>SantaCruz</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Spires</surname>
<given-names>T.</given-names>
</string-name> et al. (<year>2005</year>) <article-title>Tau suppression in a neurodegenerative mouse model improves memory function</article-title>. <source/>Science
<volume>309</volume>, <fpage>476</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">16020737</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0208">
<mixed-citation id="jnc13600-cit-0208" publication-type="journal">
<string-name>
<surname>Santarella</surname>
<given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Skiniotis</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Goldie</surname>
<given-names>K. N.</given-names>
</string-name>, <string-name>
<surname>Tittmann</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Hoenger</surname>
<given-names>A.</given-names>
</string-name> (<year>2004</year>) <article-title>Surface‐decoration of microtubules by human tau</article-title>. <source/>J. Mol. Biol.
<volume>339</volume>, <fpage>539</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">15147841</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0209">
<mixed-citation id="jnc13600-cit-0209" publication-type="journal">
<string-name>
<surname>Sapir</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Frotscher</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.‐M.</given-names>
</string-name> and <string-name>
<surname>Reiner</surname>
<given-names>O.</given-names>
</string-name> (<year>2012</year>) <article-title>Tau's role in the developing brain: implications for intellectual disability</article-title>. <source/>Hum. Mol. Genet.
<volume>21</volume>, <fpage>1681</fpage>–<lpage>1692</lpage>.<pub-id pub-id-type="pmid">22194194</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0210">
<mixed-citation id="jnc13600-cit-0210" publication-type="journal">
<string-name>
<surname>Scattoni</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Gasparini</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Alleva</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Calamandrei</surname>
<given-names>G.</given-names>
</string-name> and <string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name> (<year>2010</year>) <article-title>Early behavioural markers of disease in P301S tau transgenic mice</article-title>. <source/>Behav. Brain Res.
<volume>208</volume>, <fpage>250</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">20004218</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0211">
<mixed-citation id="jnc13600-cit-0211" publication-type="journal">
<string-name>
<surname>Schultz</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Hubbard</surname>
<given-names>G. B.</given-names>
</string-name>, <string-name>
<surname>Rüb</surname>
<given-names>U.</given-names>
</string-name>, <string-name>
<surname>Braak</surname>
<given-names>E.</given-names>
</string-name> and <string-name>
<surname>Braak</surname>
<given-names>H.</given-names>
</string-name> (<year>2000</year>) <article-title>Age‐related progression of tau pathology in brains of baboons</article-title>. <source/>Neurobiol. Aging
<volume>21</volume>, <fpage>905</fpage>–<lpage>912</lpage>.<pub-id pub-id-type="pmid">11124441</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0212">
<mixed-citation id="jnc13600-cit-0212" publication-type="journal">
<string-name>
<surname>Schweers</surname>
<given-names>O.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Biernat</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>1995</year>) <article-title>Oxidation of cysteine‐322 in the repeat domain of microtubule‐associated protein tau controls the in vitro assembly of paired helical filaments</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>92</volume>, <fpage>8463</fpage>–<lpage>8467</lpage>.<pub-id pub-id-type="pmid">7667312</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0213">
<mixed-citation id="jnc13600-cit-0213" publication-type="journal">
<string-name>
<surname>Semenova</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Burakov</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Berardone</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zaliapin</surname>
<given-names>I.</given-names>
</string-name>, <string-name>
<surname>Slepchenko</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Svitkina</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kashina</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Rodionov</surname>
<given-names>V.</given-names>
</string-name> (<year>2008</year>) <article-title>Actin dynamics is essential for myosin‐based transport of membrane organelles</article-title>. <source/>Curr. Biol.
<volume>18</volume>, <fpage>1581</fpage>–<lpage>1586</lpage>.<pub-id pub-id-type="pmid">18951026</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0214">
<mixed-citation id="jnc13600-cit-0214" publication-type="journal">
<string-name>
<surname>Sennvik</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Boekhoorn</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Lasrado</surname>
<given-names>R.</given-names>
</string-name>
<italic>et al</italic> (<year>2007</year>) <article-title>Tau‐4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice</article-title>. <source/>FASEB J.
<volume>21</volume>, <fpage>2149</fpage>–<lpage>2161</lpage>.<pub-id pub-id-type="pmid">17341679</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0215">
<mixed-citation id="jnc13600-cit-0215" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>V. M.</given-names>
</string-name>, <string-name>
<surname>Litersky</surname>
<given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Bhaskar</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>G.</given-names>
</string-name> (<year>2007</year>) <article-title>Tau impacts on growth‐factor‐stimulated actin remodeling</article-title>. <source/>J. Cell Sci.
<volume>120</volume>, <fpage>748</fpage>–<lpage>757</lpage>.<pub-id pub-id-type="pmid">17284520</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0216">
<mixed-citation id="jnc13600-cit-0216" publication-type="journal">
<string-name>
<surname>Shipton</surname>
<given-names>O. A.</given-names>
</string-name>, <string-name>
<surname>Leitz</surname>
<given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Dworzak</surname>
<given-names>J.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>Tau protein is required for amyloid ‐induced impairment of hippocampal long‐term potentiation</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>1688</fpage>–<lpage>1692</lpage>.<pub-id pub-id-type="pmid">21289177</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0217">
<mixed-citation id="jnc13600-cit-0217" publication-type="journal">
<string-name>
<surname>Sperfeld A</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Collatz</surname>
<given-names>M. B.</given-names>
</string-name>, <string-name>
<surname>Baier</surname>
<given-names>H.</given-names>
</string-name>
<italic>et al</italic> (<year>1999</year>) <article-title>FTDP‐17: an early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation</article-title>. <source/>Ann. Neurol.
<volume>46</volume>, <fpage>708</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">10553987</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0218">
<mixed-citation id="jnc13600-cit-0218" publication-type="journal">
<string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name> and <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name> (<year>2013</year>) <article-title>Tau pathology and neurodegeneration</article-title>. <source/>Lancet Neurol.
<volume>12</volume>, <fpage>609</fpage>–<lpage>622</lpage>.<pub-id pub-id-type="pmid">23684085</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0219">
<mixed-citation id="jnc13600-cit-0219" publication-type="journal">
<string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Crowther</surname>
<given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Kamphorst</surname>
<given-names>W.</given-names>
</string-name>, <string-name>
<surname>Heutink</surname>
<given-names>P.</given-names>
</string-name> and <string-name>van<surname>Swieten</surname>
<given-names>J. C.</given-names>
</string-name> (<year>1998a</year>) <article-title>Tau pathology in two dutch families with mutations in the microtubule‐binding region of tau</article-title>. <source/>Am. J. Pathol.
<volume>153</volume>, <fpage>1359</fpage>–<lpage>1363</lpage>.<pub-id pub-id-type="pmid">9811325</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0220">
<mixed-citation id="jnc13600-cit-0220" publication-type="journal">
<string-name>
<surname>Spillantini</surname>
<given-names>M. G.</given-names>
</string-name>, <string-name>
<surname>Murrell</surname>
<given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Farlow</surname>
<given-names>M. R.</given-names>
</string-name>, <string-name>
<surname>Klug</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Ghetti</surname>
<given-names>B.</given-names>
</string-name> (<year>1998b</year>) <article-title>Mutation in the tau gene in familial multiple system tauopathy with presenile dementia</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>95</volume>, <fpage>7737</fpage>–<lpage>7741</lpage>.<pub-id pub-id-type="pmid">9636220</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0221">
<mixed-citation id="jnc13600-cit-0221" publication-type="journal">
<string-name>
<surname>Stefansson</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Helgason</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Thorleifsson</surname>
<given-names>G.</given-names>
</string-name>
<italic>et al</italic> (<year>2005</year>) <article-title>A common inversion under selection in Europeans</article-title>. <source/>Nat. Genet.
<volume>37</volume>, <fpage>129</fpage>–<lpage>137</lpage>.<pub-id pub-id-type="pmid">15654335</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0222">
<mixed-citation id="jnc13600-cit-0222" publication-type="journal">
<string-name>
<surname>Steinhilb</surname>
<given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Dias‐Santagata</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fulga</surname>
<given-names>T. A.</given-names>
</string-name>, <string-name>
<surname>Felch</surname>
<given-names>D. L.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2007</year>) <article-title>Tau phosphorylation sites work in concert to promote neurotoxicity in vivo</article-title>. <source/>Mol. Biol. Cell
<volume>18</volume>, <fpage>5060</fpage>–<lpage>5068</lpage>.<pub-id pub-id-type="pmid">17928404</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0223">
<mixed-citation id="jnc13600-cit-0223" publication-type="journal">
<string-name>
<surname>Sun</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>
<given-names>L.</given-names>
</string-name> (<year>2015</year>) <article-title>Studying tauopathies in Drosophila: a fruitful model</article-title>. <source/>Exp. Neurol.
<volume>274</volume>, <fpage>52</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">25862286</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0224">
<mixed-citation id="jnc13600-cit-0224" publication-type="journal">
<string-name>
<surname>Sundar</surname>
<given-names>P. D.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>C.‐E.</given-names>
</string-name>, <string-name>
<surname>Sieh</surname>
<given-names>W.</given-names>
</string-name>
<italic>et al</italic> (<year>2006</year>) <article-title>Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia</article-title>. <source/>Hum. Mol. Genet.
<volume>16</volume>, <fpage>295</fpage>–<lpage>306</lpage>.<pub-id pub-id-type="pmid">17185385</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0225">
<mixed-citation id="jnc13600-cit-0225" publication-type="journal">
<string-name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Ishida</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Komano</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Takahashi</surname>
<given-names>H.</given-names>
</string-name> (<year>2008</year>) <article-title>SUMO‐1 immunoreactivity co‐localizes with phospho‐Tau in APP transgenic mice but not in mutant tau transgenic mice</article-title>. <source/>Neurosci. Lett.
<volume>441</volume>, <fpage>90</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">18586401</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0226">
<mixed-citation id="jnc13600-cit-0226" publication-type="journal">
<string-name>
<surname>Takashima</surname>
<given-names>A.</given-names>
</string-name> (<year>2013</year>) <article-title>Tauopathies and tau oligomers</article-title>. <source/>J. Alzheimer's Dis.
<volume>37</volume>, <fpage>565</fpage>–<lpage>568</lpage>.<pub-id pub-id-type="pmid">23948895</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0227">
<mixed-citation id="jnc13600-cit-0227" publication-type="journal">
<string-name>
<surname>Takei</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>A.</given-names>
</string-name> and <string-name>
<surname>Hirokawa</surname>
<given-names>N.</given-names>
</string-name> (<year>2000</year>) <article-title>Defects axonal elongation and neuronal migration in mice with disrupted tau and map1b genes</article-title>. <source/>J. Cell Biol.
<volume>150</volume>, <fpage>989</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">10973990</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0228">
<mixed-citation id="jnc13600-cit-0228" publication-type="journal">
<string-name>
<surname>Takeuchi</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Iba</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>H.</given-names>
</string-name>
<italic>et al</italic> (<year>2011</year>) <article-title>P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating</article-title>. <source/>PLoS ONE
<volume>6</volume>, <fpage>e21050</fpage>.<pub-id pub-id-type="pmid">21698260</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0229">
<mixed-citation id="jnc13600-cit-0229" publication-type="journal">
<string-name>
<surname>Tanaka</surname>
<given-names>E. M.</given-names>
</string-name> and <string-name>
<surname>Kirschner</surname>
<given-names>M. W.</given-names>
</string-name> (<year>1991</year>) <article-title>Microtubule behavior in the growth cones of living neurons during axon elongation</article-title>. <source/>J. Cell Biol.
<volume>115</volume>, <fpage>345</fpage>–<lpage>363</lpage>.<pub-id pub-id-type="pmid">1918145</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0230">
<mixed-citation id="jnc13600-cit-0230" publication-type="journal">
<string-name>
<surname>Tanemura</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Akagi</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Murayama</surname>
<given-names>M.</given-names>
</string-name>
<italic>et al</italic> (<year>2001</year>) <article-title>Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau</article-title>. <source/>Neurobiol. Dis.
<volume>8</volume>, <fpage>1036</fpage>–<lpage>1045</lpage>.<pub-id pub-id-type="pmid">11741399</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0231">
<mixed-citation id="jnc13600-cit-0231" publication-type="journal">
<string-name>
<surname>Tatebayashi</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Miyasaka</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Chui</surname>
<given-names>D.‐H.</given-names>
</string-name>
<italic>et al</italic> (<year>2002</year>) <article-title>Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>99</volume>, <fpage>13896</fpage>–<lpage>13901</lpage>.<pub-id pub-id-type="pmid">12368474</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0232">
<mixed-citation id="jnc13600-cit-0232" publication-type="journal">
<string-name>
<surname>Tell</surname>
<given-names>V.</given-names>
</string-name> and <string-name>
<surname>Hilgeroth</surname>
<given-names>A.</given-names>
</string-name> (<year>2013</year>) <article-title>Recent developments of protein kinase inhibitors as potential AD therapeutics</article-title>. <source/>Front. Cell. Neurosci.
<volume>7</volume>, <fpage>189</fpage>.<pub-id pub-id-type="pmid">24312003</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0233">
<mixed-citation id="jnc13600-cit-0233" publication-type="journal">
<string-name>
<surname>Tepper</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Biernat</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wegmann</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Timm</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Hübschmann</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Redecke</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E.‐M.</given-names>
</string-name>, <string-name>
<surname>Müller</surname>
<given-names>D. J.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2014</year>) <article-title>Oligomer formation of tau protein hyperphosphorylated in cells</article-title>. <source/>J. Biol. Chem.
<volume>289</volume>, <fpage>34389</fpage>–<lpage>34407</lpage>.<pub-id pub-id-type="pmid">25339173</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0234">
<mixed-citation id="jnc13600-cit-0234" publication-type="journal">
<string-name>
<surname>Tien</surname>
<given-names>N.‐W.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>G.‐H.</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>C.‐C.</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>C.‐Y.</given-names>
</string-name> and <string-name>
<surname>Wagner</surname>
<given-names>O. I.</given-names>
</string-name> (<year>2011</year>) <article-title>Tau/PTL‐1 associates with kinesin‐3 KIF1A/UNC‐104 and affects the motor's motility characteristics in C. elegans neurons</article-title>. <source/>Neurobiol. Dis.
<volume>43</volume>, <fpage>495</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">21569846</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0235">
<mixed-citation id="jnc13600-cit-0235" publication-type="journal">
<string-name>
<surname>Tomasiewicz</surname>
<given-names>H. G.</given-names>
</string-name>, <string-name>
<surname>Flaherty</surname>
<given-names>D. B.</given-names>
</string-name>, <string-name>
<surname>Soria</surname>
<given-names>J. P.</given-names>
</string-name> and <string-name>
<surname>Wood</surname>
<given-names>J. G.</given-names>
</string-name> (<year>2002</year>) <article-title>Transgenic zebrafish model of neurodegeneration</article-title>. <source/>J. Neurosci. Res.
<volume>70</volume>, <fpage>734</fpage>–<lpage>745</lpage>.<pub-id pub-id-type="pmid">12444595</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0236">
<mixed-citation id="jnc13600-cit-0236" publication-type="journal">
<string-name>
<surname>Trinczek</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Ebneth</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mandelkow</surname>
<given-names>E. M.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>1999</year>) <article-title>Tau regulates the attachment/detachment but not the speed of motors in microtubule‐dependent transport of single vesicles and organelles</article-title>. <source/>J. Cell Sci.
<volume>112</volume> (Pt 1, <fpage>2355</fpage>–<lpage>2367</lpage>.<pub-id pub-id-type="pmid">10381391</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0237">
<mixed-citation id="jnc13600-cit-0237" publication-type="journal">
<string-name>
<surname>Tu</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>S.‐I.</given-names>
</string-name>, <string-name>
<surname>Lipton</surname>
<given-names>S. A.</given-names>
</string-name> and <string-name>
<surname>Xu</surname>
<given-names>H.</given-names>
</string-name> (<year>2014</year>) <article-title>Oligomeric Aβ‐induced synaptic dysfunction in Alzheimer's disease</article-title>. <source/>Mol. Neurodegener.
<volume>9</volume>, <fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">24386896</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0238">
<mixed-citation id="jnc13600-cit-0238" publication-type="journal">
<string-name>
<surname>Tucker</surname>
<given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Barde</surname>
<given-names>Y. A.</given-names>
</string-name> (<year>2001</year>) <article-title>Neurotrophins are required for nerve growth during development</article-title>. <source/>Nat. Neurosci.
<volume>4</volume>, <fpage>29</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">11135642</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0239">
<mixed-citation id="jnc13600-cit-0239" publication-type="journal">
<string-name>
<surname>Umeda</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ohnishi</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Takuma</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Ozeki</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Takashima</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Tomiyama</surname>
<given-names>T.</given-names>
</string-name> and <string-name>
<surname>Mori</surname>
<given-names>H.</given-names>
</string-name> (<year>2013</year>) <article-title>Neurodegenerative disorder FTDP‐17‐related tau intron 10 + 16C→T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice</article-title>. <source/>Am. J. Pathol.
<volume>183</volume>, <fpage>211</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">23680655</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0240">
<mixed-citation id="jnc13600-cit-0240" publication-type="journal">
<string-name>
<surname>Umeda</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Maekawa</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Takashima</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Tomiyama</surname>
<given-names>T.</given-names>
</string-name> and <string-name>
<surname>Mori</surname>
<given-names>H.</given-names>
</string-name> (<year>2014</year>) <article-title>Neurofibrillary tangle formation by introducing wild‐type human tau into APP transgenic mice</article-title>. <source/>Acta Neuropathol.
<volume>127</volume>, <fpage>685</fpage>–<lpage>698</lpage>.<pub-id pub-id-type="pmid">24531886</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0241">
<mixed-citation id="jnc13600-cit-0241" publication-type="journal">
<string-name>
<surname>Usenovic</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Niroomand</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Drolet</surname>
<given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Gaspar</surname>
<given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Hatcher</surname>
<given-names>N. G.</given-names>
</string-name>, <string-name>
<surname>Schachter</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Renger</surname>
<given-names>J. J.</given-names>
</string-name> and <string-name>
<surname>Parmentier‐Batteur</surname>
<given-names>S.</given-names>
</string-name> (<year>2015</year>) <article-title>Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>14234</fpage>–<lpage>14250</lpage>.<pub-id pub-id-type="pmid">26490863</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0242">
<mixed-citation id="jnc13600-cit-0242" publication-type="journal">
<string-name>
<surname>Varki</surname>
<given-names>A.</given-names>
</string-name> (<year>2007</year>) <article-title>Glycan‐based interactions involving vertebrate sialic‐acid‐recognizing proteins</article-title>. <source/>Nature
<volume>446</volume>, <fpage>1023</fpage>–<lpage>1029</lpage>.<pub-id pub-id-type="pmid">17460663</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0243">
<mixed-citation id="jnc13600-cit-0243" publication-type="journal">
<string-name>
<surname>Vossel</surname>
<given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Brodbeck</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Daub</surname>
<given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Finkbeiner</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>B.</given-names>
</string-name> and <string-name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</string-name> (<year>2010</year>) <article-title>Tau reduction prevents Aß‐induced defects in axonal transport</article-title>. <source/>Science (80‐.). <volume>330</volume>, <fpage>198</fpage>.<pub-id pub-id-type="pmid">20829454</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0244">
<mixed-citation id="jnc13600-cit-0244" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Udeshi</surname>
<given-names>N. D.</given-names>
</string-name>, <string-name>
<surname>O'Malley</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Shabanowitz</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>D. F.</given-names>
</string-name> and <string-name>
<surname>Hart</surname>
<given-names>G. W.</given-names>
</string-name> (<year>2010</year>) <article-title>Enrichment and site mapping of O‐linked N‐acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry</article-title>. <source/>Mol. Cell Proteomics
<volume>9</volume>, <fpage>153</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">19692427</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0245">
<mixed-citation id="jnc13600-cit-0245" publication-type="journal">
<string-name>
<surname>Warmus</surname>
<given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Sekar</surname>
<given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>McCutchen</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Schellenberg</surname>
<given-names>G. D.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>L. L.</given-names>
</string-name> and <string-name>
<surname>Roberson</surname>
<given-names>E. D.</given-names>
</string-name> (<year>2014</year>) <article-title>Tau‐mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia</article-title>. <source/>J. Neurosci.
<volume>34</volume>, <fpage>16482</fpage>–<lpage>16495</lpage>.<pub-id pub-id-type="pmid">25471585</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0246">
<mixed-citation id="jnc13600-cit-0246" publication-type="journal">
<string-name>
<surname>Wegmann</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Maury</surname>
<given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Kirk</surname>
<given-names>M. J.</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity</article-title>. <source/>EMBO J.
<volume>34</volume>, <fpage>3028</fpage>–<lpage>3041</lpage>.<pub-id pub-id-type="pmid">26538322</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0247">
<mixed-citation id="jnc13600-cit-0247" publication-type="journal">
<string-name>
<surname>Wei</surname>
<given-names>M. L.</given-names>
</string-name> and <string-name>
<surname>Andreadis</surname>
<given-names>A.</given-names>
</string-name> (<year>1998</year>) <article-title>Splicing of a regulated exon reveals additional complexity in the axonal microtubule‐associated protein tau</article-title>. <source/>J. Neurochem.
<volume>70</volume>, <fpage>1346</fpage>–<lpage>1356</lpage>.<pub-id pub-id-type="pmid">9523550</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0248">
<mixed-citation id="jnc13600-cit-0248" publication-type="journal">
<string-name>
<surname>Weingarten</surname>
<given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Lockwood</surname>
<given-names>A. H.</given-names>
</string-name>, <string-name>
<surname>Hwo</surname>
<given-names>S. Y.</given-names>
</string-name> and <string-name>
<surname>Kirschner</surname>
<given-names>M. W.</given-names>
</string-name> (<year>1975</year>) <article-title>A protein factor essential for microtubule assembly</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>72</volume>, <fpage>1858</fpage>–<lpage>1862</lpage>.<pub-id pub-id-type="pmid">1057175</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0249">
<mixed-citation id="jnc13600-cit-0249" publication-type="journal">
<string-name>
<surname>Wilhelmsen</surname>
<given-names>K. C.</given-names>
</string-name>, <string-name>
<surname>Lynch</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Pavlou</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Higgins</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Nygaard</surname>
<given-names>T. G.</given-names>
</string-name> (<year>1994</year>) <article-title>Localization of disinhibition‐dementia‐parkinsonism‐amyotrophy complex to 17q21‐22</article-title>. <source/>Am. J. Hum. Genet.
<volume>55</volume>, <fpage>1159</fpage>–<lpage>1165</lpage>.<pub-id pub-id-type="pmid">7977375</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0250">
<mixed-citation id="jnc13600-cit-0250" publication-type="journal">
<string-name>
<surname>Williams</surname>
<given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Holton</surname>
<given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Strand</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pittman</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>Lees. A. J.</given-names>
</string-name> and <string-name>
<surname>Revesz</surname>
<given-names>T.</given-names>
</string-name> (<year>2007</year>) <article-title>Pathological tau burden and distribution distinguishes progressive supranuclear palsy‐parkinsonism from Richardson's syndrome</article-title>. <source/>Brain
<volume>130</volume>, <fpage>1566</fpage>–<lpage>1576</lpage>.<pub-id pub-id-type="pmid">17525140</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0251">
<mixed-citation id="jnc13600-cit-0251" publication-type="journal">
<string-name>
<surname>Wischik</surname>
<given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Thøgersen</surname>
<given-names>H. C.</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>P. C.</given-names>
</string-name>, <string-name>
<surname>Runswick</surname>
<given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Jakes</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Milstein</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Roth</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Klug</surname>
<given-names>A.</given-names>
</string-name> (<year>1988</year>) <article-title>Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>85</volume>, <fpage>4506</fpage>–<lpage>4510</lpage>.<pub-id pub-id-type="pmid">3132715</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0252">
<mixed-citation id="jnc13600-cit-0252" publication-type="journal">
<string-name>
<surname>Wittmann</surname>
<given-names>C. W.</given-names>
</string-name>, <string-name>
<surname>Wszolek</surname>
<given-names>M. F.</given-names>
</string-name>, <string-name>
<surname>Shulman</surname>
<given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Salvaterra</surname>
<given-names>P. M.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</string-name> and <string-name>
<surname>Feany</surname>
<given-names>M. B.</given-names>
</string-name> (<year>2001</year>) <article-title>Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles</article-title>. <source/>Science
<volume>293</volume>, <fpage>711</fpage>–<lpage>714</lpage>.<pub-id pub-id-type="pmid">11408621</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0253">
<mixed-citation id="jnc13600-cit-0253" publication-type="journal">
<string-name>
<surname>Wood</surname>
<given-names>J. G.</given-names>
</string-name>, <string-name>
<surname>Mirra</surname>
<given-names>S. S.</given-names>
</string-name>, <string-name>
<surname>Pollock</surname>
<given-names>N. J.</given-names>
</string-name> and <string-name>
<surname>Binder</surname>
<given-names>L. I.</given-names>
</string-name> (<year>1986</year>) <article-title>Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule‐associated protein tau (tau)</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>83</volume>, <fpage>4040</fpage>–<lpage>4043</lpage>.<pub-id pub-id-type="pmid">2424015</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0254">
<mixed-citation id="jnc13600-cit-0254" publication-type="journal">
<string-name>
<surname>Xia</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C.</given-names>
</string-name> and <string-name>
<surname>Götz</surname>
<given-names>J.</given-names>
</string-name> (<year>2015</year>) <article-title>Pseudophosphorylation of tau at distinct epitopes or the presence of the P301L mutation targets the microtubule‐associated protein tau to dendritic spines</article-title>. <source/>Biochim. Biophys. Acta
<volume>1852</volume>, <fpage>913</fpage>–<lpage>924</lpage>.<pub-id pub-id-type="pmid">25558816</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0255">
<mixed-citation id="jnc13600-cit-0255" publication-type="journal">
<string-name>
<surname>Xie</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Miyasaka</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Yoshimura</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hatsuta</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yoshina</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kage‐Nakadai</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mitani</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Murayama</surname>
<given-names>S.</given-names>
</string-name> and <string-name>
<surname>Ihara</surname>
<given-names>Y.</given-names>
</string-name> (<year>2014</year>) <article-title>The homologous carboxyl‐terminal domains of microtubule‐associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tangles</article-title>. <source/>PLoS ONE
<volume>9</volume>, <fpage>e89796</fpage>.<pub-id pub-id-type="pmid">24587039</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0256">
<mixed-citation id="jnc13600-cit-0256" publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>X. J.</given-names>
</string-name> and <string-name>
<surname>Seto</surname>
<given-names>E.</given-names>
</string-name> (<year>2008</year>) <article-title>Lysine Acetylation: codified Crosstalk with Other Posttranslational Modifications</article-title>. <source/>Mol. Cell
<volume>31</volume>, <fpage>449</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">18722172</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0257">
<mixed-citation id="jnc13600-cit-0257" publication-type="journal">
<string-name>
<surname>Yoshida</surname>
<given-names>M.</given-names>
</string-name> (<year>2014</year>) <article-title>Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration</article-title>. <source/>Neuropathology
<volume>34</volume>, <fpage>555</fpage>–<lpage>570</lpage>.<pub-id pub-id-type="pmid">25124031</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0258">
<mixed-citation id="jnc13600-cit-0258" publication-type="journal">
<string-name>
<surname>Yoshiyama</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>S.‐M.</given-names>
</string-name>, <string-name>
<surname>Iwata</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Saido</surname>
<given-names>T. C.</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Suhara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> (<year>2007</year>) <article-title>Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model</article-title>. <source/>Neuron
<volume>53</volume>, <fpage>337</fpage>–<lpage>351</lpage>.<pub-id pub-id-type="pmid">17270732</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0259">
<mixed-citation id="jnc13600-cit-0259" publication-type="journal">
<string-name>
<surname>Yuan</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</string-name>, <string-name>
<surname>Peterhoff</surname>
<given-names>C.</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Nixon</surname>
<given-names>R. A.</given-names>
</string-name> (<year>2008</year>) <article-title>Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice</article-title>. <source/>J. Neurosci.
<volume>28</volume>, <fpage>1682</fpage>–<lpage>1687</lpage>.<pub-id pub-id-type="pmid">18272688</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0260">
<mixed-citation id="jnc13600-cit-0260" publication-type="journal">
<string-name>
<surname>Yuzwa</surname>
<given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Yadav</surname>
<given-names>A. K.</given-names>
</string-name>, <string-name>
<surname>Skorobogatko</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Vosseller</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Vocadlo</surname>
<given-names>D. J.</given-names>
</string-name> (<year>2011</year>) <article-title>Mapping O‐GlcNAc modification sites on tau and generation of a site‐specific O‐GlcNAc tau antibody</article-title>. <source/>Amino Acids
<volume>40</volume>, <fpage>857</fpage>–<lpage>868</lpage>.<pub-id pub-id-type="pmid">20706749</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0261">
<mixed-citation id="jnc13600-cit-0261" publication-type="journal">
<string-name>
<surname>Yuzwa</surname>
<given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Shan</surname>
<given-names>X.</given-names>
</string-name>, <string-name>
<surname>Macauley</surname>
<given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Skorobogatko</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Vosseller</surname>
<given-names>K.</given-names>
</string-name> and <string-name>
<surname>Vocadlo</surname>
<given-names>D. J.</given-names>
</string-name> (<year>2012</year>) <article-title>Increasing O‐GlcNAc slows neurodegeneration and stabilizes tau against aggregation</article-title>. <source/>Nat. Chem. Biol.
<volume>8</volume>, <fpage>393</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">22366723</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0262">
<mixed-citation id="jnc13600-cit-0262" publication-type="journal">
<string-name>
<surname>van der Zee</surname>
<given-names>J.</given-names>
</string-name> and <string-name>
<surname>Van Broeckhoven</surname>
<given-names>C.</given-names>
</string-name> (<year>2014</year>) <article-title>Dementia in 2013: frontotemporal lobar degeneration—building on breakthroughs</article-title>. <source/>Nat. Rev. Neurol.
<volume>10</volume>, <fpage>70</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">24394289</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0263">
<mixed-citation id="jnc13600-cit-0263" publication-type="journal">
<string-name>
<surname>Zempel</surname>
<given-names>H.</given-names>
</string-name> and <string-name>
<surname>Mandelkow</surname>
<given-names>E.</given-names>
</string-name> (<year>2014</year>) <article-title>Lost after translation: missorting of tau protein and consequences for Alzheimer disease</article-title>. <source/>Trends Neurosci.
<volume>37</volume>, <fpage>721</fpage>–<lpage>732</lpage>.<pub-id pub-id-type="pmid">25223701</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0264">
<mixed-citation id="jnc13600-cit-0264" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yoshiyama</surname>
<given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>T.</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>D.</given-names>
</string-name>, <string-name>
<surname>Joyce</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Trojanowski</surname>
<given-names>J. Q.</given-names>
</string-name> and <string-name>
<surname>Lee</surname>
<given-names>V. M.‐Y.</given-names>
</string-name> (<year>2004</year>) <article-title>Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy</article-title>. <source/>J. Neurosci.
<volume>24</volume>, <fpage>4657</fpage>–<lpage>4667</lpage>.<pub-id pub-id-type="pmid">15140937</pub-id></mixed-citation>
</ref>
<ref id="jnc13600-bib-0265">
<mixed-citation id="jnc13600-cit-0265" publication-type="journal">
<string-name>
<surname>Zmuda</surname>
<given-names>J. F.</given-names>
</string-name> and <string-name>
<surname>Rivas</surname>
<given-names>R. J.</given-names>
</string-name> (<year>2000</year>) <article-title>Actin disruption alters the localization of tau in the growth cones of cerebellar granule neurons</article-title>. <source/>J. Cell Sci.
<volume>113</volume>, <fpage>2797</fpage>–<lpage>2809</lpage>.<pub-id pub-id-type="pmid">10893194</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>